{
  "session_id": "vh_session_1762672447",
  "total_logs": 42,
  "generated_at": "2025-11-09T15:14:07.295150",
  "node_meta": {
    "root_patient_drug": { "should_activate": true, "risk_level": "low" },
    "organ_gut": { "should_activate": true, "risk_level": "high" },
    "tissue_gut_gut": { "should_activate": true, "risk_level": "high" },
    "cell_gut_cell_gut": { "should_activate": true, "risk_level": "high" },
    "target_gut_HMGCR": { "should_activate": true, "risk_level": "high" },
    "target_gut_SLCO1B1": { "should_activate": true, "risk_level": "high" },
    "target_gut_LDLR": { "should_activate": true, "risk_level": "medium" },
    "target_gut_ABCA1": { "should_activate": true, "risk_level": "medium" },
    "target_gut_PCSK9": { "should_activate": true, "risk_level": "high" },

    "organ_liver": { "should_activate": true, "risk_level": "medium" },
    "tissue_liver_liver": { "should_activate": true, "risk_level": "medium" },
    "cell_liver_cell_liver": { "should_activate": true, "risk_level": "medium" },
    "target_liver_HMGCR": { "should_activate": true, "risk_level": "medium" },
    "target_liver_SLCO1B1": { "should_activate": true, "risk_level": "high" },
    "target_liver_LDLR": { "should_activate": true, "risk_level": "medium" },
    "target_liver_ABCA1": { "should_activate": true, "risk_level": "low" },
    "target_liver_PCSK9": { "should_activate": true, "risk_level": "high" },

    "organ_cns": { "should_activate": true, "risk_level": "low" },
    "tissue_cns_cns": { "should_activate": true, "risk_level": "low" },
    "cell_cns_cell_cns": { "should_activate": true, "risk_level": "low" },
    "target_cns_HMGCR": { "should_activate": true, "risk_level": "low" },
    "target_cns_SLCO1B1": { "should_activate": true, "risk_level": "medium" },
    "target_cns_LDLR": { "should_activate": true, "risk_level": "low" },
    "target_cns_ABCA1": { "should_activate": true, "risk_level": "low" },
    "target_cns_PCSK9": { "should_activate": true, "risk_level": "medium" },

    "organ_kidney": { "should_activate": false, "risk_level": "medium" },
    "tissue_kidney_kidney": { "should_activate": false, "risk_level": "medium" },
    "cell_kidney_cell_kidney": { "should_activate": false, "risk_level": "medium" },
    "target_kidney_HMGCR": { "should_activate": false, "risk_level": "medium" },
    "target_kidney_SLCO1B1": { "should_activate": false, "risk_level": "medium" },
    "target_kidney_LDLR": { "should_activate": false, "risk_level": "medium" },
    "target_kidney_ABCA1": { "should_activate": false, "risk_level": "medium" },
    "target_kidney_PCSK9": { "should_activate": false, "risk_level": "medium" },

    "organ_heart": { "should_activate": true, "risk_level": "low" },
    "tissue_heart_heart": { "should_activate": true, "risk_level": "low" },
    "cell_heart_cell_heart": { "should_activate": true, "risk_level": "low" },
    "target_heart_LDLR": { "should_activate": false, "risk_level": "low" },
    "target_heart_HMGCR": { "should_activate": false, "risk_level": "medium" },
    "target_heart_PCSK9": { "should_activate": false, "risk_level": "medium" },
    "target_heart_ABCA1": { "should_activate": true, "risk_level": "low" },
    "target_heart_SLCO1B1": { "should_activate": true, "risk_level": "medium" }
  },
  "logs": [
    {
      "log_id": "log_1762672581260_organ_gut",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:16:21.261219",
      "level": 1,
      "level_name": "器官层",
      "agent_id": "organ_gut",
      "agent_name": "organ",
      "agent_type": "organ",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "organ_flows": {
          "drug_flow": "Analysis of Statin + SLCO1B1 for Hypercholesterolemia",
          "bio_signals": "Patient baseline: 45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg",
          "literature_flow": "Starting literature review process"
        }
      },
      "output_data": {
        "round1_analysis": "# Organ Status Report: gut\n- **General State:** The gut is processing Simvastatin, with enzyme activity reflecting genetic influences on drug metabolism.\n- **Key Drug Observations:**\n  - Simvastatin is undergoing first-pass metabolism, affecting its bioavailability.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin.\n- **Key Bio-Signals Emitted:**\n  - Increased CYP3A4 enzyme activity detected, indicating enhanced or altered drug metabolism.\n  - Emission of stress signals related to potential statin-induced myopathy risk due to genetic factors.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Organ Status Report: gut\n- **General State:** The gut is processing Simvastatin, with enzyme activity reflecting genetic influences on drug metabolism.\n- **Key Drug Observations:**\n  - Simvastatin is undergoing first-pass metabolism, affecting its bioavailability.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin.\n- **Key Bio-Signals Emitted:**\n  - Increased CYP3A4 enzyme activity detected, indicating enhanced or altered drug metabolism.\n  - Emission of stress signals related to potential statin-induced myopathy risk due to genetic factors.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What are the implications of SLCO1B1 polymorphisms on statin metabolism and risk of myopathy?",
              "What are the current guidelines for statin therapy in patients with high LDL-C and no ASCVD?"
            ],
            "tool_result": "- **Tool Name:** tavily_search  \n  **Summary:** SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly alter the transport activity of the hepatic OATP1B1 transporter. These variants are strongly associated with statin-induced myopathy, statin intolerance, and adverse drug reactions (ADRs).  \n  **Key Findings:**  \n  - **Genes:** SLCO1B1 (variants rs4149056, rs2306283)  \n  - **Drugs:** Simvastatin  \n  - **Clinical Trials:** SEARCH trial (NCT identifier not specified)  \n  - **Quantitative Information:** Genomewide significant association with myopathy, higher risk of statin-induced muscle toxicity in carriers of these polymorphisms.  \n  - **Dosing Algorithms:** Testing for SLCO1B1 polymorphisms can guide statin therapy to minimize myopathy risk, especially when prescribing high-dose simvastatin.  \n  - **Additional Notes:** No resistance markers noted. Importance of genotype-guided dosing to reduce statin intolerance and muscle toxicity emphasized.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Statins are primarily metabolized in the liver by the enzyme CYP3A4 and subsequently excreted. Genetic polymorphisms in statin-metabolizing enzymes and transport proteins significantly influence individual variability in statin metabolism, therapeutic efficacy, and adverse effects.  \n  **Key Findings:**  \n  - **Genes:** CYP3A4  \n  - **Drugs:** Statins  \n  - **Additional Notes:** Personalized therapy targeting metabolic enzymes, transporters, transcription factors, and epigenetic regulators is emphasized. Age-related pharmacokinetic changes notably affect statin clearance.\n\n- **Tool Name:** tavily_search  \n  **Summary:** SLCO1B1 polymorphisms, particularly the *5 allele (rs4149056, c.521T>C), significantly impact statin metabolism and the risk of statin-induced myopathy.  \n  **Key Findings:**  \n  - **Genes:** SLCO1B1 (*5 allele, rs4149056)  \n  - **Drugs:** Simvastatin  \n  - **Clinical Trials:** SEARCH genomewide association study, Heart Protection Study (n=18,000 on 40 mg simvastatin)  \n  - **Quantitative Information:** LDL-C reductions (C/C: 44 ± 25 mg/dL, T/C: 55 ± 19 mg/dL, T/T: 57 ± 22 mg/dL; P=0.038 and P=0.008 without multiple testing correction).  \n  - **Dosing Algorithms:** Genotyping for SLCO1B1 variants is advised to personalize therapy.  \n  - **Safety/Adverse Events:** Increased incidence of statin-induced myopathy and CK elevations >3× upper limit of normal in *SLCO1B1* *5* allele carriers.\n\n- **Tool Name:** get_general_info_by_disease_name  \n  **Summary:** Statin-induced myopathy (MONDO_0009722) is associated with multiple gene targets.  \n  **Key Findings:**  \n  - **Genes:** STAC3, HMGCR, RPL17, UCN2, ATP6V0A4, INSR, PDCD1, PCSK9, CALM1, CALM2, CALM3  \n  - **Additional Notes:** No specific drugs or treatment regimens identified. Key phenotypic features linked to statin-induced myopathy detailed.\n\n- **Tool Name:** tavily_search  \n  **Summary:** SLCO1B1 polymorphisms, particularly the SLCO1B1*5 variant (rs4149056), significantly increase the risk of statin-induced myopathy.  \n  **Key Findings:**  \n  - **Genes:** SLCO1B1 (*5 allele, rs4149056), CYP3A4  \n  - **Drugs:** Simvastatin  \n  - **Clinical Trials:** Heart Protection Study (18,000 participants on 40 mg simvastatin)  \n  - **Quantitative Information:** CK levels (>3× upper limit of normal), mild statin-induced muscle side effects associated with female sex and SLCO1B1*5.  \n  - **Dosing Algorithms:** Genotyping for SLCO1B1 is suggested to guide statin choice and dosing.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Current guidelines recommend statin therapy primarily for adults aged 40 to 75 years with cardiovascular disease (CVD) risk factors.  \n  **Key Findings:**  \n  - **Drugs:** Statins  \n  - **Additional Notes:** Moderate-intensity statin therapy indicated for primary prevention in patients aged 40-75 with diabetes. Statin therapy is considered for adults with one or more CVD risk factors and a calculated 10-year ASCVD risk ≥5%.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Management of high LDL-C involves lifestyle modifications and pharmacologic therapy primarily with statins.  \n  **Key Findings:**  \n  - **Drugs:** Statins, Ezetimibe, PCSK9 inhibitors  \n  - **Quantitative Information:** LDL-C thresholds (≥70 mg/dL, >190 mg/dL), relative risk reduction per 39 mg/dL LDL-C lowering.  \n  - **Dosing Algorithms:** High-intensity statin therapy or moderate-intensity plus ezetimibe recommended for severe primary hypercholesterolemia.  \n  - **Additional Notes:** Safety/adverse event data on PCSK9 inhibitors not detailed.\n\n- **Tool Name:** tavily_search  \n  **Summary:** The 2022 USPSTF recommendation on statin therapy for primary prevention of ASCVD in adults without cardiovascular disease updates the 2016 guideline.  \n  **Key Findings:**  \n  - **Drugs:** Statins  \n  - **Quantitative Information:** 10-year ASCVD risk of 10% or greater is a threshold for statin therapy.  \n  - **Clinical Trials:** 22 randomized clinical trials (RCTs) informing efficacy, with 3 additional trials added in the 2022 update.  \n  - **Dosing Algorithms:** Low- to moderate-dose statins recommended for specified populations.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Statin therapy guidelines for patients with high LDL-C without ASCVD are as follows:  \n  **Key Findings:**  \n  - **Drugs:** Statins, Ezetimibe, PCSK9 inhibitors  \n  - **Quantitative Information:** LDL-C thresholds (≥190 mg/dL, 70-189 mg/dL), adverse event rates not detailed.  \n  - **Dosing Algorithms:** High-intensity statin therapy recommended for LDL-C ≥190 mg/dL; moderate-intensity statin therapy recommended for LDL-C 70-189 mg/dL.  \n  - **Clinical Guidelines:** 2018 ACC/AHA guidelines, Cholesterol Treatment Trialists data, USPSTF recommendations.  \n  - **Additional Notes:** Risk enhancers and biomarkers guide personalized therapy.",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly alter the transport activity of the hepatic OATP1B1 transporter. These variants are strongly associated with statin-induced myopathy, statin intolerance, and adverse drug reactions (ADRs). \n\nKey findings include:  \n- The SEARCH trial (NCT identifier not specified) demonstrated a genomewide significant association between SLCO1B1 rs4149056 and an increased risk of myopathy in patients on high-dose simvastatin, highlighting a genetic predisposition to statin-induced muscle toxicity.  \n- Meta-analyses confirm that carriers of these polymorphisms have a higher risk of statin-related myopathy and myalgia.  \n- SLCO1B1 variants also contribute to milder forms of statin intolerance, though prospective data remain limited.  \n- Allele and haplotype frequencies (e.g., *SLCO1B1* *1a*, *1b*, *5*, *15*) vary by population; for example, a study of 1,205 healthy Thai individuals showed distribution of these variants across regions, relevant for pharmacogenomic considerations.  \n\nClinically, testing for SLCO1B1 polymorphisms can guide statin therapy to minimize myopathy risk, especially when prescribing simvastatin at high doses. The presence of rs4149056 in particular predicts reduced OATP1B1 function, leading to higher systemic statin exposure and increased adverse effects.\n\nNo resistance markers beyond these genetic variants were noted. Safety data emphasize the importance of genotype-guided dosing to reduce statin intolerance and muscle toxicity.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4045
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Statins are primarily metabolized in the liver by the enzyme CYP3A4 and subsequently excreted. Genetic polymorphisms in statin-metabolizing enzymes and transport proteins significantly influence individual variability in statin metabolism, therapeutic efficacy, and adverse effects. Age-related pharmacokinetic changes notably affect liver extraction, metabolism, and excretion of statins, impacting their clearance. Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Personalized statin therapy targeting metabolic enzymes, transporters, transcription factors, and epigenetic regulators holds promise for optimizing therapeutic outcomes and minimizing adverse reactions. Additionally, statins may blunt the beneficial effects of aerobic exercise on cardiorespiratory fitness due to their impact on muscle metabolism.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3235
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly the *5 allele (rs4149056, c.521T>C), significantly impact statin metabolism and the risk of statin-induced myopathy. The *5 allele reduces statin clearance, notably simvastatin, leading to increased risk of myopathy characterized by muscle symptoms and elevated creatine kinase (CK) >3× upper limit of normal. A composite adverse event (CAE), including discontinuation due to side effects or myalgia, is more frequent in carriers of ≥1 *SLCO1B1* *5* allele.\n\nKey clinical findings include:\n\n- The SEARCH genomewide association study identified *SLCO1B1* variants as strongly associated with simvastatin-induced myopathy, especially at high doses.\n- In the Heart Protection Study (n=18,000 on 40 mg simvastatin), *SLCO1B1* genotype had a minimal effect (~1% per C allele) on LDL-C reduction and no significant impact on vascular outcomes.\n- A candidate-gene study showed that *SLCO1B1* 521C allele influenced cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks in white patients, with LDL-C reductions of 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T); total cholesterol reductions were 43 ± 27, 57 ± 21, and 60 ± 24 mg/dL respectively (P=0.038 and P=0.008 without multiple testing correction).\n- Clinical implementation of *SLCO1B1* genotyping to guide simvastatin therapy has shown noninferior lipid-lowering outcomes and reduced statin-associated muscle symptoms by avoiding simvastatin prescription in patients with decreased or poor OATP1B1 function phenotypes.\n\nRecommendations:\n\n- Genotyping for *SLCO1B1* variants, especially the *5 allele, is advised to personalize statin therapy, minimize myopathy risk, and improve adherence.\n- Physicians should consider alternative statins or dose adjustments in patients with at-risk genotypes.\n- Despite effects on statin pharmacokinetics and myopathy risk, *SLCO1B1* polymorphisms have limited influence on overall statin efficacy and vascular outcomes.\n\nSafety/Adverse Events:\n\n- Increased incidence of statin-induced myopathy and CK elevations >3× upper limit of normal in *SLCO1B1* *5* allele carriers.\n- Genotype-guided therapy reduces muscle symptoms without compromising lipid-lowering efficacy.\n\nNo specific resistance markers beyond the *SLCO1B1* polymorphisms were reported.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5948
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_disease_name",
                "toolsuite": "opentargets",
                "success": true,
                "sse_summary": "Statin-induced myopathy (MONDO_0009722) is associated with multiple gene targets, with the highest relevance score for STAC3 (0.7858), followed by HMGCR (0.0193), RPL17 (0.0137), and others including UCN2, ATP6V0A4, INSR, PDCD1, PCSK9, and several calmodulin genes (CALM1, CALM2, CALM3). No specific drugs or treatment regimens were identified.\n\nKey phenotypic features linked to statin-induced myopathy include:  \n- Musculoskeletal and developmental abnormalities such as hypotonia, proximal muscle weakness, motor delay, fatty replacement of skeletal muscle, increased intramyocellular lipid droplets, and myopathic facies.  \n- Craniofacial abnormalities including short palpebral fissures, blepharophimosis, ptosis, micrognathia, microcephaly, brachycephaly, low-set ears, downslanted palpebral fissures, downturned corners of the mouth.  \n- Growth and structural defects such as short stature, scoliosis, and congenital onset.  \n- Respiratory involvement characterized by restrictive ventilatory defect and hypoxemia.  \n- Neuromuscular signs including Gowers sign and weakness of facial musculature.  \n- Other congenital anomalies such as cryptorchidism and bilateral talipes equinovarus.\n\nNo clinical trial data, drug dosages, efficacy statistics, safety/adverse event rates, or resistance markers were reported in this output.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 12823
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly the SLCO1B1*5 variant (rs4149056), significantly increase the risk of statin-induced myopathy, especially with simvastatin. Evidence from the large Heart Protection Study (18,000 participants on 40 mg simvastatin) showed that the SLCO1B1 genotype has at most a small effect (~1% per C allele) on LDL cholesterol reduction and no significant impact on vascular outcomes. The SLCO1B1*5 allele impairs statin clearance, leading to elevated creatine kinase (CK) levels (>3× upper limit of normal) and higher rates of muscle side effects, including myalgia and statin discontinuation due to adverse events. Female sex and the SLCO1B1*5 allele are associated with increased mild statin-induced muscle side effects.\n\nGenotyping for SLCO1B1 is suggested to guide statin choice and dosing to reduce myopathy risk and improve adherence. Ethnic variation in the frequency of the rs4149056 variant exists, with Amerindians in the Brazilian population identified as a high-risk group. Other candidate genes (e.g., CYP3A4) have been studied but lack convincing statistical associations compared to SLCO1B1.\n\nIn summary, SLCO1B1 genotyping, especially for the rs4149056 (SLCO1B1*5) variant, is clinically relevant for managing simvastatin therapy to mitigate myopathy risk without significantly affecting lipid-lowering efficacy.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5443
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Current guidelines recommend statin therapy primarily for adults aged 40 to 75 years with cardiovascular disease (CVD) risk factors. Specifically:\n\n- Moderate-intensity statin therapy is indicated for primary prevention in patients aged 40-75 with diabetes (2019 ACC/AHA Guideline).\n- Statin therapy should be considered for adults aged 40-75 who have one or more CVD risk factors (hypertension, dyslipidemia, diabetes, smoking) and a calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥5% (ACC guidelines).\n- The USPSTF recommends prescribing statins for primary prevention in adults 40-75 years with one or more CVD risk factors.\n- Guidelines emphasize assessing risk-enhancing factors in adults 40-75 to guide statin initiation decisions.\n- The Pooled Cohort Equations (PCE) predicted 10-year risk ≥5% is a key threshold for considering statin therapy.\n\nKey points:\n\n- Age group: 40-75 years\n- Indications: diabetes, hypertension, dyslipidemia, smoking, other CVD risk factors\n- Risk threshold: ≥5% 10-year ASCVD risk (PCE)\n- Statin intensity: moderate-intensity recommended for primary prevention in diabetes and others meeting criteria\n\nNo specific drug names, dosages, adverse event rates, or resistance markers were detailed in the provided data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 2709
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Management of high LDL-C involves lifestyle modifications and pharmacologic therapy primarily with statins. According to the 2018 guidelines (NHLBI/ACC):\n\n- For patients at very high risk of atherosclerotic cardiovascular disease (ASCVD) with LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe, PCSK9 inhibitors are recommended as add-on therapy.\n- In severe primary hypercholesterolemia (LDL-C >190 mg/dL [>4.9 mmol/L]) without ASCVD, initiate high-intensity statin therapy or moderate-intensity statin plus ezetimibe aiming for LDL-C <100 mg/dL; if this target is unmet, consider adding PCSK9 inhibitors in selected high-risk patients.\n- The Cholesterol Treatment Trialists meta-analysis showed a consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C lowering, regardless of baseline LDL-C.\n- Diabetes-specific risk enhancers (e.g., long duration ≥10 years for type 2 diabetes, albuminuria ≥30 mcg/mg creatinine, eGFR <60 ml/min/1.73 m², retinopathy, neuropathy, ABI <0.9) and other ASCVD risk enhancers (family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory diseases like rheumatoid arthritis, psoriasis, HIV, and certain ethnicities such as South Asian ancestry) guide treatment intensification.\n- Lipid and biomarker risk enhancers include persistently elevated triglycerides ≥175 mg/dL, hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL (>125 nmol/L), and apoB ≥130 mg/dL.\n- Lifestyle recommendations emphasize reducing saturated and trans fats, weight loss of 5-10%, and a heart-healthy diet rich in plant-based foods.\n- Safety/adverse event data on PCSK9 inhibitors were not detailed in the sources, but their use is reserved for high-risk patients not at goal despite statins and ezetimibe.\n\nIn summary, management prioritizes high-intensity statins +/- ezetimibe, with PCSK9 inhibitors added for persistent LDL-C elevation in very high-risk individuals, supported by comprehensive risk assessment including diabetes-specific and other risk enhancers.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5954
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "The 2022 USPSTF recommendation on statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults without cardiovascular disease updates and largely aligns with the 2016 guideline. Statin therapy is recommended for adults aged 40 to 75 years who have one or more cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year ASCVD risk of 10% or greater. This recommendation is supported by an updated evidence review including 22 randomized clinical trials (RCTs), which demonstrated that statin use in this population reduces all-cause mortality, fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, revascularization, and composite cardiovascular outcomes.\n\nFor adults older than 75 years without clinical ASCVD, evidence is insufficient to make a broad recommendation, and guidelines suggest an individualized approach to statin therapy. Safety data from 19 RCTs and 3 large cohort studies indicate acceptable harm profiles in the indicated populations.\n\nKey points:\n- Population: Adults 40-75 years without ASCVD but with ≥1 risk factor and ≥10% 10-year ASCVD risk.\n- Statin intensity: Low- to moderate-dose statins are recommended (per 2016 USPSTF; the 2022 update supports these recommendations).\n- Efficacy: Statins reduce all-cause mortality, myocardial infarction, stroke, revascularization, and composite cardiovascular events.\n- Older adults (>75 years): Individualized decision-making recommended due to limited data.\n- Safety: Harms assessed across multiple RCTs and cohorts show acceptable safety.\n- No specific resistance markers reported or relevant to statin therapy.\n\nClinical trials referenced include a total of 22 RCTs informing efficacy, with 3 additional trials added in the 2022 update. The recommendations emphasize primary prevention in patients without symptomatic coronary artery disease or ischemic stroke.\n\nNo specific drug dosages beyond low- to moderate-intensity statins are detailed in the summary data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3876
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Statin therapy guidelines for patients with high LDL-C without ASCVD are as follows:\n\n1. **LDL-C ≥190 mg/dL (≥4.9 mmol/L) without ASCVD:**  \n   - Initiate **high-intensity statin therapy** (Class I recommendation).  \n   - Alternatively, moderate-intensity statin plus ezetimibe can be used if high-intensity statin is not tolerated.  \n   - LDL-C goal is <100 mg/dL; if not achieved on maximally tolerated statin plus ezetimibe, consider adding a **PCSK9 inhibitor** in selected higher-risk patients.  \n   - This is supported by 2018 ACC/AHA guidelines and Cholesterol Treatment Trialists data showing consistent relative risk reduction per 39 mg/dL LDL-C reduction regardless of baseline LDL-C.\n\n2. **LDL-C 70-189 mg/dL without diabetes (age 40-75 years) and intermediate ASCVD risk:**  \n   - Moderate-intensity statin therapy is recommended based on high-quality RCT evidence.  \n   - For patients aged 40-75 with LDL-C 70-189 mg/dL and 10-year ASCVD risk of 7.5%-19.9%, obtaining a coronary artery calcium (CAC) score is reasonable if statin decision is uncertain.  \n   - This is supported by ACC/AHA and AAFP guidelines.\n\n3. **Very high-risk patients:**  \n   - Consider addition of **PCSK9 inhibitors** if LDL-C remains ≥70 mg/dL (or non-HDL-C >100 mg/dL) despite maximally tolerated statin plus ezetimibe.\n\n4. **Risk enhancers to consider in therapy decisions:**  \n   - Family history of premature ASCVD  \n   - Persistently elevated LDL-C ≥160 mg/dL  \n   - Chronic kidney disease, metabolic syndrome  \n   - Conditions specific to women (preeclampsia, premature menopause)  \n   - Inflammatory diseases (rheumatoid arthritis, psoriasis, HIV)  \n   - South Asian ancestry  \n   - Elevated triglycerides (≥175 mg/dL)  \n   - Biomarkers if available: hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL or >125 nmol/L, apoB ≥130 mg/dL, ABI <0.9\n\n5. **Age considerations:**  \n   - Adults aged 20-39 with LDL-C ≥190 mg/dL should be evaluated clinically for statin initiation.  \n   - In diabetes patients aged 40-75, moderate-intensity statin is recommended; high-intensity statin may be considered based on risk assessment.\n\n6. **Safety and adverse events:**  \n   - Guidelines emphasize maximally tolerated statin therapy; adverse event rates are not detailed in the summary but imply monitoring and adjustment based on tolerance.\n\n7. **Additional recommendations:**  \n   - USPSTF recommends low- to moderate-dose statins for adults aged 40-75 without CVD but with ≥10% 10-year risk and one or more risk factors (dyslipidemia, diabetes, hypertension, smoking).\n\n**Key clinical trials and guideline references:**  \n- 2018 ACC/AHA Cholesterol Guideline  \n- Cholesterol Treatment Trialists meta-analyses  \n- USPSTF 2016 and updated recommendations  \n- AAFP 2019 guideline summary  \n\n**Summary:** High-intensity statin therapy is the cornerstone for LDL-C ≥190 mg/dL patients without ASCVD; moderate-intensity statins are recommended for LDL-C 70-189 mg/dL with intermediate risk. PCSK9 inhibitors are reserved for very high-risk patients not achieving LDL-C goals on statins plus ezetimibe. Risk enhancers and biomarkers guide personalized therapy.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5909
                },
                "additional_info_type": "Others",
                "additional_info": ""
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": true
      },
      "execution_time": 109.1141300201416,
      "error_message": null
    },
    {
      "log_id": "log_1762672587202_tissue_gut_gut",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:16:27.203054",
      "level": 2,
      "level_name": "组织层",
      "agent_id": "tissue_gut_gut",
      "agent_name": "tissue",
      "agent_type": "tissue",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "organ",
          "output_data": {
            "round1_analysis": "# Organ Status Report: gut\n- **General State:** The gut is processing Simvastatin, with enzyme activity reflecting genetic influences on drug metabolism.\n- **Key Drug Observations:**\n  - Simvastatin is undergoing first-pass metabolism, affecting its bioavailability.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin.\n- **Key Bio-Signals Emitted:**\n  - Increased CYP3A4 enzyme activity detected, indicating enhanced or altered drug metabolism.\n  - Emission of stress signals related to potential statin-induced myopathy risk due to genetic factors.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Organ Status Report: gut\n- **General State:** The gut is processing Simvastatin, with enzyme activity reflecting genetic influences on drug metabolism.\n- **Key Drug Observations:**\n  - Simvastatin is undergoing first-pass metabolism, affecting its bioavailability.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin.\n- **Key Bio-Signals Emitted:**\n  - Increased CYP3A4 enzyme activity detected, indicating enhanced or altered drug metabolism.\n  - Emission of stress signals related to potential statin-induced myopathy risk due to genetic factors.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [
                  "What are the implications of SLCO1B1 polymorphisms on statin metabolism and risk of myopathy?",
                  "What are the current guidelines for statin therapy in patients with high LDL-C and no ASCVD?"
                ],
                "tool_result": "- **Tool Name:** tavily_search  \n  **Summary:** SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly alter the transport activity of the hepatic OATP1B1 transporter. These variants are strongly associated with statin-induced myopathy, statin intolerance, and adverse drug reactions (ADRs).  \n  **Key Findings:**  \n  - **Genes:** SLCO1B1 (variants rs4149056, rs2306283)  \n  - **Drugs:** Simvastatin  \n  - **Clinical Trials:** SEARCH trial (NCT identifier not specified)  \n  - **Quantitative Information:** Genomewide significant association with myopathy, higher risk of statin-induced muscle toxicity in carriers of these polymorphisms.  \n  - **Dosing Algorithms:** Testing for SLCO1B1 polymorphisms can guide statin therapy to minimize myopathy risk, especially when prescribing high-dose simvastatin.  \n  - **Additional Notes:** No resistance markers noted. Importance of genotype-guided dosing to reduce statin intolerance and muscle toxicity emphasized.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Statins are primarily metabolized in the liver by the enzyme CYP3A4 and subsequently excreted. Genetic polymorphisms in statin-metabolizing enzymes and transport proteins significantly influence individual variability in statin metabolism, therapeutic efficacy, and adverse effects.  \n  **Key Findings:**  \n  - **Genes:** CYP3A4  \n  - **Drugs:** Statins  \n  - **Additional Notes:** Personalized therapy targeting metabolic enzymes, transporters, transcription factors, and epigenetic regulators is emphasized. Age-related pharmacokinetic changes notably affect statin clearance.\n\n- **Tool Name:** tavily_search  \n  **Summary:** SLCO1B1 polymorphisms, particularly the *5 allele (rs4149056, c.521T>C), significantly impact statin metabolism and the risk of statin-induced myopathy.  \n  **Key Findings:**  \n  - **Genes:** SLCO1B1 (*5 allele, rs4149056)  \n  - **Drugs:** Simvastatin  \n  - **Clinical Trials:** SEARCH genomewide association study, Heart Protection Study (n=18,000 on 40 mg simvastatin)  \n  - **Quantitative Information:** LDL-C reductions (C/C: 44 ± 25 mg/dL, T/C: 55 ± 19 mg/dL, T/T: 57 ± 22 mg/dL; P=0.038 and P=0.008 without multiple testing correction).  \n  - **Dosing Algorithms:** Genotyping for SLCO1B1 variants is advised to personalize therapy.  \n  - **Safety/Adverse Events:** Increased incidence of statin-induced myopathy and CK elevations >3× upper limit of normal in *SLCO1B1* *5* allele carriers.\n\n- **Tool Name:** get_general_info_by_disease_name  \n  **Summary:** Statin-induced myopathy (MONDO_0009722) is associated with multiple gene targets.  \n  **Key Findings:**  \n  - **Genes:** STAC3, HMGCR, RPL17, UCN2, ATP6V0A4, INSR, PDCD1, PCSK9, CALM1, CALM2, CALM3  \n  - **Additional Notes:** No specific drugs or treatment regimens identified. Key phenotypic features linked to statin-induced myopathy detailed.\n\n- **Tool Name:** tavily_search  \n  **Summary:** SLCO1B1 polymorphisms, particularly the SLCO1B1*5 variant (rs4149056), significantly increase the risk of statin-induced myopathy.  \n  **Key Findings:**  \n  - **Genes:** SLCO1B1 (*5 allele, rs4149056), CYP3A4  \n  - **Drugs:** Simvastatin  \n  - **Clinical Trials:** Heart Protection Study (18,000 participants on 40 mg simvastatin)  \n  - **Quantitative Information:** CK levels (>3× upper limit of normal), mild statin-induced muscle side effects associated with female sex and SLCO1B1*5.  \n  - **Dosing Algorithms:** Genotyping for SLCO1B1 is suggested to guide statin choice and dosing.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Current guidelines recommend statin therapy primarily for adults aged 40 to 75 years with cardiovascular disease (CVD) risk factors.  \n  **Key Findings:**  \n  - **Drugs:** Statins  \n  - **Additional Notes:** Moderate-intensity statin therapy indicated for primary prevention in patients aged 40-75 with diabetes. Statin therapy is considered for adults with one or more CVD risk factors and a calculated 10-year ASCVD risk ≥5%.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Management of high LDL-C involves lifestyle modifications and pharmacologic therapy primarily with statins.  \n  **Key Findings:**  \n  - **Drugs:** Statins, Ezetimibe, PCSK9 inhibitors  \n  - **Quantitative Information:** LDL-C thresholds (≥70 mg/dL, >190 mg/dL), relative risk reduction per 39 mg/dL LDL-C lowering.  \n  - **Dosing Algorithms:** High-intensity statin therapy or moderate-intensity plus ezetimibe recommended for severe primary hypercholesterolemia.  \n  - **Additional Notes:** Safety/adverse event data on PCSK9 inhibitors not detailed.\n\n- **Tool Name:** tavily_search  \n  **Summary:** The 2022 USPSTF recommendation on statin therapy for primary prevention of ASCVD in adults without cardiovascular disease updates the 2016 guideline.  \n  **Key Findings:**  \n  - **Drugs:** Statins  \n  - **Quantitative Information:** 10-year ASCVD risk of 10% or greater is a threshold for statin therapy.  \n  - **Clinical Trials:** 22 randomized clinical trials (RCTs) informing efficacy, with 3 additional trials added in the 2022 update.  \n  - **Dosing Algorithms:** Low- to moderate-dose statins recommended for specified populations.\n\n- **Tool Name:** tavily_search  \n  **Summary:** Statin therapy guidelines for patients with high LDL-C without ASCVD are as follows:  \n  **Key Findings:**  \n  - **Drugs:** Statins, Ezetimibe, PCSK9 inhibitors  \n  - **Quantitative Information:** LDL-C thresholds (≥190 mg/dL, 70-189 mg/dL), adverse event rates not detailed.  \n  - **Dosing Algorithms:** High-intensity statin therapy recommended for LDL-C ≥190 mg/dL; moderate-intensity statin therapy recommended for LDL-C 70-189 mg/dL.  \n  - **Clinical Guidelines:** 2018 ACC/AHA guidelines, Cholesterol Treatment Trialists data, USPSTF recommendations.  \n  - **Additional Notes:** Risk enhancers and biomarkers guide personalized therapy.",
                "raw_tool_results": [
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly alter the transport activity of the hepatic OATP1B1 transporter. These variants are strongly associated with statin-induced myopathy, statin intolerance, and adverse drug reactions (ADRs). \n\nKey findings include:  \n- The SEARCH trial (NCT identifier not specified) demonstrated a genomewide significant association between SLCO1B1 rs4149056 and an increased risk of myopathy in patients on high-dose simvastatin, highlighting a genetic predisposition to statin-induced muscle toxicity.  \n- Meta-analyses confirm that carriers of these polymorphisms have a higher risk of statin-related myopathy and myalgia.  \n- SLCO1B1 variants also contribute to milder forms of statin intolerance, though prospective data remain limited.  \n- Allele and haplotype frequencies (e.g., *SLCO1B1* *1a*, *1b*, *5*, *15*) vary by population; for example, a study of 1,205 healthy Thai individuals showed distribution of these variants across regions, relevant for pharmacogenomic considerations.  \n\nClinically, testing for SLCO1B1 polymorphisms can guide statin therapy to minimize myopathy risk, especially when prescribing simvastatin at high doses. The presence of rs4149056 in particular predicts reduced OATP1B1 function, leading to higher systemic statin exposure and increased adverse effects.\n\nNo resistance markers beyond these genetic variants were noted. Safety data emphasize the importance of genotype-guided dosing to reduce statin intolerance and muscle toxicity.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4045
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Statins are primarily metabolized in the liver by the enzyme CYP3A4 and subsequently excreted. Genetic polymorphisms in statin-metabolizing enzymes and transport proteins significantly influence individual variability in statin metabolism, therapeutic efficacy, and adverse effects. Age-related pharmacokinetic changes notably affect liver extraction, metabolism, and excretion of statins, impacting their clearance. Statins lower cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Personalized statin therapy targeting metabolic enzymes, transporters, transcription factors, and epigenetic regulators holds promise for optimizing therapeutic outcomes and minimizing adverse reactions. Additionally, statins may blunt the beneficial effects of aerobic exercise on cardiorespiratory fitness due to their impact on muscle metabolism.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 3235
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly the *5 allele (rs4149056, c.521T>C), significantly impact statin metabolism and the risk of statin-induced myopathy. The *5 allele reduces statin clearance, notably simvastatin, leading to increased risk of myopathy characterized by muscle symptoms and elevated creatine kinase (CK) >3× upper limit of normal. A composite adverse event (CAE), including discontinuation due to side effects or myalgia, is more frequent in carriers of ≥1 *SLCO1B1* *5* allele.\n\nKey clinical findings include:\n\n- The SEARCH genomewide association study identified *SLCO1B1* variants as strongly associated with simvastatin-induced myopathy, especially at high doses.\n- In the Heart Protection Study (n=18,000 on 40 mg simvastatin), *SLCO1B1* genotype had a minimal effect (~1% per C allele) on LDL-C reduction and no significant impact on vascular outcomes.\n- A candidate-gene study showed that *SLCO1B1* 521C allele influenced cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks in white patients, with LDL-C reductions of 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T); total cholesterol reductions were 43 ± 27, 57 ± 21, and 60 ± 24 mg/dL respectively (P=0.038 and P=0.008 without multiple testing correction).\n- Clinical implementation of *SLCO1B1* genotyping to guide simvastatin therapy has shown noninferior lipid-lowering outcomes and reduced statin-associated muscle symptoms by avoiding simvastatin prescription in patients with decreased or poor OATP1B1 function phenotypes.\n\nRecommendations:\n\n- Genotyping for *SLCO1B1* variants, especially the *5 allele, is advised to personalize statin therapy, minimize myopathy risk, and improve adherence.\n- Physicians should consider alternative statins or dose adjustments in patients with at-risk genotypes.\n- Despite effects on statin pharmacokinetics and myopathy risk, *SLCO1B1* polymorphisms have limited influence on overall statin efficacy and vascular outcomes.\n\nSafety/Adverse Events:\n\n- Increased incidence of statin-induced myopathy and CK elevations >3× upper limit of normal in *SLCO1B1* *5* allele carriers.\n- Genotype-guided therapy reduces muscle symptoms without compromising lipid-lowering efficacy.\n\nNo specific resistance markers beyond the *SLCO1B1* polymorphisms were reported.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5948
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_disease_name",
                    "toolsuite": "opentargets",
                    "success": true,
                    "sse_summary": "Statin-induced myopathy (MONDO_0009722) is associated with multiple gene targets, with the highest relevance score for STAC3 (0.7858), followed by HMGCR (0.0193), RPL17 (0.0137), and others including UCN2, ATP6V0A4, INSR, PDCD1, PCSK9, and several calmodulin genes (CALM1, CALM2, CALM3). No specific drugs or treatment regimens were identified.\n\nKey phenotypic features linked to statin-induced myopathy include:  \n- Musculoskeletal and developmental abnormalities such as hypotonia, proximal muscle weakness, motor delay, fatty replacement of skeletal muscle, increased intramyocellular lipid droplets, and myopathic facies.  \n- Craniofacial abnormalities including short palpebral fissures, blepharophimosis, ptosis, micrognathia, microcephaly, brachycephaly, low-set ears, downslanted palpebral fissures, downturned corners of the mouth.  \n- Growth and structural defects such as short stature, scoliosis, and congenital onset.  \n- Respiratory involvement characterized by restrictive ventilatory defect and hypoxemia.  \n- Neuromuscular signs including Gowers sign and weakness of facial musculature.  \n- Other congenital anomalies such as cryptorchidism and bilateral talipes equinovarus.\n\nNo clinical trial data, drug dosages, efficacy statistics, safety/adverse event rates, or resistance markers were reported in this output.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 12823
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly the SLCO1B1*5 variant (rs4149056), significantly increase the risk of statin-induced myopathy, especially with simvastatin. Evidence from the large Heart Protection Study (18,000 participants on 40 mg simvastatin) showed that the SLCO1B1 genotype has at most a small effect (~1% per C allele) on LDL cholesterol reduction and no significant impact on vascular outcomes. The SLCO1B1*5 allele impairs statin clearance, leading to elevated creatine kinase (CK) levels (>3× upper limit of normal) and higher rates of muscle side effects, including myalgia and statin discontinuation due to adverse events. Female sex and the SLCO1B1*5 allele are associated with increased mild statin-induced muscle side effects.\n\nGenotyping for SLCO1B1 is suggested to guide statin choice and dosing to reduce myopathy risk and improve adherence. Ethnic variation in the frequency of the rs4149056 variant exists, with Amerindians in the Brazilian population identified as a high-risk group. Other candidate genes (e.g., CYP3A4) have been studied but lack convincing statistical associations compared to SLCO1B1.\n\nIn summary, SLCO1B1 genotyping, especially for the rs4149056 (SLCO1B1*5) variant, is clinically relevant for managing simvastatin therapy to mitigate myopathy risk without significantly affecting lipid-lowering efficacy.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5443
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Current guidelines recommend statin therapy primarily for adults aged 40 to 75 years with cardiovascular disease (CVD) risk factors. Specifically:\n\n- Moderate-intensity statin therapy is indicated for primary prevention in patients aged 40-75 with diabetes (2019 ACC/AHA Guideline).\n- Statin therapy should be considered for adults aged 40-75 who have one or more CVD risk factors (hypertension, dyslipidemia, diabetes, smoking) and a calculated 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥5% (ACC guidelines).\n- The USPSTF recommends prescribing statins for primary prevention in adults 40-75 years with one or more CVD risk factors.\n- Guidelines emphasize assessing risk-enhancing factors in adults 40-75 to guide statin initiation decisions.\n- The Pooled Cohort Equations (PCE) predicted 10-year risk ≥5% is a key threshold for considering statin therapy.\n\nKey points:\n\n- Age group: 40-75 years\n- Indications: diabetes, hypertension, dyslipidemia, smoking, other CVD risk factors\n- Risk threshold: ≥5% 10-year ASCVD risk (PCE)\n- Statin intensity: moderate-intensity recommended for primary prevention in diabetes and others meeting criteria\n\nNo specific drug names, dosages, adverse event rates, or resistance markers were detailed in the provided data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 2709
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Management of high LDL-C involves lifestyle modifications and pharmacologic therapy primarily with statins. According to the 2018 guidelines (NHLBI/ACC):\n\n- For patients at very high risk of atherosclerotic cardiovascular disease (ASCVD) with LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe, PCSK9 inhibitors are recommended as add-on therapy.\n- In severe primary hypercholesterolemia (LDL-C >190 mg/dL [>4.9 mmol/L]) without ASCVD, initiate high-intensity statin therapy or moderate-intensity statin plus ezetimibe aiming for LDL-C <100 mg/dL; if this target is unmet, consider adding PCSK9 inhibitors in selected high-risk patients.\n- The Cholesterol Treatment Trialists meta-analysis showed a consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C lowering, regardless of baseline LDL-C.\n- Diabetes-specific risk enhancers (e.g., long duration ≥10 years for type 2 diabetes, albuminuria ≥30 mcg/mg creatinine, eGFR <60 ml/min/1.73 m², retinopathy, neuropathy, ABI <0.9) and other ASCVD risk enhancers (family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory diseases like rheumatoid arthritis, psoriasis, HIV, and certain ethnicities such as South Asian ancestry) guide treatment intensification.\n- Lipid and biomarker risk enhancers include persistently elevated triglycerides ≥175 mg/dL, hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL (>125 nmol/L), and apoB ≥130 mg/dL.\n- Lifestyle recommendations emphasize reducing saturated and trans fats, weight loss of 5-10%, and a heart-healthy diet rich in plant-based foods.\n- Safety/adverse event data on PCSK9 inhibitors were not detailed in the sources, but their use is reserved for high-risk patients not at goal despite statins and ezetimibe.\n\nIn summary, management prioritizes high-intensity statins +/- ezetimibe, with PCSK9 inhibitors added for persistent LDL-C elevation in very high-risk individuals, supported by comprehensive risk assessment including diabetes-specific and other risk enhancers.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5954
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "The 2022 USPSTF recommendation on statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults without cardiovascular disease updates and largely aligns with the 2016 guideline. Statin therapy is recommended for adults aged 40 to 75 years who have one or more cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year ASCVD risk of 10% or greater. This recommendation is supported by an updated evidence review including 22 randomized clinical trials (RCTs), which demonstrated that statin use in this population reduces all-cause mortality, fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, revascularization, and composite cardiovascular outcomes.\n\nFor adults older than 75 years without clinical ASCVD, evidence is insufficient to make a broad recommendation, and guidelines suggest an individualized approach to statin therapy. Safety data from 19 RCTs and 3 large cohort studies indicate acceptable harm profiles in the indicated populations.\n\nKey points:\n- Population: Adults 40-75 years without ASCVD but with ≥1 risk factor and ≥10% 10-year ASCVD risk.\n- Statin intensity: Low- to moderate-dose statins are recommended (per 2016 USPSTF; the 2022 update supports these recommendations).\n- Efficacy: Statins reduce all-cause mortality, myocardial infarction, stroke, revascularization, and composite cardiovascular events.\n- Older adults (>75 years): Individualized decision-making recommended due to limited data.\n- Safety: Harms assessed across multiple RCTs and cohorts show acceptable safety.\n- No specific resistance markers reported or relevant to statin therapy.\n\nClinical trials referenced include a total of 22 RCTs informing efficacy, with 3 additional trials added in the 2022 update. The recommendations emphasize primary prevention in patients without symptomatic coronary artery disease or ischemic stroke.\n\nNo specific drug dosages beyond low- to moderate-intensity statins are detailed in the summary data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 3876
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Statin therapy guidelines for patients with high LDL-C without ASCVD are as follows:\n\n1. **LDL-C ≥190 mg/dL (≥4.9 mmol/L) without ASCVD:**  \n   - Initiate **high-intensity statin therapy** (Class I recommendation).  \n   - Alternatively, moderate-intensity statin plus ezetimibe can be used if high-intensity statin is not tolerated.  \n   - LDL-C goal is <100 mg/dL; if not achieved on maximally tolerated statin plus ezetimibe, consider adding a **PCSK9 inhibitor** in selected higher-risk patients.  \n   - This is supported by 2018 ACC/AHA guidelines and Cholesterol Treatment Trialists data showing consistent relative risk reduction per 39 mg/dL LDL-C reduction regardless of baseline LDL-C.\n\n2. **LDL-C 70-189 mg/dL without diabetes (age 40-75 years) and intermediate ASCVD risk:**  \n   - Moderate-intensity statin therapy is recommended based on high-quality RCT evidence.  \n   - For patients aged 40-75 with LDL-C 70-189 mg/dL and 10-year ASCVD risk of 7.5%-19.9%, obtaining a coronary artery calcium (CAC) score is reasonable if statin decision is uncertain.  \n   - This is supported by ACC/AHA and AAFP guidelines.\n\n3. **Very high-risk patients:**  \n   - Consider addition of **PCSK9 inhibitors** if LDL-C remains ≥70 mg/dL (or non-HDL-C >100 mg/dL) despite maximally tolerated statin plus ezetimibe.\n\n4. **Risk enhancers to consider in therapy decisions:**  \n   - Family history of premature ASCVD  \n   - Persistently elevated LDL-C ≥160 mg/dL  \n   - Chronic kidney disease, metabolic syndrome  \n   - Conditions specific to women (preeclampsia, premature menopause)  \n   - Inflammatory diseases (rheumatoid arthritis, psoriasis, HIV)  \n   - South Asian ancestry  \n   - Elevated triglycerides (≥175 mg/dL)  \n   - Biomarkers if available: hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL or >125 nmol/L, apoB ≥130 mg/dL, ABI <0.9\n\n5. **Age considerations:**  \n   - Adults aged 20-39 with LDL-C ≥190 mg/dL should be evaluated clinically for statin initiation.  \n   - In diabetes patients aged 40-75, moderate-intensity statin is recommended; high-intensity statin may be considered based on risk assessment.\n\n6. **Safety and adverse events:**  \n   - Guidelines emphasize maximally tolerated statin therapy; adverse event rates are not detailed in the summary but imply monitoring and adjustment based on tolerance.\n\n7. **Additional recommendations:**  \n   - USPSTF recommends low- to moderate-dose statins for adults aged 40-75 without CVD but with ≥10% 10-year risk and one or more risk factors (dyslipidemia, diabetes, hypertension, smoking).\n\n**Key clinical trials and guideline references:**  \n- 2018 ACC/AHA Cholesterol Guideline  \n- Cholesterol Treatment Trialists meta-analyses  \n- USPSTF 2016 and updated recommendations  \n- AAFP 2019 guideline summary  \n\n**Summary:** High-intensity statin therapy is the cornerstone for LDL-C ≥190 mg/dL patients without ASCVD; moderate-intensity statins are recommended for LDL-C 70-189 mg/dL with intermediate risk. PCSK9 inhibitors are reserved for very high-risk patients not achieving LDL-C goals on statins plus ezetimibe. Risk enhancers and biomarkers guide personalized therapy.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5909
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  }
                ]
              }
            }
          }
        },
        "agent_properties": {
          "organ_name": "gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Tissue Status Report: gut\n- **General State:** The gut is processing Simvastatin with enzyme activity reflecting genetic influences on drug metabolism, indicating a complex interaction between drug and tissue. \n- **Key Drug Observations:**\n  - Simvastatin undergoes first-pass metabolism, which affects its bioavailability and therapeutic efficacy.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin, increasing the risk of adverse effects.\n  - Elevated CYP3A4 enzyme activity suggests altered drug metabolism, potentially leading to enhanced systemic exposure.\n- **Cellular Impact:**\n  - Increased stress signals related to potential statin-induced myopathy risk due to genetic factors.\n  - Evidence of cellular damage linked to altered metabolism and potential muscle toxicity.\n  - Activation of repair mechanisms may be occurring but could be insufficient to counteract the stress induced by Simvastatin.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Tissue Status Report: gut\n- **General State:** The gut is processing Simvastatin with enzyme activity reflecting genetic influences on drug metabolism, indicating a complex interaction between drug and tissue. \n- **Key Drug Observations:**\n  - Simvastatin undergoes first-pass metabolism, which affects its bioavailability and therapeutic efficacy.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin, increasing the risk of adverse effects.\n  - Elevated CYP3A4 enzyme activity suggests altered drug metabolism, potentially leading to enhanced systemic exposure.\n- **Cellular Impact:**\n  - Increased stress signals related to potential statin-induced myopathy risk due to genetic factors.\n  - Evidence of cellular damage linked to altered metabolism and potential muscle toxicity.\n  - Activation of repair mechanisms may be occurring but could be insufficient to counteract the stress induced by Simvastatin.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 5.940732955932617,
      "error_message": null
    },
    {
      "log_id": "log_1762672595478_cell_gut_cell_gut",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:16:35.478222",
      "level": 3,
      "level_name": "细胞层",
      "agent_id": "cell_gut_cell_gut",
      "agent_name": "cell",
      "agent_type": "cell",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "tissue",
          "output_data": {
            "round1_analysis": "# Tissue Status Report: gut\n- **General State:** The gut is processing Simvastatin with enzyme activity reflecting genetic influences on drug metabolism, indicating a complex interaction between drug and tissue. \n- **Key Drug Observations:**\n  - Simvastatin undergoes first-pass metabolism, which affects its bioavailability and therapeutic efficacy.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin, increasing the risk of adverse effects.\n  - Elevated CYP3A4 enzyme activity suggests altered drug metabolism, potentially leading to enhanced systemic exposure.\n- **Cellular Impact:**\n  - Increased stress signals related to potential statin-induced myopathy risk due to genetic factors.\n  - Evidence of cellular damage linked to altered metabolism and potential muscle toxicity.\n  - Activation of repair mechanisms may be occurring but could be insufficient to counteract the stress induced by Simvastatin.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Tissue Status Report: gut\n- **General State:** The gut is processing Simvastatin with enzyme activity reflecting genetic influences on drug metabolism, indicating a complex interaction between drug and tissue. \n- **Key Drug Observations:**\n  - Simvastatin undergoes first-pass metabolism, which affects its bioavailability and therapeutic efficacy.\n  - Genetic variations in SLCO1B1 are likely impacting the transport and efficacy of Simvastatin, increasing the risk of adverse effects.\n  - Elevated CYP3A4 enzyme activity suggests altered drug metabolism, potentially leading to enhanced systemic exposure.\n- **Cellular Impact:**\n  - Increased stress signals related to potential statin-induced myopathy risk due to genetic factors.\n  - Evidence of cellular damage linked to altered metabolism and potential muscle toxicity.\n  - Activation of repair mechanisms may be occurring but could be insufficient to counteract the stress induced by Simvastatin.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "tissue_name": "gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 8.274374961853027,
      "error_message": null
    },
    {
      "log_id": "log_1762672603320_target_gut_HMGCR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:16:43.320557",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_gut_HMGCR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: HMGCR\n- **General State:** HMGCR is actively targeted by statins, leading to reduced cholesterol synthesis and lower LDL-C levels.\n- **Key Drug Observations:**\n  - Statins competitively inhibit HMGCR activity, resulting in decreased cholesterol production.\n  - Enhanced expression of LDL receptors in the liver increases clearance of LDL from circulation.\n  - Statin therapy is linked with a reduction in cardiovascular risk factors in hypercholesterolemic patients.\n- **Binding Characteristics:**\n  - Statins exhibit high binding affinity to the HMGCR active site, effectively blocking substrate access.\n  - The inhibition is reversible and concentration-dependent.\n  - Variations in SLCO1B1 may affect statin pharmacokinetics and efficacy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: HMGCR\n- **General State:** HMGCR is actively targeted by statins, leading to reduced cholesterol synthesis and lower LDL-C levels.\n- **Key Drug Observations:**\n  - Statins competitively inhibit HMGCR activity, resulting in decreased cholesterol production.\n  - Enhanced expression of LDL receptors in the liver increases clearance of LDL from circulation.\n  - Statin therapy is linked with a reduction in cardiovascular risk factors in hypercholesterolemic patients.\n- **Binding Characteristics:**\n  - Statins exhibit high binding affinity to the HMGCR active site, effectively blocking substrate access.\n  - The inhibition is reversible and concentration-dependent.\n  - Variations in SLCO1B1 may affect statin pharmacokinetics and efficacy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.354297876358032,
      "error_message": null
    },
    {
      "log_id": "log_1762672610676_target_gut_SLCO1B1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:16:50.676191",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_gut_SLCO1B1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning optimally for statin transport, facilitating effective drug uptake in the liver. \n- **Key Drug Observations:**\n  - Simvastatin enhances SLCO1B1-mediated uptake, leading to increased efficacy in lowering lipid levels.\n  - The interaction may influence the pharmacokinetics, necessitating monitoring of drug levels and effects.\n  - Patients with SLCO1B1 polymorphisms may experience altered responses to simvastatin.\n- **Binding Characteristics:**\n  - Strong affinity of simvastatin for SLCO1B1, promoting effective hepatic uptake.\n  - Competitive inhibition potential with other substrates of SLCO1B1 may affect overall drug metabolism.\n  - Variability in binding efficiency among different patient genotypes may influence therapeutic outcomes.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning optimally for statin transport, facilitating effective drug uptake in the liver. \n- **Key Drug Observations:**\n  - Simvastatin enhances SLCO1B1-mediated uptake, leading to increased efficacy in lowering lipid levels.\n  - The interaction may influence the pharmacokinetics, necessitating monitoring of drug levels and effects.\n  - Patients with SLCO1B1 polymorphisms may experience altered responses to simvastatin.\n- **Binding Characteristics:**\n  - Strong affinity of simvastatin for SLCO1B1, promoting effective hepatic uptake.\n  - Competitive inhibition potential with other substrates of SLCO1B1 may affect overall drug metabolism.\n  - Variability in binding efficiency among different patient genotypes may influence therapeutic outcomes.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 7.355279922485352,
      "error_message": null
    },
    {
      "log_id": "log_1762672615249_target_gut_LDLR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:16:55.249503",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_gut_LDLR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: LDLR\n- **General State:** The LDLR is upregulated in response to statin treatment, which effectively lowers serum LDL cholesterol levels.\n- **Key Drug Observations:**\n  - Simvastatin enhances LDLR expression, promoting LDL clearance.\n  - The drug effectively reduces LDL-C levels, contributing to the management of hypercholesterolemia.\n  - Patient's risk of cardiovascular events may be reduced due to lower LDL-C levels.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to increased LDLR synthesis.\n  - The binding of simvastatin is reversible and depends on the statin concentration.\n  - Statins demonstrate a strong affinity for the target enzyme, enhancing their efficacy in cholesterol management.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: LDLR\n- **General State:** The LDLR is upregulated in response to statin treatment, which effectively lowers serum LDL cholesterol levels.\n- **Key Drug Observations:**\n  - Simvastatin enhances LDLR expression, promoting LDL clearance.\n  - The drug effectively reduces LDL-C levels, contributing to the management of hypercholesterolemia.\n  - Patient's risk of cardiovascular events may be reduced due to lower LDL-C levels.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to increased LDLR synthesis.\n  - The binding of simvastatin is reversible and depends on the statin concentration.\n  - Statins demonstrate a strong affinity for the target enzyme, enhancing their efficacy in cholesterol management.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.572983264923096,
      "error_message": null
    },
    {
      "log_id": "log_1762672621930_target_gut_ABCA1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:17:01.930574",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_gut_ABCA1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is involved in cholesterol efflux and reverse cholesterol transport, playing a critical role in lipid metabolism.\n- **Key Drug Observations:**\n  - Statins indirectly influence ABCA1 activity by lowering intracellular cholesterol levels, promoting cholesterol efflux.\n  - Enhanced activity of SLCO1B1 may improve statin efficacy in lowering LDL-C.\n- **Binding Characteristics:**\n  - Statins have high affinity for HMG-CoA reductase rather than direct binding to ABCA1.\n  - The interaction with SLCO1B1 can affect the pharmacokinetics of statins, impacting their therapeutic efficacy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is involved in cholesterol efflux and reverse cholesterol transport, playing a critical role in lipid metabolism.\n- **Key Drug Observations:**\n  - Statins indirectly influence ABCA1 activity by lowering intracellular cholesterol levels, promoting cholesterol efflux.\n  - Enhanced activity of SLCO1B1 may improve statin efficacy in lowering LDL-C.\n- **Binding Characteristics:**\n  - Statins have high affinity for HMG-CoA reductase rather than direct binding to ABCA1.\n  - The interaction with SLCO1B1 can affect the pharmacokinetics of statins, impacting their therapeutic efficacy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.680311679840088,
      "error_message": null
    },
    {
      "log_id": "log_1762672626898_target_gut_PCSK9",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:17:06.898577",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_gut_PCSK9",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_gut\n- **General State:** The cell is actively responding to statin treatment, effectively lowering cholesterol synthesis while maintaining viability.\n- **Key Drug Observations:**\n  - Statin administration leads to a significant decrease in intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors due to reduced plasma LDL-C levels.\n  - Potential compensatory mechanisms may activate to counteract lipid depletion.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity.\n  - Altered synthesis of isoprenoids affecting cell signaling pathways.\n  - Decreased levels of coenzyme Q10, which may impact mitochondrial function.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_gut"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is involved in the regulation of LDL receptor levels, impacting cholesterol metabolism.\n- **Key Drug Observations:**\n  - Statins lower LDL-C levels through HMG-CoA reductase inhibition.\n  - SLCO1B1 polymorphisms can influence statin efficacy and safety.\n  - PCSK9 inhibitors can further enhance LDL receptor recycling when combined with statins.\n- **Binding Characteristics:**\n  - Statins bind competitively to HMG-CoA reductase, inhibiting its activity.\n  - SLCO1B1 facilitates the uptake of statins into hepatocytes, influencing plasma levels.\n  - PCSK9 binding to LDL receptors leads to their degradation, affecting cholesterol homeostasis.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is involved in the regulation of LDL receptor levels, impacting cholesterol metabolism.\n- **Key Drug Observations:**\n  - Statins lower LDL-C levels through HMG-CoA reductase inhibition.\n  - SLCO1B1 polymorphisms can influence statin efficacy and safety.\n  - PCSK9 inhibitors can further enhance LDL receptor recycling when combined with statins.\n- **Binding Characteristics:**\n  - Statins bind competitively to HMG-CoA reductase, inhibiting its activity.\n  - SLCO1B1 facilitates the uptake of statins into hepatocytes, influencing plasma levels.\n  - PCSK9 binding to LDL receptors leads to their degradation, affecting cholesterol homeostasis.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.967385768890381,
      "error_message": null
    },
    {
      "log_id": "log_1762672699765_organ_liver",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:19.765093",
      "level": 1,
      "level_name": "器官层",
      "agent_id": "organ_liver",
      "agent_name": "organ",
      "agent_type": "organ",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "organ_flows": {
          "drug_flow": "Analysis of Statin + SLCO1B1 for Hypercholesterolemia",
          "bio_signals": "Patient baseline: 45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg",
          "literature_flow": "Starting literature review process"
        }
      },
      "output_data": {
        "round1_analysis": "# Organ Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants, particularly rs4149056 and SLCO1B1*5, are associated with increased exposure to simvastatin acid and a higher risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, which may impact muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted in relation to SLCO1B1 polymorphisms.\n- **Key Bio-Signals Emitted:**\n  - Stress signals related to potential muscle toxicity are being emitted, indicating a need for monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Organ Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants, particularly rs4149056 and SLCO1B1*5, are associated with increased exposure to simvastatin acid and a higher risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, which may impact muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted in relation to SLCO1B1 polymorphisms.\n- **Key Bio-Signals Emitted:**\n  - Stress signals related to potential muscle toxicity are being emitted, indicating a need for monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What are the common SLCO1B1 genetic variants and their impact on simvastatin metabolism?",
              "What is the relationship between high LDL-C levels and the risk of developing ASCVD in patients without prior history?"
            ],
            "tool_result": "- **Tool Result: tavily_search**\n  - **Gene Names:** SLCO1B1\n  - **Genetic Variants:** rs4149056, rs2306283\n  - **Drugs:** Statins\n  - **Quantitative Information:**\n    - ORmeta-analysis for risk haplotypes involving SLCO1B1 variants: 1.76 [95% CI 1.16, 2.69]\n    - ORmeta-analysis for Val174Ala variant: 1.99 [95% CI 1.01, 3.95]\n  - **Clinical Observations:**\n    - High-risk haplotypes associated with statin intolerance, myopathy, and rhabdomyolysis.\n    - Rare SLCO1B1 variants have a modest effect on statin intolerance.\n    - Deletions affecting SLCO1B1 and SLCO1B3 lead to no functional transporter protein.\n  - **Additional Information:** Genetic risk scoring using SLCO1B1 missense variants proposed for predicting statin intolerance risk.\n\n- **Tool Result: tavily_search**\n  - **Drug Names:** Simvastatin, simvastatin acid (SVA)\n  - **Gene Names:** SLCO1B1\n  - **Genetic Variants:** rs4149056 (c.521T>C)\n  - **Quantitative Information:**\n    - Approximately 40% of simvastatin delivered into the lung is converted into SVA.\n  - **Clinical Observations:**\n    - Genetic variation in SLCO1B1 significantly increases systemic exposure to simvastatin acid.\n    - In vitro studies show effects on glucose metabolism, mitochondrial respiration, and insulin signaling.\n  - **Key Conclusions/Recommendations:**\n    - Consider SLCO1B1 rs4149056 genotype for muscle toxicity risk assessment.\n    - Both lactone and acid forms of simvastatin affect muscle energy metabolism.\n  - **Additional Information:** No clinical trial identifiers or phase data reported.\n\n- **Tool Result: tavily_search**\n  - **Gene Names:** SLCO1B1\n  - **Genetic Variants:** SLCO1B1*5 (c.521T>C)\n  - **Quantitative Information:**\n    - Increased simvastatin acid exposure: approximately 40% (p < 0.05).\n    - Elevated creatine kinase (CK) levels >3× upper limit of normal.\n  - **Clinical Observations:**\n    - SLCO1B1*5 variant associated with statin-induced myopathy and adverse events.\n    - Female sex correlates with increased mild statin side effects.\n  - **Recommendations:** Lower simvastatin doses or alternative statins for patients with SLCO1B1 variants.\n  - **Additional Information:** Genome-wide association studies confirm the impact of SLCO1B1 and CYP3A4 variants.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - LDL-C targets: <70 mg/dL for high-risk individuals; <55 mg/dL for very high-risk patients.\n    - Approximately 70% of treated patients do not achieve LDL-C reductions.\n  - **Clinical Observations:**\n    - High LDL-C is a major risk factor for heart attacks and strokes.\n    - Lifestyle changes and medications are essential for LDL-C reduction.\n  - **Additional Information:** No specific clinical trial names or identifiers reported.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - ASCVD risk over 10 years categorized as intermediate (7.5% to 19.9%) or high (20% or more).\n  - **Clinical Observations:**\n    - Major risk factors: diabetes and elevated LDL-C levels.\n    - ASCVD risk calculators, such as the 2013 AHA/ACC ASCVD Risk Calculator, are used for estimating risk.\n  - **Additional Information:** No clinical trial names, identifiers, or drug regimens reported.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - Early exposure to elevated LDL-C increases future ASCVD risk.\n  - **Clinical Observations:**\n    - High LDL-C levels correlate with increased ASCVD risk.\n    - Maintaining low LDL-C levels is crucial for secondary prevention.\n  - **Additional Information:** No clinical trial names, study identifiers, or drug regimens reported.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - 10-year predicted ASCVD risk ≥7.5% significantly increases the risk of incident ASCVD.\n    - Family history of early-onset ASCVD increases risk by 22%.\n  - **Clinical Observations:**\n    - Individuals without coronary artery calcium (CAC) are generally at low risk for ASCVD events.\n  - **Additional Information:** Current guidelines, including ESC/EAS, are used for risk evaluation.",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "The most common SLCO1B1 genetic variants are rs4149056 and rs2306283, which affect the transport of statins into the liver and are linked to statin intolerance and myopathy. Meta-analyses, including the PREDICTION-ADR cohort and Tayside Bioresources, show that risk haplotypes involving SLCO1B1 variants produce a more precise and robust association with statin intolerance (ORmeta-analysis 1.76 [95% CI 1.16, 2.69]) than the Val174Ala variant alone (ORmeta-analysis 1.99 [95% CI 1.01, 3.95]). High-risk haplotypes are strongly associated with earlier onset of general statin intolerance, statin-induced myopathy, and rhabdomyolysis, especially in patients on high-dose statin therapy. Rare SLCO1B1 variants have a modest effect on statin intolerance but are currently not considered actionable due to limited evidence. The SLCO1B1 gene encodes the OATP1B1 protein responsible for hepatic uptake of statins; deletions affecting SLCO1B1 and SLCO1B3 result in no functional transporter protein, causing elevated systemic compound levels. Genetic risk scoring using multiple SLCO1B1 missense variants has been proposed as a practical tool to predict statin intolerance risk.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4730
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin is a prodrug metabolized into its active form, simvastatin acid (SVA), primarily via carboxylesterase (CES) and cytochrome P450 (CYP) enzymes. It acts by competitively inhibiting HMG-CoA reductase, thereby lowering LDL cholesterol and triglyceride levels, with proven benefits in coronary artery disease.\n\nGenetic variation in the SLCO1B1 gene, specifically the rs4149056 (c.521T>C) polymorphism, significantly increases systemic exposure to simvastatin acid and is a well-established risk factor for statin-induced muscle toxicity.\n\nIn vitro studies on primary human skeletal muscle cells show that both lactone- and acid-forms of simvastatin impair glucose metabolism, mitochondrial respiration, and insulin signaling, with differential effects observed between these forms. Simvastatin also promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells, evidenced by increased alkaline phosphatase activity and expression of osteopontin, BMP-2, and osteocalcin.\n\nPharmacokinetic studies demonstrate that about 40% of simvastatin delivered directly into the lung (via pMDI, DPI, or nebulized nanoparticle suspension) is converted intracellularly into its active metabolite SVA.\n\nIn animal models, simvastatin increases lipid droplet accumulation and improves skeletal muscle glucose uptake, particularly in mice overexpressing muscle PGC-1α, which also show increased expression of fatty acid transporter CD36, fatty acid binding protein 4, perilipin 5, and CPT1b.\n\nKey conclusions/recommendations:\n- SLCO1B1 rs4149056 genotype should be considered to assess risk for muscle toxicity during simvastatin therapy.\n- Both lactone and acid forms of simvastatin affect muscle energy metabolism and insulin signaling, which may contribute to adverse effects.\n- Simvastatin's active metabolite formation and intracellular conversion are significant for its pharmacological effects, including in lung delivery systems.\n\nNo clinical trial identifiers (NCT numbers) or phase data were reported in the provided information.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 6380
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 genetic variants, particularly the *SLCO1B1*5 allele (c.521T>C), significantly impact simvastatin metabolism by increasing simvastatin acid exposure by approximately 40% (p < 0.05) and overall simvastatin levels. This leads to a higher risk of statin-induced muscle side effects, including myopathy and myalgia, often evidenced by elevated creatine kinase (CK) levels (>3× upper limit of normal). The *SLCO1B1*5 variant is strongly associated with statin-induced myopathy and a composite adverse event (CAE) defined as discontinuation due to side effects, myalgia, or CK elevation. Female sex also correlates with increased mild statin side effects.\n\nPharmacogenetic guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC, 2022 update) recommend considering lower simvastatin doses or alternative statins for patients with these SLCO1B1 variants to mitigate muscle toxicity risk. Genome-wide association studies confirm that SLCO1B1 and CYP3A4 variants affect simvastatin pharmacokinetics, suggesting simvastatin may be best avoided in individuals carrying risk alleles.\n\nMetabolomic analyses identified 31 novel metabolites associated with the SLCO1B1 rs4149056-C variant in both simvastatin-treated and untreated participants, indicating altered metabolite profiles linked to this genetic variant.\n\nIn summary, SLCO1B1*5 carriers have increased simvastatin exposure and a higher incidence of muscle-related adverse events, supporting genotype-guided dosing adjustments to improve safety.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4861
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "High LDL-C (low-density lipoprotein cholesterol) is a major risk factor for heart attacks and strokes due to its role in cholesterol buildup in arteries. For individuals at high cardiovascular risk, guidelines recommend lowering LDL-C to below 70 mg/dL, with the American College of Cardiology advising an even lower target of below 55 mg/dL for those with a major cardiovascular event plus two or more high-risk conditions. \n\nDespite available lipid-lowering therapies, approximately 70% of treated patients do not achieve these guideline-recommended LDL-C reductions, leaving them at ongoing risk for serious cardiovascular events. Lifestyle changes combined with medications, including those targeting primary hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH), are essential for LDL-C reduction.\n\nKey points:\n- LDL-C targets: <70 mg/dL for high-risk individuals; <55 mg/dL for very high-risk patients (e.g., post-major cardiovascular event with multiple risk factors).\n- High LDL-C promotes atherosclerosis, increasing heart attack and stroke risk.\n- 70% of patients on lipid-lowering therapy fail to meet LDL-C goals.\n- Treatment includes diet, lifestyle changes, and cholesterol-lowering medications (e.g., statins, PCSK9 inhibitors such as Repatha).\n- Risk factors include family history, age, gender, and obesity.\n- Monitoring LDL-C levels via blood tests is critical for managing cardiovascular risk.\n\nNo specific clinical trial names, NCT numbers, or detailed adverse event rates were provided in the source content.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5486
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "The risk of developing atherosclerotic cardiovascular disease (ASCVD) over 10 years is categorized as intermediate (7.5% to 19.9%) or high (20% or more). Major risk factors include diabetes, which significantly enhances ASCVD risk by damaging arteries, and elevated cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C). ASCVD risk calculators, such as the 2013 AHA/ACC ASCVD Risk Calculator, estimate the 10-year risk of hard ASCVD events (myocardial infarction, stroke, or death due to coronary heart disease or stroke) in adults without known ASCVD and LDL levels between 70-189 mg/dL. These tools guide statin therapy decisions, balancing risk reduction against potential statin-related adverse effects, which are generally intensity-dependent. Additional biochemical and inflammatory markers associated with ASCVD risk include high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (Apo B), lipoprotein(a) [Lp(a)], high sensitivity C-reactive protein (Hs-CRP), and atherogenic indices. Adults with a predicted 10-year ASCVD risk ≥7.5% but without established risk factors still show high ASCVD incidence, highlighting the importance of comprehensive risk assessment.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4336
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "High LDL-C levels are strongly associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Epidemiologic studies confirm this association, and lowering LDL-C reduces ASCVD risk. Early exposure to elevated LDL-C confers a greater future ASCVD risk compared to later exposure. Maintaining low LDL-C levels is crucial, especially for secondary prevention in very high-risk ASCVD patients, to reduce cardiovascular event risk.\n\nAdditional lipid parameters such as very low-density lipoprotein cholesterol (VLDL-C) and lipid discordance also correlate with higher ASCVD risk and can be assessed via standard lipid panels to improve risk prediction.\n\nRegarding high-density lipoprotein cholesterol (HDL-C), a U-shaped relationship with all-cause mortality has been observed: both very low and extremely high HDL-C levels (>97 mg/dL in men, >116 mg/dL in women) are linked to increased risk. The European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines note ASCVD risk may increase when HDL-C exceeds 90 mg/dL (2.3 mmol/L). However, conclusions on very high HDL-C levels are limited by small sample sizes in studies.\n\nNo clinical trial names, study identifiers, drug regimens, or resistance markers were reported in the provided data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3130
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "ASCVD risk assessment is essential for primary prevention in patients without prior clinical ASCVD, severe hypercholesterolemia, or diabetes. Individuals without coronary artery calcium (CAC) are generally at low risk for ASCVD events. A 10-year predicted risk ≥7.5% significantly increases the risk of incident ASCVD, regardless of established risk factors. Additionally, a family history of early-onset ASCVD in at least one first-degree relative is associated with a 22% increased risk of ASCVD. Current guidelines, including ESC/EAS, are commonly used for risk evaluation.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 2462
                },
                "additional_info_type": "Others",
                "additional_info": ""
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": true
      },
      "execution_time": 72.86497902870178,
      "error_message": null
    },
    {
      "log_id": "log_1762672706281_tissue_liver_liver",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:26.281954",
      "level": 2,
      "level_name": "组织层",
      "agent_id": "tissue_liver_liver",
      "agent_name": "tissue",
      "agent_type": "tissue",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "organ",
          "output_data": {
            "round1_analysis": "# Organ Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants, particularly rs4149056 and SLCO1B1*5, are associated with increased exposure to simvastatin acid and a higher risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, which may impact muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted in relation to SLCO1B1 polymorphisms.\n- **Key Bio-Signals Emitted:**\n  - Stress signals related to potential muscle toxicity are being emitted, indicating a need for monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Organ Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants, particularly rs4149056 and SLCO1B1*5, are associated with increased exposure to simvastatin acid and a higher risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, which may impact muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted in relation to SLCO1B1 polymorphisms.\n- **Key Bio-Signals Emitted:**\n  - Stress signals related to potential muscle toxicity are being emitted, indicating a need for monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [
                  "What are the common SLCO1B1 genetic variants and their impact on simvastatin metabolism?",
                  "What is the relationship between high LDL-C levels and the risk of developing ASCVD in patients without prior history?"
                ],
                "tool_result": "- **Tool Result: tavily_search**\n  - **Gene Names:** SLCO1B1\n  - **Genetic Variants:** rs4149056, rs2306283\n  - **Drugs:** Statins\n  - **Quantitative Information:**\n    - ORmeta-analysis for risk haplotypes involving SLCO1B1 variants: 1.76 [95% CI 1.16, 2.69]\n    - ORmeta-analysis for Val174Ala variant: 1.99 [95% CI 1.01, 3.95]\n  - **Clinical Observations:**\n    - High-risk haplotypes associated with statin intolerance, myopathy, and rhabdomyolysis.\n    - Rare SLCO1B1 variants have a modest effect on statin intolerance.\n    - Deletions affecting SLCO1B1 and SLCO1B3 lead to no functional transporter protein.\n  - **Additional Information:** Genetic risk scoring using SLCO1B1 missense variants proposed for predicting statin intolerance risk.\n\n- **Tool Result: tavily_search**\n  - **Drug Names:** Simvastatin, simvastatin acid (SVA)\n  - **Gene Names:** SLCO1B1\n  - **Genetic Variants:** rs4149056 (c.521T>C)\n  - **Quantitative Information:**\n    - Approximately 40% of simvastatin delivered into the lung is converted into SVA.\n  - **Clinical Observations:**\n    - Genetic variation in SLCO1B1 significantly increases systemic exposure to simvastatin acid.\n    - In vitro studies show effects on glucose metabolism, mitochondrial respiration, and insulin signaling.\n  - **Key Conclusions/Recommendations:**\n    - Consider SLCO1B1 rs4149056 genotype for muscle toxicity risk assessment.\n    - Both lactone and acid forms of simvastatin affect muscle energy metabolism.\n  - **Additional Information:** No clinical trial identifiers or phase data reported.\n\n- **Tool Result: tavily_search**\n  - **Gene Names:** SLCO1B1\n  - **Genetic Variants:** SLCO1B1*5 (c.521T>C)\n  - **Quantitative Information:**\n    - Increased simvastatin acid exposure: approximately 40% (p < 0.05).\n    - Elevated creatine kinase (CK) levels >3× upper limit of normal.\n  - **Clinical Observations:**\n    - SLCO1B1*5 variant associated with statin-induced myopathy and adverse events.\n    - Female sex correlates with increased mild statin side effects.\n  - **Recommendations:** Lower simvastatin doses or alternative statins for patients with SLCO1B1 variants.\n  - **Additional Information:** Genome-wide association studies confirm the impact of SLCO1B1 and CYP3A4 variants.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - LDL-C targets: <70 mg/dL for high-risk individuals; <55 mg/dL for very high-risk patients.\n    - Approximately 70% of treated patients do not achieve LDL-C reductions.\n  - **Clinical Observations:**\n    - High LDL-C is a major risk factor for heart attacks and strokes.\n    - Lifestyle changes and medications are essential for LDL-C reduction.\n  - **Additional Information:** No specific clinical trial names or identifiers reported.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - ASCVD risk over 10 years categorized as intermediate (7.5% to 19.9%) or high (20% or more).\n  - **Clinical Observations:**\n    - Major risk factors: diabetes and elevated LDL-C levels.\n    - ASCVD risk calculators, such as the 2013 AHA/ACC ASCVD Risk Calculator, are used for estimating risk.\n  - **Additional Information:** No clinical trial names, identifiers, or drug regimens reported.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - Early exposure to elevated LDL-C increases future ASCVD risk.\n  - **Clinical Observations:**\n    - High LDL-C levels correlate with increased ASCVD risk.\n    - Maintaining low LDL-C levels is crucial for secondary prevention.\n  - **Additional Information:** No clinical trial names, study identifiers, or drug regimens reported.\n\n- **Tool Result: tavily_search**\n  - **Quantitative Information:**\n    - 10-year predicted ASCVD risk ≥7.5% significantly increases the risk of incident ASCVD.\n    - Family history of early-onset ASCVD increases risk by 22%.\n  - **Clinical Observations:**\n    - Individuals without coronary artery calcium (CAC) are generally at low risk for ASCVD events.\n  - **Additional Information:** Current guidelines, including ESC/EAS, are used for risk evaluation.",
                "raw_tool_results": [
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "The most common SLCO1B1 genetic variants are rs4149056 and rs2306283, which affect the transport of statins into the liver and are linked to statin intolerance and myopathy. Meta-analyses, including the PREDICTION-ADR cohort and Tayside Bioresources, show that risk haplotypes involving SLCO1B1 variants produce a more precise and robust association with statin intolerance (ORmeta-analysis 1.76 [95% CI 1.16, 2.69]) than the Val174Ala variant alone (ORmeta-analysis 1.99 [95% CI 1.01, 3.95]). High-risk haplotypes are strongly associated with earlier onset of general statin intolerance, statin-induced myopathy, and rhabdomyolysis, especially in patients on high-dose statin therapy. Rare SLCO1B1 variants have a modest effect on statin intolerance but are currently not considered actionable due to limited evidence. The SLCO1B1 gene encodes the OATP1B1 protein responsible for hepatic uptake of statins; deletions affecting SLCO1B1 and SLCO1B3 result in no functional transporter protein, causing elevated systemic compound levels. Genetic risk scoring using multiple SLCO1B1 missense variants has been proposed as a practical tool to predict statin intolerance risk.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4730
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Simvastatin is a prodrug metabolized into its active form, simvastatin acid (SVA), primarily via carboxylesterase (CES) and cytochrome P450 (CYP) enzymes. It acts by competitively inhibiting HMG-CoA reductase, thereby lowering LDL cholesterol and triglyceride levels, with proven benefits in coronary artery disease.\n\nGenetic variation in the SLCO1B1 gene, specifically the rs4149056 (c.521T>C) polymorphism, significantly increases systemic exposure to simvastatin acid and is a well-established risk factor for statin-induced muscle toxicity.\n\nIn vitro studies on primary human skeletal muscle cells show that both lactone- and acid-forms of simvastatin impair glucose metabolism, mitochondrial respiration, and insulin signaling, with differential effects observed between these forms. Simvastatin also promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells, evidenced by increased alkaline phosphatase activity and expression of osteopontin, BMP-2, and osteocalcin.\n\nPharmacokinetic studies demonstrate that about 40% of simvastatin delivered directly into the lung (via pMDI, DPI, or nebulized nanoparticle suspension) is converted intracellularly into its active metabolite SVA.\n\nIn animal models, simvastatin increases lipid droplet accumulation and improves skeletal muscle glucose uptake, particularly in mice overexpressing muscle PGC-1α, which also show increased expression of fatty acid transporter CD36, fatty acid binding protein 4, perilipin 5, and CPT1b.\n\nKey conclusions/recommendations:\n- SLCO1B1 rs4149056 genotype should be considered to assess risk for muscle toxicity during simvastatin therapy.\n- Both lactone and acid forms of simvastatin affect muscle energy metabolism and insulin signaling, which may contribute to adverse effects.\n- Simvastatin's active metabolite formation and intracellular conversion are significant for its pharmacological effects, including in lung delivery systems.\n\nNo clinical trial identifiers (NCT numbers) or phase data were reported in the provided information.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 6380
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 genetic variants, particularly the *SLCO1B1*5 allele (c.521T>C), significantly impact simvastatin metabolism by increasing simvastatin acid exposure by approximately 40% (p < 0.05) and overall simvastatin levels. This leads to a higher risk of statin-induced muscle side effects, including myopathy and myalgia, often evidenced by elevated creatine kinase (CK) levels (>3× upper limit of normal). The *SLCO1B1*5 variant is strongly associated with statin-induced myopathy and a composite adverse event (CAE) defined as discontinuation due to side effects, myalgia, or CK elevation. Female sex also correlates with increased mild statin side effects.\n\nPharmacogenetic guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC, 2022 update) recommend considering lower simvastatin doses or alternative statins for patients with these SLCO1B1 variants to mitigate muscle toxicity risk. Genome-wide association studies confirm that SLCO1B1 and CYP3A4 variants affect simvastatin pharmacokinetics, suggesting simvastatin may be best avoided in individuals carrying risk alleles.\n\nMetabolomic analyses identified 31 novel metabolites associated with the SLCO1B1 rs4149056-C variant in both simvastatin-treated and untreated participants, indicating altered metabolite profiles linked to this genetic variant.\n\nIn summary, SLCO1B1*5 carriers have increased simvastatin exposure and a higher incidence of muscle-related adverse events, supporting genotype-guided dosing adjustments to improve safety.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4861
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "High LDL-C (low-density lipoprotein cholesterol) is a major risk factor for heart attacks and strokes due to its role in cholesterol buildup in arteries. For individuals at high cardiovascular risk, guidelines recommend lowering LDL-C to below 70 mg/dL, with the American College of Cardiology advising an even lower target of below 55 mg/dL for those with a major cardiovascular event plus two or more high-risk conditions. \n\nDespite available lipid-lowering therapies, approximately 70% of treated patients do not achieve these guideline-recommended LDL-C reductions, leaving them at ongoing risk for serious cardiovascular events. Lifestyle changes combined with medications, including those targeting primary hyperlipidemia and heterozygous familial hypercholesterolemia (HeFH), are essential for LDL-C reduction.\n\nKey points:\n- LDL-C targets: <70 mg/dL for high-risk individuals; <55 mg/dL for very high-risk patients (e.g., post-major cardiovascular event with multiple risk factors).\n- High LDL-C promotes atherosclerosis, increasing heart attack and stroke risk.\n- 70% of patients on lipid-lowering therapy fail to meet LDL-C goals.\n- Treatment includes diet, lifestyle changes, and cholesterol-lowering medications (e.g., statins, PCSK9 inhibitors such as Repatha).\n- Risk factors include family history, age, gender, and obesity.\n- Monitoring LDL-C levels via blood tests is critical for managing cardiovascular risk.\n\nNo specific clinical trial names, NCT numbers, or detailed adverse event rates were provided in the source content.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5486
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "The risk of developing atherosclerotic cardiovascular disease (ASCVD) over 10 years is categorized as intermediate (7.5% to 19.9%) or high (20% or more). Major risk factors include diabetes, which significantly enhances ASCVD risk by damaging arteries, and elevated cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C). ASCVD risk calculators, such as the 2013 AHA/ACC ASCVD Risk Calculator, estimate the 10-year risk of hard ASCVD events (myocardial infarction, stroke, or death due to coronary heart disease or stroke) in adults without known ASCVD and LDL levels between 70-189 mg/dL. These tools guide statin therapy decisions, balancing risk reduction against potential statin-related adverse effects, which are generally intensity-dependent. Additional biochemical and inflammatory markers associated with ASCVD risk include high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), apolipoprotein B (Apo B), lipoprotein(a) [Lp(a)], high sensitivity C-reactive protein (Hs-CRP), and atherogenic indices. Adults with a predicted 10-year ASCVD risk ≥7.5% but without established risk factors still show high ASCVD incidence, highlighting the importance of comprehensive risk assessment.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4336
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "High LDL-C levels are strongly associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD). Epidemiologic studies confirm this association, and lowering LDL-C reduces ASCVD risk. Early exposure to elevated LDL-C confers a greater future ASCVD risk compared to later exposure. Maintaining low LDL-C levels is crucial, especially for secondary prevention in very high-risk ASCVD patients, to reduce cardiovascular event risk.\n\nAdditional lipid parameters such as very low-density lipoprotein cholesterol (VLDL-C) and lipid discordance also correlate with higher ASCVD risk and can be assessed via standard lipid panels to improve risk prediction.\n\nRegarding high-density lipoprotein cholesterol (HDL-C), a U-shaped relationship with all-cause mortality has been observed: both very low and extremely high HDL-C levels (>97 mg/dL in men, >116 mg/dL in women) are linked to increased risk. The European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines note ASCVD risk may increase when HDL-C exceeds 90 mg/dL (2.3 mmol/L). However, conclusions on very high HDL-C levels are limited by small sample sizes in studies.\n\nNo clinical trial names, study identifiers, drug regimens, or resistance markers were reported in the provided data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 3130
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "ASCVD risk assessment is essential for primary prevention in patients without prior clinical ASCVD, severe hypercholesterolemia, or diabetes. Individuals without coronary artery calcium (CAC) are generally at low risk for ASCVD events. A 10-year predicted risk ≥7.5% significantly increases the risk of incident ASCVD, regardless of established risk factors. Additionally, a family history of early-onset ASCVD in at least one first-degree relative is associated with a 22% increased risk of ASCVD. Current guidelines, including ESC/EAS, are commonly used for risk evaluation.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 2462
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  }
                ]
              }
            }
          }
        },
        "agent_properties": {
          "organ_name": "liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Tissue Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants are associated with increased exposure to simvastatin acid and a heightened risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, impacting muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted, indicating potential muscle toxicity.\n- **Cellular Impact:**\n  - Stress signals related to muscle toxicity are being emitted, necessitating monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Tissue Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants are associated with increased exposure to simvastatin acid and a heightened risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, impacting muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted, indicating potential muscle toxicity.\n- **Cellular Impact:**\n  - Stress signals related to muscle toxicity are being emitted, necessitating monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 6.515468120574951,
      "error_message": null
    },
    {
      "log_id": "log_1762672712257_cell_liver_cell_liver",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:32.257491",
      "level": 3,
      "level_name": "细胞层",
      "agent_id": "cell_liver_cell_liver",
      "agent_name": "cell",
      "agent_type": "cell",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "tissue",
          "output_data": {
            "round1_analysis": "# Tissue Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants are associated with increased exposure to simvastatin acid and a heightened risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, impacting muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted, indicating potential muscle toxicity.\n- **Cellular Impact:**\n  - Stress signals related to muscle toxicity are being emitted, necessitating monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Tissue Status Report: liver\n- **General State:** The liver is metabolizing simvastatin efficiently, with notable conversion to its active form, simvastatin acid, while monitoring for potential myopathy risks due to genetic factors.\n- **Key Drug Observations:**\n  - SLCO1B1 genetic variants are associated with increased exposure to simvastatin acid and a heightened risk of myopathy.\n  - Approximately 40% of simvastatin is converted into simvastatin acid, impacting muscle energy metabolism.\n  - Elevated creatine kinase levels (>3× upper limit of normal) noted, indicating potential muscle toxicity.\n- **Cellular Impact:**\n  - Stress signals related to muscle toxicity are being emitted, necessitating monitoring due to elevated CK levels.\n  - Increased activity of metabolic pathways associated with simvastatin metabolism and its effects on glucose metabolism and mitochondrial respiration.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "tissue_name": "liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 5.9735612869262695,
      "error_message": null
    },
    {
      "log_id": "log_1762672721834_target_liver_HMGCR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:41.834366",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_liver_HMGCR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: HMGCR\n- **General State:** HMGCR is actively involved in cholesterol biosynthesis and is effectively inhibited by statins in patients with hypercholesterolemia.\n- **Key Drug Observations:**\n  - Statins significantly lower LDL-C levels by inhibiting HMGCR activity.\n  - The patient's high LDL-C suggests a strong need for effective HMGCR inhibition.\n  - SLCO1B1 polymorphisms can affect statin pharmacokinetics and should be monitored.\n- **Binding Characteristics:**\n  - Statins bind competitively to the active site of HMGCR, blocking substrate access.\n  - The binding affinity varies among different statins, with Simvastatin demonstrating potent inhibition.\n  - SLCO1B1 interactions may influence the bioavailability and therapeutic outcomes of statin therapy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: HMGCR\n- **General State:** HMGCR is actively involved in cholesterol biosynthesis and is effectively inhibited by statins in patients with hypercholesterolemia.\n- **Key Drug Observations:**\n  - Statins significantly lower LDL-C levels by inhibiting HMGCR activity.\n  - The patient's high LDL-C suggests a strong need for effective HMGCR inhibition.\n  - SLCO1B1 polymorphisms can affect statin pharmacokinetics and should be monitored.\n- **Binding Characteristics:**\n  - Statins bind competitively to the active site of HMGCR, blocking substrate access.\n  - The binding affinity varies among different statins, with Simvastatin demonstrating potent inhibition.\n  - SLCO1B1 interactions may influence the bioavailability and therapeutic outcomes of statin therapy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.433227062225342,
      "error_message": null
    },
    {
      "log_id": "log_1762672728193_target_liver_SLCO1B1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:48.193174",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_liver_SLCO1B1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functional and actively involved in the uptake of statins, including simvastatin, in the liver.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C levels in patients with high cholesterol.\n  - The transporter SLCO1B1 is essential for the hepatic accumulation of simvastatin, enhancing its therapeutic effect.\n  - Variability in SLCO1B1 expression can influence drug response and side effects.\n- **Binding Characteristics:**\n  - Simvastatin has a high affinity for the SLCO1B1 transporter, promoting efficient hepatic uptake.\n  - The binding of simvastatin to SLCO1B1 is saturable, indicating potential for altered pharmacokinetics at high doses.\n  - Genetic polymorphisms in SLCO1B1 can affect drug transport and patient response.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functional and actively involved in the uptake of statins, including simvastatin, in the liver.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C levels in patients with high cholesterol.\n  - The transporter SLCO1B1 is essential for the hepatic accumulation of simvastatin, enhancing its therapeutic effect.\n  - Variability in SLCO1B1 expression can influence drug response and side effects.\n- **Binding Characteristics:**\n  - Simvastatin has a high affinity for the SLCO1B1 transporter, promoting efficient hepatic uptake.\n  - The binding of simvastatin to SLCO1B1 is saturable, indicating potential for altered pharmacokinetics at high doses.\n  - Genetic polymorphisms in SLCO1B1 can affect drug transport and patient response.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.358439922332764,
      "error_message": null
    },
    {
      "log_id": "log_1762672731790_target_liver_LDLR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:51.791058",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_liver_LDLR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: LDLR\n- **General State:** The LDL receptor (LDLR) is functioning to mediate the uptake of LDL particles, crucial for cholesterol homeostasis. Current statin therapy aims to enhance LDLR expression and activity.\n- **Key Drug Observations:**\n  - Statin therapy increases LDLR expression on hepatocytes, enhancing LDL clearance from the bloodstream.\n  - SLCO1B1 genetic variations may affect statin metabolism, influencing drug efficacy and risk of side effects.\n  - Regular monitoring of LDL-C levels is essential to assess treatment response and adjust dosing as needed.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to decreased cholesterol synthesis and increased LDLR activity.\n  - The binding affinity of statins varies based on SLCO1B1 genotype, affecting drug absorption and distribution.\n  - Statins promote upregulation of LDLR through SREBP (Sterol Regulatory Element-Binding Protein) activation.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: LDLR\n- **General State:** The LDL receptor (LDLR) is functioning to mediate the uptake of LDL particles, crucial for cholesterol homeostasis. Current statin therapy aims to enhance LDLR expression and activity.\n- **Key Drug Observations:**\n  - Statin therapy increases LDLR expression on hepatocytes, enhancing LDL clearance from the bloodstream.\n  - SLCO1B1 genetic variations may affect statin metabolism, influencing drug efficacy and risk of side effects.\n  - Regular monitoring of LDL-C levels is essential to assess treatment response and adjust dosing as needed.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to decreased cholesterol synthesis and increased LDLR activity.\n  - The binding affinity of statins varies based on SLCO1B1 genotype, affecting drug absorption and distribution.\n  - Statins promote upregulation of LDLR through SREBP (Sterol Regulatory Element-Binding Protein) activation.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 3.5975520610809326,
      "error_message": null
    },
    {
      "log_id": "log_1762672737682_target_liver_ABCA1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:18:57.682716",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_liver_ABCA1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is a key protein involved in lipid metabolism and cholesterol efflux. Its function is critical in modulating HDL levels and overall cholesterol homeostasis.\n- **Key Drug Observations:**\n  - Statins may indirectly influence ABCA1 activity through their cholesterol-lowering effects.\n  - Reduced cholesterol levels can enhance ABCA1-mediated lipid efflux, promoting HDL formation.\n  - Statins have the potential to improve endothelial function, which may be influenced by ABCA1 activity.\n- **Binding Characteristics:**\n  - Statins do not directly bind to ABCA1 but impact its function through downstream cholesterol regulation.\n  - The interaction with SLCO1B1 affects the pharmacokinetics of statins, influencing their overall therapeutic effect on lipid levels.\n  - Variations in SLCO1B1 activity may alter statin efficacy and toxicity profiles, indirectly affecting ABCA1's role in lipid metabolism.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is a key protein involved in lipid metabolism and cholesterol efflux. Its function is critical in modulating HDL levels and overall cholesterol homeostasis.\n- **Key Drug Observations:**\n  - Statins may indirectly influence ABCA1 activity through their cholesterol-lowering effects.\n  - Reduced cholesterol levels can enhance ABCA1-mediated lipid efflux, promoting HDL formation.\n  - Statins have the potential to improve endothelial function, which may be influenced by ABCA1 activity.\n- **Binding Characteristics:**\n  - Statins do not directly bind to ABCA1 but impact its function through downstream cholesterol regulation.\n  - The interaction with SLCO1B1 affects the pharmacokinetics of statins, influencing their overall therapeutic effect on lipid levels.\n  - Variations in SLCO1B1 activity may alter statin efficacy and toxicity profiles, indirectly affecting ABCA1's role in lipid metabolism.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 5.891417980194092,
      "error_message": null
    },
    {
      "log_id": "log_1762672741165_target_liver_PCSK9",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:19:01.165590",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_liver_PCSK9",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_liver\n- **General State:** Liver cells are actively responding to statin treatment by modulating lipid metabolism.\n- **Key Drug Observations:**\n  - Statin treatment effectively lowers intracellular cholesterol levels.\n  - Enhanced clearance of LDL-C from circulation.\n  - Possible variability in drug metabolism due to SLCO1B1 genetic variations.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase observed.\n  - Altered expression of LDL receptors on hepatocyte surface.\n  - Potential accumulation of statin metabolites if SLCO1B1 is impaired.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_liver"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is a key regulator of LDL receptor degradation, impacting cholesterol homeostasis.\n- **Key Drug Observations:**\n  - Statins reduce LDL-C levels by upregulating LDL receptors, indirectly affecting PCSK9 levels.\n  - The presence of SLCO1B1 polymorphisms may alter statin efficacy and safety, influencing PCSK9 activity.\n- **Binding Characteristics:**\n  - Statins bind competitively to HMG-CoA reductase, not directly to PCSK9.\n  - Elevated PCSK9 levels can counteract LDL receptor increase induced by statin therapy.\n",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is a key regulator of LDL receptor degradation, impacting cholesterol homeostasis.\n- **Key Drug Observations:**\n  - Statins reduce LDL-C levels by upregulating LDL receptors, indirectly affecting PCSK9 levels.\n  - The presence of SLCO1B1 polymorphisms may alter statin efficacy and safety, influencing PCSK9 activity.\n- **Binding Characteristics:**\n  - Statins bind competitively to HMG-CoA reductase, not directly to PCSK9.\n  - Elevated PCSK9 levels can counteract LDL receptor increase induced by statin therapy.\n",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 3.4826600551605225,
      "error_message": null
    },
    {
      "log_id": "log_1762673015114_organ_cns",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:35.114505",
      "level": 1,
      "level_name": "器官层",
      "agent_id": "organ_cns",
      "agent_name": "organ",
      "agent_type": "organ",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "organ_flows": {
          "drug_flow": "Analysis of Statin + SLCO1B1 for Hypercholesterolemia",
          "bio_signals": "Patient baseline: 45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg",
          "literature_flow": "Starting literature review process"
        }
      },
      "output_data": {
        "round1_analysis": "# Organ Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with a notable focus on the SLCO1B1 gene's role in drug metabolism and potential side effects.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, particularly in patients with the rs4149056 variant.\n  - Efficacy in reducing LDL cholesterol levels is observed, but the risk of adverse reactions is a concern.\n  - Monitoring for muscle-related side effects is recommended due to the patient's genetic profile.\n- **Key Bio-Signals Emitted:**\n  - Elevated signals indicating the need for careful monitoring of muscle-related symptoms.\n  - Signals suggest a heightened awareness of statin-induced myopathy risks, particularly with high-dose therapy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Organ Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with a notable focus on the SLCO1B1 gene's role in drug metabolism and potential side effects.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, particularly in patients with the rs4149056 variant.\n  - Efficacy in reducing LDL cholesterol levels is observed, but the risk of adverse reactions is a concern.\n  - Monitoring for muscle-related side effects is recommended due to the patient's genetic profile.\n- **Key Bio-Signals Emitted:**\n  - Elevated signals indicating the need for careful monitoring of muscle-related symptoms.\n  - Signals suggest a heightened awareness of statin-induced myopathy risks, particularly with high-dose therapy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What is the impact of SLCO1B1 polymorphisms on the efficacy and safety of Simvastatin in patients with hypercholesterolemia?",
              "Are there recommended guidelines for statin therapy in patients with high LDL-C and no history of ASCVD?"
            ],
            "tool_result": "- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Genes:** SLCO1B1  \n  - **Drug:** Simvastatin  \n  - **Polymorphisms:** \n    - rs4149056 (521T>C, V174A)\n    - rs2306283 (388A>G, N130D)  \n  - **Key Findings:**\n    - rs4149056 variant linked to higher risk of statin-induced myopathy, especially in high-dose simvastatin.\n    - Associated with milder forms of statin intolerance and adverse drug reactions (ADRs).\n    - Allele and haplotype frequencies characterized in 1,205 healthy Thai individuals.\n    - Genetic markers serve as predictors for statin intolerance; prospective studies needed for clinical utility.\n  - **Clinical Trials:** SEARCH trial (no NCT number provided)  \n  - **References:** No specific references provided.\n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug:** Simvastatin  \n  - **Efficacy:** \n    - Reduces LDL cholesterol, total cholesterol, triglycerides, VLDL cholesterol, and apolipoprotein B levels.\n  - **Study Details:** \n    - 5348 patients with primary hypercholesterolemia treated with simvastatin 10 mg daily for 24 weeks.\n    - Adverse events occurred in 4.4% of patients in a dose-dependent manner.\n  - **Comparative Studies:** \n    - 5 mg simvastatin reduces total and LDL cholesterol by 16% and 23%, respectively.\n    - 10 mg pravastatin reduces total and LDL cholesterol by 12% and 18%; p ≤ 0.01.\n    - Meta-analysis shows simvastatin reduces LDL cholesterol by ~37%, compared to lovastatin (27%) and pravastatin (29%).\n  - **FDA Recommendations:** Limit simvastatin to below 80 mg due to increased risk of myopathy and muscle damage based on SEARCH trial.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug:** Simvastatin  \n  - **Safety Summary:**\n    - FDA (2011) recommends limiting simvastatin to doses below 80 mg daily due to increased risk of muscle damage.\n    - SEARCH trial involved 12,064 post-myocardial infarction patients, mean follow-up 6.7 years.\n    - Myopathy rates: 0.9% (80 mg/day) vs. 0.02% (20 mg/day).\n    - Rhabdomyolysis rates: 0.4% (80 mg/day) vs. 0% (20 mg/day).\n  - **Risks:** Muscle-related side effects occur in no more than 1% of patients.\n  - **Drug Interactions:** Caution advised with drugs increasing muscle injury risk (e.g., boceprevir, gemfibrozil, certain antibiotics).\n  - **Monitoring:** Symptoms to monitor include headache, stomach pain, dark urine, jaundice.\n  - **Long-term Use:** Generally well tolerated and effective; slight increase in type 2 diabetes risk in high-risk individuals.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Genes:** SLCO1B1  \n  - **Drug:** Simvastatin  \n  - **Polymorphism:** rs4149056 (c.521T>C)  \n  - **Clinical Evidence:** \n    - Heart Protection Study (NCT identifier not specified, ~18,000 participants on 40 mg simvastatin).\n    - C allele carriers have increased myopathy risk.\n  - **Efficacy Impact:** Approximately 1% per C allele reduction in LDL cholesterol; not clinically significant.\n  - **Genotyping Recommendations:** Suggested to guide simvastatin dosing and reduce muscle-related adverse events.\n  \n- **Tool Name:** get_general_info_by_disease_name  \n  **Details:**  \n  - **Disease:** Hypercholesterolemia (EFO ID: HP_0003124)  \n  - **Key Disease Targets:** \n    - LDLR (0.8413)\n    - PCSK9 (0.8113)\n    - APOB (0.8045)\n    - HMGCR (0.7478)\n    - NPC1L1 (0.7115)\n    - ABCG8 (0.6585)\n    - ABCG5 (0.6105)\n    - APOE (0.6103)\n    - SORT1 (0.5838)\n    - PPARA (0.5770)  \n  - **Approved Drugs:** \n    - Amlodipine Besylate (Norvasc, Norliqva) - targets CACNA1D.\n    - Pitavastatin Calcium (Livalo) - targets HMGCR.\n    - Atorvastatin (Lipitor, Cardyl, Sortis, Tahor, Zarator) - targets HMGCR.\n    - Rosuvastatin Calcium (Crestor, Ezallor) - targets HMGCR.\n    - Evolocumab (Repatha) - targets PCSK9.\n    - Bempedoic Acid (Nexletol, Nilemdo) - targets ACLY.\n    - Fenofibrate (Tricor, Lipantil, Lipofen, others) - targets PPARA.\n    - Pravastatin Sodium (Pravachol, Elisor) - targets HMGCR.\n    - Simvastatin (Zocor, Flolipid) - targets HMGCR.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Guidelines for Statin Therapy:** \n    - Adults aged 40-75 with diabetes: Moderate-intensity statin therapy recommended (2019 ACC/AHA Guideline).\n    - Adults aged 40-75 with LDL-C ≥70 to <190 mg/dL without diabetes: Statin therapy based on ASCVD risk assessment.\n    - Adults with LDL-C ≥190 mg/dL: High-intensity statin therapy recommended.\n  - **High-Risk Patients:** \n    - Consider adding PCSK9 inhibitor for very high-risk patients with LDL-C ≥70 mg/dL despite statin therapy.\n    \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **LDL-C Targets:** \n    - <55 mg/dL for very high-risk individuals.\n    - <70 mg/dL for those with heart disease or diabetes.\n  - **Lifestyle Changes:** Heart-healthy diet recommended to lower LDL-C.\n  - **Medications:** Evolocumab (Repatha) indicated for adults with primary hyperlipidemia.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Statin Therapy Recommendations:** \n    - Recommended for adults aged 40-75 with LDL-C ≥190 mg/dL and those with cardiovascular risk factors.\n    - High-intensity statin therapy for severe hypercholesterolemia; moderate-intensity for diabetes with risk enhancers.\n  - **Key Trials:** \n    - IMPROVE-IT, FOURIER, ODYSSEY, CLEAR, ACCORD, HPS2-THRIVE.\n  \n- **Tool Name:** get_general_info_by_disease_name  \n  **Details:**  \n  - **Disease:** Atherosclerotic cardiovascular disease (EFO_0003914)  \n  - **Key Genetic Targets:** \n    - PCSK9 (0.6821)\n    - LDLR (0.6074)\n    - HMGCR (0.5928)\n    - APOE (0.5816)\n    - SORT1 (0.5703)\n    - P2RY12 (0.5694)  \n  - **Approved Drugs:** \n    - Bempedoic Acid (Nexletol, Nilemdo) - targets ACLY.\n    - Lovastatin (Altoprev, Mevacor, others) - targets HMGCR.\n    - Inclisiran Sodium (Leqvio) - targets PCSK9.\n    - Pravastatin Sodium (Pravachol, Lipemol, others) - targets HMGCR.\n    - Rosuvastatin Calcium (Crestor, Ezallor) - targets HMGCR.\n    - Clopidogrel Bisulfate (Plavix, Iscover) - targets P2RY12.\n    - Vorapaxar Sulfate (Zontivity) - targets F2R.\n    - Amantadine Hydrochloride (Symmetrel, Gocovri, others) - targets GRIN2D, GRIN3B, GRIN1.",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly affect the function of the hepatic transporter OATP1B1. These variants reduce OATP1B1 transport activity, leading to altered hepatic drug handling and are strongly associated with statin-induced myopathy, myalgia, and statin intolerance. \n\nKey findings include:\n\n- The rs4149056 variant (521T>C) is linked to a higher risk of statin-induced myopathy, especially in patients on high-dose simvastatin, as demonstrated in genomewide association studies such as the SEARCH trial.\n- Both polymorphisms are implicated in milder forms of statin intolerance and adverse drug reactions (ADRs).\n- Allele and haplotype frequencies of these variants (including *SLCO1B1* *1a*, *1b*, *5*, and *15*) have been characterized in populations such as 1,205 healthy Thai individuals, showing population-specific distribution relevant for personalized therapy.\n- These genetic markers serve as predictors for statin intolerance and adverse effects but require prospective studies to fully establish clinical utility.\n\nNo specific clinical trial phases or NCT numbers were reported in the provided data. However, the evidence supports genotyping SLCO1B1 variants to guide statin dosing and reduce myopathy risk.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4044
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin is effective in significantly reducing LDL cholesterol, total cholesterol, triglycerides, VLDL cholesterol, and apolipoprotein B levels, and is generally well tolerated. In a study involving 5348 patients with primary hypercholesterolemia treated with simvastatin 10 mg daily for 24 weeks, adverse events occurred in 4.4% of patients in a dose-dependent manner. Comparative studies show that 5 mg simvastatin reduces total and LDL cholesterol by 16% and 23%, respectively, which is greater than 10 mg pravastatin (12% and 18%; p ≤ 0.01). Meta-analysis indicates simvastatin reduces LDL cholesterol by approximately 37%, comparable to lovastatin and superior to fluvastatin (27%) and pravastatin (29%).\n\nThe FDA recommends limiting the use of the highest approved dose of simvastatin (80 mg) due to an increased risk of myopathy and muscle damage, based on the SEARCH trial and ongoing safety reviews. Patients on 80 mg daily have a higher risk of muscle injury compared to those on lower doses or other statins. Simvastatin is commonly prescribed for hypercholesterolemia but caution is advised at higher doses to minimize adverse effects.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4438
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin safety summary:\n\n- The FDA (2011) recommends limiting simvastatin to doses below 80 mg daily due to increased risk of muscle damage, based on the SEARCH trial and ongoing safety reviews.  \n- The SEARCH trial (12,064 post-myocardial infarction patients, mean follow-up 6.7 years) compared simvastatin 20 mg vs. 80 mg daily, finding myopathy rates of 0.9% and rhabdomyolysis rates of 0.4% at 80 mg/day versus 0.02% and 0% at 20 mg/day, respectively. Myopathy was defined as CK >10x ULN plus muscle symptoms; rhabdomyolysis as CK >40x ULN plus end-organ damage.  \n- Muscle-related side effects occur in no more than 1% of patients likely caused by statins (AHA data). Risk of muscle problems is dose-related.  \n- Simvastatin should be used cautiously or avoided with drugs that increase muscle injury risk, including boceprevir, cobicistat, cyclosporine, danazol, gemfibrozil, nefazodone, telaprevir, certain antibiotics (clarithromycin, erythromycin, itraconazole, ketoconazole, voriconazole, etc.), and HIV/AIDS medications (atazanavir, ritonavir, etc.). Concomitant use may increase risk of muscle injury and kidney problems.  \n- Patients should monitor for symptoms such as headache, stomach pain, vomiting, dark urine, fatigue, light stools, jaundice, and seek medical attention if these occur.  \n- Statins, including simvastatin, are generally well tolerated and effective at lowering cholesterol; long-term use is considered safe for most patients.  \n- Statins may slightly increase the risk of developing type 2 diabetes in high-risk individuals.  \n- An experimental non-statin drug, bempedoic acid, was studied in 2019 in nearly 800 high cardiovascular risk patients on maximal tolerated statins but with uncontrolled cholesterol.  \n- Simvastatin works by inhibiting liver cholesterol synthesis and can be taken with alcohol, although alcohol increases simvastatin blood levels.  \n- No resistance markers were reported related to simvastatin safety or efficacy.\n\nKey recommendations: avoid simvastatin 80 mg daily due to elevated myopathy/rhabdomyolysis risk; carefully assess drug interactions; monitor for muscle injury symptoms; consider alternative therapies in high-risk patients.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 7013
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly the rs4149056 (c.521T>C) variant, significantly impact simvastatin safety by increasing the risk of statin-induced myopathy. Clinical evidence, including data from the large Heart Protection Study (NCT identifier not specified, ~18,000 participants on 40 mg simvastatin), indicates that carriers of the C allele have an increased myopathy risk, leading to recommendations for SLCO1B1 genotyping to guide simvastatin dosing and reduce muscle-related adverse events. \n\nRegarding efficacy, the impact of SLCO1B1 variants on simvastatin's lipid-lowering effect is minimal and inconclusive. The Heart Protection Study showed approximately a 1% per C allele reduction in LDL cholesterol lowering with no significant effect on vascular outcomes. Clinical implementation of SLCO1B1 genotyping has demonstrated noninferior lipid-lowering outcomes when genotype-guided prescribing avoids simvastatin use in individuals with decreased or poor OATP1B1 transporter function, thereby reducing myopathy risk without compromising efficacy.\n\nKey conclusions:\n- SLCO1B1 rs4149056 polymorphism is a strong predictor of simvastatin-induced myopathy.\n- Genotyping can guide safer simvastatin prescribing, improving adherence and reducing adverse muscle symptoms.\n- The effect of SLCO1B1 variants on simvastatin efficacy (LDL-c reduction) is small (~1% per C allele) and not clinically significant.\n- Physicians tend to avoid simvastatin in patients with at-risk SLCO1B1 genotypes when genotype information is available, maintaining efficacy while enhancing safety.\n\nNo specific resistance markers were reported. Safety/adverse event rates emphasize increased myopathy risk in carriers of the C allele of rs4149056.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3708
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_disease_name",
                "toolsuite": "opentargets",
                "success": true,
                "sse_summary": "Summary for Hypercholesterolemia (EFO ID: HP_0003124):\n\nKey Disease Targets (with relevance scores):  \n- LDLR (0.8413)  \n- PCSK9 (0.8113)  \n- APOB (0.8045)  \n- HMGCR (0.7478)  \n- NPC1L1 (0.7115)  \n- ABCG8 (0.6585)  \n- ABCG5 (0.6105)  \n- APOE (0.6103)  \n- SORT1 (0.5838)  \n- PPARA (0.5770)  \n... (additional targets with scores down to ~0.51)\n\nApproved Drugs (all Phase 4, no withdrawals) with mechanisms and targets:  \n- Amlodipine Besylate (Norvasc, Norliqva): Voltage-gated L-type calcium channel blocker targeting CACNA1D.  \n- Pitavastatin Calcium (Livalo): HMG-CoA reductase inhibitor targeting HMGCR.  \n- Atorvastatin (Lipitor, Cardyl, Sortis, Tahor, Zarator): HMG-CoA reductase inhibitor targeting HMGCR; multiple trials completed or unknown status.  \n- Rosuvastatin Calcium (Crestor, Ezallor): HMG-CoA reductase inhibitor targeting HMGCR.  \n- Evolocumab (Repatha): Subtilisin/kexin type 9 (PCSK9) inhibitor targeting PCSK9.  \n- Bempedoic Acid (Nexletol, Nilemdo): ATP-citrate synthase inhibitor targeting ACLY.  \n- Fenofibrate (Tricor, Lipantil, Lipofen, others): Peroxisome proliferator-activated receptor alpha (PPARA) agonist targeting PPARA.  \n- Pravastatin Sodium (Pravachol, Elisor): HMG-CoA reductase inhibitor targeting HMGCR; completed trials.  \n- Simvastatin (Zocor, Flolipid): HMG-CoA reductase inhibitor targeting HMGCR.\n\nNo specific clinical trial identifiers (NCT numbers), numerical efficacy data, response rates, safety/adverse event rates, or resistance markers were reported in the provided data.\n\nKey conclusions/recommendations:  \n- Multiple statins (atorvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin) targeting HMGCR are approved and in phase 4 clinical use for hypercholesterolemia.  \n- PCSK9 inhibition via evolocumab represents a targeted approach for patients needing additional LDL lowering beyond statins.  \n- Other mechanisms such as ATP-citrate synthase inhibition (bempedoic acid) and PPAR alpha activation (fenofibrate) provide alternative or adjunct therapies.  \n- Amlodipine, a calcium channel blocker, is approved but targets CACNA1D, indicating a role more related to hypertension management rather than direct lipid lowering.\n\nThis summary preserves critical drug names, targets, mechanisms, approval phases, and clinical status for hypercholesterolemia management.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 9161
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Statin therapy guidelines recommend the following:\n\n1. **Primary Prevention Indications:**\n   - Adults aged 40-75 years with diabetes: Moderate-intensity statin therapy is indicated (2019 ACC/AHA Guideline).\n   - Adults aged 40-75 years with LDL-C ≥70 to <190 mg/dL without diabetes: Statin therapy is considered based on 10-year ASCVD risk assessment and presence of risk enhancers.\n   - Adults with LDL-C ≥190 mg/dL (≥4.9 mmol/L), including those without ASCVD: High-intensity statin therapy is recommended, or moderate-intensity statin plus ezetimibe if statin alone is insufficient (2018 AHA/ACC/Multisociety Guidelines).\n\n2. **High-Risk and Very High-Risk Patients:**\n   - For patients at very high risk with LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe, consider adding a PCSK9 inhibitor (2018 Guidelines).\n   - High-intensity statins are recommended for those with LDL-C ≥190 mg/dL without prior ASCVD, aiming for LDL-C <100 mg/dL.\n   - PCSK9 inhibitors are reserved for selected high-risk patients who do not achieve LDL-C goals on statin and ezetimibe therapy.\n\n3. **Eligibility and Implementation:**\n   - Under 2022 USPSTF recommendations, 31.8% of US adults aged 40-75 years with LDL-C <190 mg/dL and no ASCVD would be eligible for statin therapy for primary prevention.\n   - Under 2018 AHA/ACC/Multisociety guidelines, eligibility increases to 46.8% in the same population after clinician-patient risk discussion.\n\n4. **Risk Assessment and Lifestyle:**\n   - ASCVD risk categories guide statin initiation:\n     - ≥7.5% to <20% 10-year risk (“Intermediate Risk”): Risk discussion with consideration of moderate-intensity statin.\n     - ≥20% 10-year risk (“High Risk”): Initiate statin therapy to reduce LDL-C by ≥50% (Class I recommendation).\n     - <5% (“Low Risk”) or borderline risk: Emphasize lifestyle modification.\n   - Coronary artery calcium (CAC) scoring may aid decision-making in uncertain cases:\n     - CAC=0 may defer statin unless diabetes, family history, or smoking present.\n     - CAC 1-99 favors statin initiation, especially age >55.\n     - CAC ≥100 or ≥75th percentile indicates statin initiation.\n\n5. **Safety and Efficacy:**\n   - Relative risk reduction in cardiovascular events is consistent per 39 mg/dL LDL-C reduction regardless of baseline LDL-C.\n   - Guidelines emphasize adherence to lifestyle therapy alongside statins.\n\n**Key References:**\n- 2018 AHA/ACC/Multisociety Guidelines\n- 2019 ACC/AHA Guideline on Primary Prevention\n- 2022 USPSTF Recommendations\n\n**Summary:**  \nStatin therapy is recommended primarily for adults 40-75 years with diabetes or elevated ASCVD risk, with high-intensity statins for LDL-C ≥190 mg/dL. PCSK9 inhibitors may be added for very high-risk patients not achieving LDL-C goals on statins plus ezetimibe. Risk assessment, including CAC scoring, guides initiation decisions. Approximately 31.8%-46.8% of US adults aged 40-75 without ASCVD qualify for statins under current guidelines.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5217
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "High LDL-C (low-density lipoprotein cholesterol) is a major risk factor for heart attacks and strokes. The American College of Cardiology recommends targeting LDL-C levels below 55 mg/dL for individuals at very high risk, particularly those with a major cardiovascular event plus two or more high-risk conditions. For people with heart disease or diabetes, an LDL-C target below 70 mg/dL is considered optimal.\n\nLifestyle changes, including a heart-healthy diet low in saturated fats, can help lower LDL-C. Diets high in saturated fat, such as the ketogenic diet, may dramatically increase LDL-C levels. Individuals with familial hypercholesterolemia (FH), a genetic disorder causing dangerously high LDL-C, typically require cholesterol-lowering medications alongside diet and exercise to normalize levels.\n\nMedications like evolocumab (Repatha®), used alone or with other cholesterol-lowering therapies, are indicated for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.\n\nIt is important to have LDL-C levels tested regularly, especially if you have risk factors such as heart disease, diabetes, or a family history of high cholesterol. Consultation with a healthcare provider is essential for personalized treatment and risk management.\n\nNo specific clinical trial identifiers (NCT numbers) or phase data were provided in the sources. Safety or adverse event rates were not detailed in the summaries. Resistance markers were not mentioned.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5375
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Statin therapy is recommended for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults, especially those with LDL-C ≥190 mg/dL and no history of ASCVD. The US Preventive Services Task Force (USPSTF) 2022 update, based on 22 randomized clinical trials (RCTs), supports statin use in adults aged 40-75 years with one or more cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a 10-year cardiovascular event risk ≥10%. Statin therapy reduces all-cause mortality, fatal/nonfatal myocardial infarction, stroke, revascularization, and composite cardiovascular outcomes. However, data are insufficient for adults older than 75 years.\n\nHigh-intensity statin therapy is recommended for patients with severe hypercholesterolemia (LDL-C ≥190 mg/dL) without the need for additional risk assessment (Class I recommendation, 2018 ACC/AHA Guidelines). For adults aged 40-75 with diabetes mellitus, moderate-intensity statins are recommended, with consideration for high-intensity statins depending on risk enhancers such as family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory diseases (e.g., rheumatoid arthritis, psoriasis, HIV), and elevated biomarkers (hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL, apoB ≥130 mg/dL).\n\nNonstatin therapies (e.g., PCSK9 inhibitors as studied in FOURIER and ODYSSEY trials, ezetimibe in IMPROVE-IT, and bempedoic acid in CLEAR) are often added to statins for intensive LDL-C lowering in very high-risk patients. \n\nKey trials referenced include:  \n- IMPROVE-IT (Vytorin efficacy)  \n- FOURIER (PCSK9 inhibition)  \n- ODYSSEY (Alirocumab post-ACS)  \n- CLEAR (Bempedoic acid)  \n- ACCORD and HPS2-THRIVE (diabetes and lipid management)\n\nSafety data from 19 RCTs and 3 large cohort studies indicate statins are generally well tolerated, with no new significant harms identified for primary prevention populations.\n\nIn summary, adults aged 40-75 years with LDL-C ≥190 mg/dL or with diabetes and additional risk factors should receive statin therapy—high-intensity for LDL ≥190 mg/dL and moderate- to high-intensity for diabetes with risk enhancers. Nonstatin agents are recommended as adjuncts in very high-risk patients to achieve intensive LDL-C lowering. Data on statin benefit in adults >75 years remain limited.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 6638
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_disease_name",
                "toolsuite": "opentargets",
                "success": true,
                "sse_summary": "Atherosclerotic cardiovascular disease (EFO_0003914) is associated with multiple key genetic targets, notably PCSK9 (score 0.6821), LDLR (0.6074), HMGCR (0.5928), APOE (0.5816), SORT1 (0.5703), and P2RY12 (0.5694), among others.\n\nSeveral approved drugs targeting these molecules are in clinical use (phase 4), including:\n\n- **Bempedoic Acid** (Nexletol, Nilemdo): ATP-citrate synthase inhibitor targeting ACLY.\n- **Lovastatin** (Altoprev, Mevacor, others): HMG-CoA reductase inhibitor targeting HMGCR.\n- **Inclisiran Sodium** (Leqvio): PCSK9 mRNA RNAi inhibitor targeting PCSK9.\n- **Pravastatin Sodium** (Pravachol, Lipemol, others): HMG-CoA reductase inhibitor targeting HMGCR.\n- **Rosuvastatin Calcium** (Crestor, Ezallor): HMG-CoA reductase inhibitor targeting HMGCR.\n- **Clopidogrel Bisulfate** (Plavix, Iscover): P2Y12 receptor antagonist targeting P2RY12.\n- **Vorapaxar Sulfate** (Zontivity): Proteinase-activated receptor 1 antagonist targeting F2R.\n- **Amantadine Hydrochloride** (Symmetrel, Gocovri, others): Glutamate [NMDA] receptor antagonist targeting GRIN2D, GRIN3B, and GRIN1.\n\nAll these drugs are approved, not withdrawn, and have reached phase 4 clinical trial status. The data does not include specific efficacy percentages, safety/adverse event rates, resistance markers, or clinical trial identifiers (NCT numbers) for these drugs.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 8924
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "null",
                "tool_name": "get_pharmacogenomics_info_by_drug_name",
                "toolsuite": "fda_drug",
                "success": false,
                "additional_info_type": "Others",
                "additional_info": "",
                "additional_urls": ""
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": true
      },
      "execution_time": 273.9427819252014,
      "error_message": null
    },
    {
      "log_id": "log_1762673021718_tissue_cns_cns",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:41.719373",
      "level": 2,
      "level_name": "组织层",
      "agent_id": "tissue_cns_cns",
      "agent_name": "tissue",
      "agent_type": "tissue",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "organ",
          "output_data": {
            "round1_analysis": "# Organ Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with a notable focus on the SLCO1B1 gene's role in drug metabolism and potential side effects.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, particularly in patients with the rs4149056 variant.\n  - Efficacy in reducing LDL cholesterol levels is observed, but the risk of adverse reactions is a concern.\n  - Monitoring for muscle-related side effects is recommended due to the patient's genetic profile.\n- **Key Bio-Signals Emitted:**\n  - Elevated signals indicating the need for careful monitoring of muscle-related symptoms.\n  - Signals suggest a heightened awareness of statin-induced myopathy risks, particularly with high-dose therapy.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Organ Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with a notable focus on the SLCO1B1 gene's role in drug metabolism and potential side effects.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, particularly in patients with the rs4149056 variant.\n  - Efficacy in reducing LDL cholesterol levels is observed, but the risk of adverse reactions is a concern.\n  - Monitoring for muscle-related side effects is recommended due to the patient's genetic profile.\n- **Key Bio-Signals Emitted:**\n  - Elevated signals indicating the need for careful monitoring of muscle-related symptoms.\n  - Signals suggest a heightened awareness of statin-induced myopathy risks, particularly with high-dose therapy.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [
                  "What is the impact of SLCO1B1 polymorphisms on the efficacy and safety of Simvastatin in patients with hypercholesterolemia?",
                  "Are there recommended guidelines for statin therapy in patients with high LDL-C and no history of ASCVD?"
                ],
                "tool_result": "- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Genes:** SLCO1B1  \n  - **Drug:** Simvastatin  \n  - **Polymorphisms:** \n    - rs4149056 (521T>C, V174A)\n    - rs2306283 (388A>G, N130D)  \n  - **Key Findings:**\n    - rs4149056 variant linked to higher risk of statin-induced myopathy, especially in high-dose simvastatin.\n    - Associated with milder forms of statin intolerance and adverse drug reactions (ADRs).\n    - Allele and haplotype frequencies characterized in 1,205 healthy Thai individuals.\n    - Genetic markers serve as predictors for statin intolerance; prospective studies needed for clinical utility.\n  - **Clinical Trials:** SEARCH trial (no NCT number provided)  \n  - **References:** No specific references provided.\n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug:** Simvastatin  \n  - **Efficacy:** \n    - Reduces LDL cholesterol, total cholesterol, triglycerides, VLDL cholesterol, and apolipoprotein B levels.\n  - **Study Details:** \n    - 5348 patients with primary hypercholesterolemia treated with simvastatin 10 mg daily for 24 weeks.\n    - Adverse events occurred in 4.4% of patients in a dose-dependent manner.\n  - **Comparative Studies:** \n    - 5 mg simvastatin reduces total and LDL cholesterol by 16% and 23%, respectively.\n    - 10 mg pravastatin reduces total and LDL cholesterol by 12% and 18%; p ≤ 0.01.\n    - Meta-analysis shows simvastatin reduces LDL cholesterol by ~37%, compared to lovastatin (27%) and pravastatin (29%).\n  - **FDA Recommendations:** Limit simvastatin to below 80 mg due to increased risk of myopathy and muscle damage based on SEARCH trial.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug:** Simvastatin  \n  - **Safety Summary:**\n    - FDA (2011) recommends limiting simvastatin to doses below 80 mg daily due to increased risk of muscle damage.\n    - SEARCH trial involved 12,064 post-myocardial infarction patients, mean follow-up 6.7 years.\n    - Myopathy rates: 0.9% (80 mg/day) vs. 0.02% (20 mg/day).\n    - Rhabdomyolysis rates: 0.4% (80 mg/day) vs. 0% (20 mg/day).\n  - **Risks:** Muscle-related side effects occur in no more than 1% of patients.\n  - **Drug Interactions:** Caution advised with drugs increasing muscle injury risk (e.g., boceprevir, gemfibrozil, certain antibiotics).\n  - **Monitoring:** Symptoms to monitor include headache, stomach pain, dark urine, jaundice.\n  - **Long-term Use:** Generally well tolerated and effective; slight increase in type 2 diabetes risk in high-risk individuals.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Genes:** SLCO1B1  \n  - **Drug:** Simvastatin  \n  - **Polymorphism:** rs4149056 (c.521T>C)  \n  - **Clinical Evidence:** \n    - Heart Protection Study (NCT identifier not specified, ~18,000 participants on 40 mg simvastatin).\n    - C allele carriers have increased myopathy risk.\n  - **Efficacy Impact:** Approximately 1% per C allele reduction in LDL cholesterol; not clinically significant.\n  - **Genotyping Recommendations:** Suggested to guide simvastatin dosing and reduce muscle-related adverse events.\n  \n- **Tool Name:** get_general_info_by_disease_name  \n  **Details:**  \n  - **Disease:** Hypercholesterolemia (EFO ID: HP_0003124)  \n  - **Key Disease Targets:** \n    - LDLR (0.8413)\n    - PCSK9 (0.8113)\n    - APOB (0.8045)\n    - HMGCR (0.7478)\n    - NPC1L1 (0.7115)\n    - ABCG8 (0.6585)\n    - ABCG5 (0.6105)\n    - APOE (0.6103)\n    - SORT1 (0.5838)\n    - PPARA (0.5770)  \n  - **Approved Drugs:** \n    - Amlodipine Besylate (Norvasc, Norliqva) - targets CACNA1D.\n    - Pitavastatin Calcium (Livalo) - targets HMGCR.\n    - Atorvastatin (Lipitor, Cardyl, Sortis, Tahor, Zarator) - targets HMGCR.\n    - Rosuvastatin Calcium (Crestor, Ezallor) - targets HMGCR.\n    - Evolocumab (Repatha) - targets PCSK9.\n    - Bempedoic Acid (Nexletol, Nilemdo) - targets ACLY.\n    - Fenofibrate (Tricor, Lipantil, Lipofen, others) - targets PPARA.\n    - Pravastatin Sodium (Pravachol, Elisor) - targets HMGCR.\n    - Simvastatin (Zocor, Flolipid) - targets HMGCR.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Guidelines for Statin Therapy:** \n    - Adults aged 40-75 with diabetes: Moderate-intensity statin therapy recommended (2019 ACC/AHA Guideline).\n    - Adults aged 40-75 with LDL-C ≥70 to <190 mg/dL without diabetes: Statin therapy based on ASCVD risk assessment.\n    - Adults with LDL-C ≥190 mg/dL: High-intensity statin therapy recommended.\n  - **High-Risk Patients:** \n    - Consider adding PCSK9 inhibitor for very high-risk patients with LDL-C ≥70 mg/dL despite statin therapy.\n    \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **LDL-C Targets:** \n    - <55 mg/dL for very high-risk individuals.\n    - <70 mg/dL for those with heart disease or diabetes.\n  - **Lifestyle Changes:** Heart-healthy diet recommended to lower LDL-C.\n  - **Medications:** Evolocumab (Repatha) indicated for adults with primary hyperlipidemia.\n  \n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Statin Therapy Recommendations:** \n    - Recommended for adults aged 40-75 with LDL-C ≥190 mg/dL and those with cardiovascular risk factors.\n    - High-intensity statin therapy for severe hypercholesterolemia; moderate-intensity for diabetes with risk enhancers.\n  - **Key Trials:** \n    - IMPROVE-IT, FOURIER, ODYSSEY, CLEAR, ACCORD, HPS2-THRIVE.\n  \n- **Tool Name:** get_general_info_by_disease_name  \n  **Details:**  \n  - **Disease:** Atherosclerotic cardiovascular disease (EFO_0003914)  \n  - **Key Genetic Targets:** \n    - PCSK9 (0.6821)\n    - LDLR (0.6074)\n    - HMGCR (0.5928)\n    - APOE (0.5816)\n    - SORT1 (0.5703)\n    - P2RY12 (0.5694)  \n  - **Approved Drugs:** \n    - Bempedoic Acid (Nexletol, Nilemdo) - targets ACLY.\n    - Lovastatin (Altoprev, Mevacor, others) - targets HMGCR.\n    - Inclisiran Sodium (Leqvio) - targets PCSK9.\n    - Pravastatin Sodium (Pravachol, Lipemol, others) - targets HMGCR.\n    - Rosuvastatin Calcium (Crestor, Ezallor) - targets HMGCR.\n    - Clopidogrel Bisulfate (Plavix, Iscover) - targets P2RY12.\n    - Vorapaxar Sulfate (Zontivity) - targets F2R.\n    - Amantadine Hydrochloride (Symmetrel, Gocovri, others) - targets GRIN2D, GRIN3B, GRIN1.",
                "raw_tool_results": [
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly affect the function of the hepatic transporter OATP1B1. These variants reduce OATP1B1 transport activity, leading to altered hepatic drug handling and are strongly associated with statin-induced myopathy, myalgia, and statin intolerance. \n\nKey findings include:\n\n- The rs4149056 variant (521T>C) is linked to a higher risk of statin-induced myopathy, especially in patients on high-dose simvastatin, as demonstrated in genomewide association studies such as the SEARCH trial.\n- Both polymorphisms are implicated in milder forms of statin intolerance and adverse drug reactions (ADRs).\n- Allele and haplotype frequencies of these variants (including *SLCO1B1* *1a*, *1b*, *5*, and *15*) have been characterized in populations such as 1,205 healthy Thai individuals, showing population-specific distribution relevant for personalized therapy.\n- These genetic markers serve as predictors for statin intolerance and adverse effects but require prospective studies to fully establish clinical utility.\n\nNo specific clinical trial phases or NCT numbers were reported in the provided data. However, the evidence supports genotyping SLCO1B1 variants to guide statin dosing and reduce myopathy risk.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4044
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Simvastatin is effective in significantly reducing LDL cholesterol, total cholesterol, triglycerides, VLDL cholesterol, and apolipoprotein B levels, and is generally well tolerated. In a study involving 5348 patients with primary hypercholesterolemia treated with simvastatin 10 mg daily for 24 weeks, adverse events occurred in 4.4% of patients in a dose-dependent manner. Comparative studies show that 5 mg simvastatin reduces total and LDL cholesterol by 16% and 23%, respectively, which is greater than 10 mg pravastatin (12% and 18%; p ≤ 0.01). Meta-analysis indicates simvastatin reduces LDL cholesterol by approximately 37%, comparable to lovastatin and superior to fluvastatin (27%) and pravastatin (29%).\n\nThe FDA recommends limiting the use of the highest approved dose of simvastatin (80 mg) due to an increased risk of myopathy and muscle damage, based on the SEARCH trial and ongoing safety reviews. Patients on 80 mg daily have a higher risk of muscle injury compared to those on lower doses or other statins. Simvastatin is commonly prescribed for hypercholesterolemia but caution is advised at higher doses to minimize adverse effects.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4438
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Simvastatin safety summary:\n\n- The FDA (2011) recommends limiting simvastatin to doses below 80 mg daily due to increased risk of muscle damage, based on the SEARCH trial and ongoing safety reviews.  \n- The SEARCH trial (12,064 post-myocardial infarction patients, mean follow-up 6.7 years) compared simvastatin 20 mg vs. 80 mg daily, finding myopathy rates of 0.9% and rhabdomyolysis rates of 0.4% at 80 mg/day versus 0.02% and 0% at 20 mg/day, respectively. Myopathy was defined as CK >10x ULN plus muscle symptoms; rhabdomyolysis as CK >40x ULN plus end-organ damage.  \n- Muscle-related side effects occur in no more than 1% of patients likely caused by statins (AHA data). Risk of muscle problems is dose-related.  \n- Simvastatin should be used cautiously or avoided with drugs that increase muscle injury risk, including boceprevir, cobicistat, cyclosporine, danazol, gemfibrozil, nefazodone, telaprevir, certain antibiotics (clarithromycin, erythromycin, itraconazole, ketoconazole, voriconazole, etc.), and HIV/AIDS medications (atazanavir, ritonavir, etc.). Concomitant use may increase risk of muscle injury and kidney problems.  \n- Patients should monitor for symptoms such as headache, stomach pain, vomiting, dark urine, fatigue, light stools, jaundice, and seek medical attention if these occur.  \n- Statins, including simvastatin, are generally well tolerated and effective at lowering cholesterol; long-term use is considered safe for most patients.  \n- Statins may slightly increase the risk of developing type 2 diabetes in high-risk individuals.  \n- An experimental non-statin drug, bempedoic acid, was studied in 2019 in nearly 800 high cardiovascular risk patients on maximal tolerated statins but with uncontrolled cholesterol.  \n- Simvastatin works by inhibiting liver cholesterol synthesis and can be taken with alcohol, although alcohol increases simvastatin blood levels.  \n- No resistance markers were reported related to simvastatin safety or efficacy.\n\nKey recommendations: avoid simvastatin 80 mg daily due to elevated myopathy/rhabdomyolysis risk; carefully assess drug interactions; monitor for muscle injury symptoms; consider alternative therapies in high-risk patients.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 7013
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly the rs4149056 (c.521T>C) variant, significantly impact simvastatin safety by increasing the risk of statin-induced myopathy. Clinical evidence, including data from the large Heart Protection Study (NCT identifier not specified, ~18,000 participants on 40 mg simvastatin), indicates that carriers of the C allele have an increased myopathy risk, leading to recommendations for SLCO1B1 genotyping to guide simvastatin dosing and reduce muscle-related adverse events. \n\nRegarding efficacy, the impact of SLCO1B1 variants on simvastatin's lipid-lowering effect is minimal and inconclusive. The Heart Protection Study showed approximately a 1% per C allele reduction in LDL cholesterol lowering with no significant effect on vascular outcomes. Clinical implementation of SLCO1B1 genotyping has demonstrated noninferior lipid-lowering outcomes when genotype-guided prescribing avoids simvastatin use in individuals with decreased or poor OATP1B1 transporter function, thereby reducing myopathy risk without compromising efficacy.\n\nKey conclusions:\n- SLCO1B1 rs4149056 polymorphism is a strong predictor of simvastatin-induced myopathy.\n- Genotyping can guide safer simvastatin prescribing, improving adherence and reducing adverse muscle symptoms.\n- The effect of SLCO1B1 variants on simvastatin efficacy (LDL-c reduction) is small (~1% per C allele) and not clinically significant.\n- Physicians tend to avoid simvastatin in patients with at-risk SLCO1B1 genotypes when genotype information is available, maintaining efficacy while enhancing safety.\n\nNo specific resistance markers were reported. Safety/adverse event rates emphasize increased myopathy risk in carriers of the C allele of rs4149056.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 3708
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_disease_name",
                    "toolsuite": "opentargets",
                    "success": true,
                    "sse_summary": "Summary for Hypercholesterolemia (EFO ID: HP_0003124):\n\nKey Disease Targets (with relevance scores):  \n- LDLR (0.8413)  \n- PCSK9 (0.8113)  \n- APOB (0.8045)  \n- HMGCR (0.7478)  \n- NPC1L1 (0.7115)  \n- ABCG8 (0.6585)  \n- ABCG5 (0.6105)  \n- APOE (0.6103)  \n- SORT1 (0.5838)  \n- PPARA (0.5770)  \n... (additional targets with scores down to ~0.51)\n\nApproved Drugs (all Phase 4, no withdrawals) with mechanisms and targets:  \n- Amlodipine Besylate (Norvasc, Norliqva): Voltage-gated L-type calcium channel blocker targeting CACNA1D.  \n- Pitavastatin Calcium (Livalo): HMG-CoA reductase inhibitor targeting HMGCR.  \n- Atorvastatin (Lipitor, Cardyl, Sortis, Tahor, Zarator): HMG-CoA reductase inhibitor targeting HMGCR; multiple trials completed or unknown status.  \n- Rosuvastatin Calcium (Crestor, Ezallor): HMG-CoA reductase inhibitor targeting HMGCR.  \n- Evolocumab (Repatha): Subtilisin/kexin type 9 (PCSK9) inhibitor targeting PCSK9.  \n- Bempedoic Acid (Nexletol, Nilemdo): ATP-citrate synthase inhibitor targeting ACLY.  \n- Fenofibrate (Tricor, Lipantil, Lipofen, others): Peroxisome proliferator-activated receptor alpha (PPARA) agonist targeting PPARA.  \n- Pravastatin Sodium (Pravachol, Elisor): HMG-CoA reductase inhibitor targeting HMGCR; completed trials.  \n- Simvastatin (Zocor, Flolipid): HMG-CoA reductase inhibitor targeting HMGCR.\n\nNo specific clinical trial identifiers (NCT numbers), numerical efficacy data, response rates, safety/adverse event rates, or resistance markers were reported in the provided data.\n\nKey conclusions/recommendations:  \n- Multiple statins (atorvastatin, rosuvastatin, pravastatin, simvastatin, pitavastatin) targeting HMGCR are approved and in phase 4 clinical use for hypercholesterolemia.  \n- PCSK9 inhibition via evolocumab represents a targeted approach for patients needing additional LDL lowering beyond statins.  \n- Other mechanisms such as ATP-citrate synthase inhibition (bempedoic acid) and PPAR alpha activation (fenofibrate) provide alternative or adjunct therapies.  \n- Amlodipine, a calcium channel blocker, is approved but targets CACNA1D, indicating a role more related to hypertension management rather than direct lipid lowering.\n\nThis summary preserves critical drug names, targets, mechanisms, approval phases, and clinical status for hypercholesterolemia management.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 9161
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Statin therapy guidelines recommend the following:\n\n1. **Primary Prevention Indications:**\n   - Adults aged 40-75 years with diabetes: Moderate-intensity statin therapy is indicated (2019 ACC/AHA Guideline).\n   - Adults aged 40-75 years with LDL-C ≥70 to <190 mg/dL without diabetes: Statin therapy is considered based on 10-year ASCVD risk assessment and presence of risk enhancers.\n   - Adults with LDL-C ≥190 mg/dL (≥4.9 mmol/L), including those without ASCVD: High-intensity statin therapy is recommended, or moderate-intensity statin plus ezetimibe if statin alone is insufficient (2018 AHA/ACC/Multisociety Guidelines).\n\n2. **High-Risk and Very High-Risk Patients:**\n   - For patients at very high risk with LDL-C ≥70 mg/dL despite maximally tolerated statin plus ezetimibe, consider adding a PCSK9 inhibitor (2018 Guidelines).\n   - High-intensity statins are recommended for those with LDL-C ≥190 mg/dL without prior ASCVD, aiming for LDL-C <100 mg/dL.\n   - PCSK9 inhibitors are reserved for selected high-risk patients who do not achieve LDL-C goals on statin and ezetimibe therapy.\n\n3. **Eligibility and Implementation:**\n   - Under 2022 USPSTF recommendations, 31.8% of US adults aged 40-75 years with LDL-C <190 mg/dL and no ASCVD would be eligible for statin therapy for primary prevention.\n   - Under 2018 AHA/ACC/Multisociety guidelines, eligibility increases to 46.8% in the same population after clinician-patient risk discussion.\n\n4. **Risk Assessment and Lifestyle:**\n   - ASCVD risk categories guide statin initiation:\n     - ≥7.5% to <20% 10-year risk (“Intermediate Risk”): Risk discussion with consideration of moderate-intensity statin.\n     - ≥20% 10-year risk (“High Risk”): Initiate statin therapy to reduce LDL-C by ≥50% (Class I recommendation).\n     - <5% (“Low Risk”) or borderline risk: Emphasize lifestyle modification.\n   - Coronary artery calcium (CAC) scoring may aid decision-making in uncertain cases:\n     - CAC=0 may defer statin unless diabetes, family history, or smoking present.\n     - CAC 1-99 favors statin initiation, especially age >55.\n     - CAC ≥100 or ≥75th percentile indicates statin initiation.\n\n5. **Safety and Efficacy:**\n   - Relative risk reduction in cardiovascular events is consistent per 39 mg/dL LDL-C reduction regardless of baseline LDL-C.\n   - Guidelines emphasize adherence to lifestyle therapy alongside statins.\n\n**Key References:**\n- 2018 AHA/ACC/Multisociety Guidelines\n- 2019 ACC/AHA Guideline on Primary Prevention\n- 2022 USPSTF Recommendations\n\n**Summary:**  \nStatin therapy is recommended primarily for adults 40-75 years with diabetes or elevated ASCVD risk, with high-intensity statins for LDL-C ≥190 mg/dL. PCSK9 inhibitors may be added for very high-risk patients not achieving LDL-C goals on statins plus ezetimibe. Risk assessment, including CAC scoring, guides initiation decisions. Approximately 31.8%-46.8% of US adults aged 40-75 without ASCVD qualify for statins under current guidelines.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5217
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "High LDL-C (low-density lipoprotein cholesterol) is a major risk factor for heart attacks and strokes. The American College of Cardiology recommends targeting LDL-C levels below 55 mg/dL for individuals at very high risk, particularly those with a major cardiovascular event plus two or more high-risk conditions. For people with heart disease or diabetes, an LDL-C target below 70 mg/dL is considered optimal.\n\nLifestyle changes, including a heart-healthy diet low in saturated fats, can help lower LDL-C. Diets high in saturated fat, such as the ketogenic diet, may dramatically increase LDL-C levels. Individuals with familial hypercholesterolemia (FH), a genetic disorder causing dangerously high LDL-C, typically require cholesterol-lowering medications alongside diet and exercise to normalize levels.\n\nMedications like evolocumab (Repatha®), used alone or with other cholesterol-lowering therapies, are indicated for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C.\n\nIt is important to have LDL-C levels tested regularly, especially if you have risk factors such as heart disease, diabetes, or a family history of high cholesterol. Consultation with a healthcare provider is essential for personalized treatment and risk management.\n\nNo specific clinical trial identifiers (NCT numbers) or phase data were provided in the sources. Safety or adverse event rates were not detailed in the summaries. Resistance markers were not mentioned.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5375
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Statin therapy is recommended for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults, especially those with LDL-C ≥190 mg/dL and no history of ASCVD. The US Preventive Services Task Force (USPSTF) 2022 update, based on 22 randomized clinical trials (RCTs), supports statin use in adults aged 40-75 years with one or more cardiovascular risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a 10-year cardiovascular event risk ≥10%. Statin therapy reduces all-cause mortality, fatal/nonfatal myocardial infarction, stroke, revascularization, and composite cardiovascular outcomes. However, data are insufficient for adults older than 75 years.\n\nHigh-intensity statin therapy is recommended for patients with severe hypercholesterolemia (LDL-C ≥190 mg/dL) without the need for additional risk assessment (Class I recommendation, 2018 ACC/AHA Guidelines). For adults aged 40-75 with diabetes mellitus, moderate-intensity statins are recommended, with consideration for high-intensity statins depending on risk enhancers such as family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory diseases (e.g., rheumatoid arthritis, psoriasis, HIV), and elevated biomarkers (hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL, apoB ≥130 mg/dL).\n\nNonstatin therapies (e.g., PCSK9 inhibitors as studied in FOURIER and ODYSSEY trials, ezetimibe in IMPROVE-IT, and bempedoic acid in CLEAR) are often added to statins for intensive LDL-C lowering in very high-risk patients. \n\nKey trials referenced include:  \n- IMPROVE-IT (Vytorin efficacy)  \n- FOURIER (PCSK9 inhibition)  \n- ODYSSEY (Alirocumab post-ACS)  \n- CLEAR (Bempedoic acid)  \n- ACCORD and HPS2-THRIVE (diabetes and lipid management)\n\nSafety data from 19 RCTs and 3 large cohort studies indicate statins are generally well tolerated, with no new significant harms identified for primary prevention populations.\n\nIn summary, adults aged 40-75 years with LDL-C ≥190 mg/dL or with diabetes and additional risk factors should receive statin therapy—high-intensity for LDL ≥190 mg/dL and moderate- to high-intensity for diabetes with risk enhancers. Nonstatin agents are recommended as adjuncts in very high-risk patients to achieve intensive LDL-C lowering. Data on statin benefit in adults >75 years remain limited.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 6638
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_disease_name",
                    "toolsuite": "opentargets",
                    "success": true,
                    "sse_summary": "Atherosclerotic cardiovascular disease (EFO_0003914) is associated with multiple key genetic targets, notably PCSK9 (score 0.6821), LDLR (0.6074), HMGCR (0.5928), APOE (0.5816), SORT1 (0.5703), and P2RY12 (0.5694), among others.\n\nSeveral approved drugs targeting these molecules are in clinical use (phase 4), including:\n\n- **Bempedoic Acid** (Nexletol, Nilemdo): ATP-citrate synthase inhibitor targeting ACLY.\n- **Lovastatin** (Altoprev, Mevacor, others): HMG-CoA reductase inhibitor targeting HMGCR.\n- **Inclisiran Sodium** (Leqvio): PCSK9 mRNA RNAi inhibitor targeting PCSK9.\n- **Pravastatin Sodium** (Pravachol, Lipemol, others): HMG-CoA reductase inhibitor targeting HMGCR.\n- **Rosuvastatin Calcium** (Crestor, Ezallor): HMG-CoA reductase inhibitor targeting HMGCR.\n- **Clopidogrel Bisulfate** (Plavix, Iscover): P2Y12 receptor antagonist targeting P2RY12.\n- **Vorapaxar Sulfate** (Zontivity): Proteinase-activated receptor 1 antagonist targeting F2R.\n- **Amantadine Hydrochloride** (Symmetrel, Gocovri, others): Glutamate [NMDA] receptor antagonist targeting GRIN2D, GRIN3B, and GRIN1.\n\nAll these drugs are approved, not withdrawn, and have reached phase 4 clinical trial status. The data does not include specific efficacy percentages, safety/adverse event rates, resistance markers, or clinical trial identifiers (NCT numbers) for these drugs.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 8924
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "null",
                    "tool_name": "get_pharmacogenomics_info_by_drug_name",
                    "toolsuite": "fda_drug",
                    "success": false,
                    "additional_info_type": "Others",
                    "additional_info": "",
                    "additional_urls": ""
                  }
                ]
              }
            }
          }
        },
        "agent_properties": {
          "organ_name": "cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Tissue Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with particular attention to the SLCO1B1 gene's influence on drug metabolism and associated myopathy risks.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, especially in patients with the rs4149056 variant.\n  - Efficacy in lowering LDL cholesterol is evident, but muscle-related side effects pose significant concerns.\n  - Monitoring for adverse reactions is crucial due to the patient's genetic profile.\n- **Cellular Impact:**\n  - Elevated risk of muscle damage observed, particularly in high-dose scenarios.\n  - Increased engagement of repair mechanisms may be necessary, yet their effectiveness could be limited by continuous drug exposure.\n  - Cellular stress responses are activated in the presence of statin therapy, necessitating vigilant monitoring of muscle health.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Tissue Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with particular attention to the SLCO1B1 gene's influence on drug metabolism and associated myopathy risks.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, especially in patients with the rs4149056 variant.\n  - Efficacy in lowering LDL cholesterol is evident, but muscle-related side effects pose significant concerns.\n  - Monitoring for adverse reactions is crucial due to the patient's genetic profile.\n- **Cellular Impact:**\n  - Elevated risk of muscle damage observed, particularly in high-dose scenarios.\n  - Increased engagement of repair mechanisms may be necessary, yet their effectiveness could be limited by continuous drug exposure.\n  - Cellular stress responses are activated in the presence of statin therapy, necessitating vigilant monitoring of muscle health.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 6.60350489616394,
      "error_message": null
    },
    {
      "log_id": "log_1762673027197_cell_cns_cell_cns",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:47.197688",
      "level": 3,
      "level_name": "细胞层",
      "agent_id": "cell_cns_cell_cns",
      "agent_name": "cell",
      "agent_type": "cell",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "tissue",
          "output_data": {
            "round1_analysis": "# Tissue Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with particular attention to the SLCO1B1 gene's influence on drug metabolism and associated myopathy risks.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, especially in patients with the rs4149056 variant.\n  - Efficacy in lowering LDL cholesterol is evident, but muscle-related side effects pose significant concerns.\n  - Monitoring for adverse reactions is crucial due to the patient's genetic profile.\n- **Cellular Impact:**\n  - Elevated risk of muscle damage observed, particularly in high-dose scenarios.\n  - Increased engagement of repair mechanisms may be necessary, yet their effectiveness could be limited by continuous drug exposure.\n  - Cellular stress responses are activated in the presence of statin therapy, necessitating vigilant monitoring of muscle health.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Tissue Status Report: CNS\n- **General State:** The CNS is currently processing the effects of Simvastatin, with particular attention to the SLCO1B1 gene's influence on drug metabolism and associated myopathy risks.\n- **Key Drug Observations:**\n  - Simvastatin is linked to an increased risk of myopathy, especially in patients with the rs4149056 variant.\n  - Efficacy in lowering LDL cholesterol is evident, but muscle-related side effects pose significant concerns.\n  - Monitoring for adverse reactions is crucial due to the patient's genetic profile.\n- **Cellular Impact:**\n  - Elevated risk of muscle damage observed, particularly in high-dose scenarios.\n  - Increased engagement of repair mechanisms may be necessary, yet their effectiveness could be limited by continuous drug exposure.\n  - Cellular stress responses are activated in the presence of statin therapy, necessitating vigilant monitoring of muscle health.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "tissue_name": "cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 5.4770190715789795,
      "error_message": null
    },
    {
      "log_id": "log_1762673030684_organ_kidney",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:50.684804",
      "level": 1,
      "level_name": "器官层",
      "agent_id": "organ_kidney",
      "agent_name": "organ",
      "agent_type": "organ",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "organ_flows": {
          "drug_flow": "Analysis of Statin + SLCO1B1 for Hypercholesterolemia",
          "bio_signals": "Patient baseline: 45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg",
          "literature_flow": "Starting literature review process"
        }
      },
      "output_data": {
        "round1_analysis": "# Organ Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - Expected conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Potential activation of pathways related to drug metabolism and excretion is occurring.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Organ Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - Expected conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Potential activation of pathways related to drug metabolism and excretion is occurring.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What is the impact of SLCO1B1 gene variants on simvastatin metabolism and risk of myopathy?",
              "Are there any specific guidelines or recommendations for prescribing simvastatin to patients with high LDL-C and without ASCVD?"
            ],
            "tool_result": "- **Tool Name:** get_general_info_by_protein_or_gene_name\n  - **Gene Names:** SLCO1B1, LST1, OATP1B1, OATP2, OATPC, SLC21A6\n  - **Drug Names:** Pravastatin, Pitavastatin, Methotrexate, Enalapril, Valsartan\n  - **Critical Quantitative Information:**\n    - Maximum velocities (pmol/min/mg protein):\n      - Estrone 3-sulfate: 60.3\n      - Pitavastatin: 230.0\n      - 17beta-estradiol 17-O-(beta-D-glucuronate): 131.0\n      - Valsartan: 3.85\n      - Enalapril: 78.0\n      - Coproporphyrin I: 17.9\n      - Coproporphyrin III: 24.9\n    - Michaelis constants (Km, µM):\n      - Taurocholate: 13.6\n      - L-thyroxine: 3.0\n      - 3,3',5'-triiodo-L-thyronine: 2.7\n      - Pravastatin: 33.8\n      - Pitavastatin: 3.0\n      - Estrone 3-sulfate: 0.458\n      - 17beta-estradiol 17-O-(beta-D-glucuronate): 8.29\n      - Valsartan: 1.39\n      - Enalapril: 262.0\n      - Coproporphyrin I: 0.13\n      - Coproporphyrin III: 0.22\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Drug Names:** Simvastatin, Simvastatin Acid (SVA)\n  - **Gene Names:** SLCO1B1\n  - **Critical Quantitative Information:**\n    - Genetic marker: SLCO1B1 rs4149056 (c.521T>C) increases simvastatin acid exposure and muscle toxicity risk.\n    - Approximately 40% of simvastatin is converted to SVA intracellularly.\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Gene Names:** SLCO1B1\n  - **Critical Quantitative Information:**\n    - Variant: SLCO1B1*5 (rs4149056-C) increases simvastatin acid levels and muscle toxicity risk.\n    - Incidence of composite adverse events (myalgia, CK elevation, treatment discontinuation) linked to SLCO1B1*5 carriers.\n    - LDL-C reductions by genotype:\n      - C/C: 44 ± 25 mg/dL\n      - T/C: 55 ± 19 mg/dL\n      - T/T: 57 ± 22 mg/dL (*P* = 0.038)\n    - Total cholesterol reductions:\n      - C/C: 43 ± 27 mg/dL\n      - T/C: 57 ± 21 mg/dL\n      - T/T: 60 ± 24 mg/dL (*P* = 0.008)\n  - **URLs/References:** CPIC 2022 guideline for dosing recommendations based on SLCO1B1 phenotypes.\n\n- **Tool Name:** get_general_info_by_disease_name\n  - **Disease Name:** Myopathy (EFO_0004145)\n  - **Gene Names:** ACTA1, RYR1, TTN, POLG, DMD, FKRP\n  - **Drug Names:** Prednisolone, Cortisone acetate, Prednisone, Hydrocortisone, Methylprednisolone, Triamcinolone acetonide\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Gene Names:** SLCO1B1\n  - **Critical Quantitative Information:**\n    - Odds ratio (OR) for statin-related myopathy: 2.51 (95% CI: 1.28–).\n  - **URLs/References:** CPIC guidelines recommend considering SLCO1B1 genotype when prescribing statins.\n\n- **Tool Name:** get_drug_names_by_animal_pharmacology_info\n  - **Drug Names:** Ezetimibe, Raloxifene hydrochloride\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Drug Names:** Simvastatin\n  - **Critical Quantitative Information:**\n    - Recommended starting dose: 10-20 mg once daily\n    - Maximum dose: 40 mg to 80 mg depending on individual factors.\n    - Increased risk of myopathy and rhabdomyolysis at 80 mg for patients aged ≥65 years.\n    - No additional cardiovascular benefit when niacin is added to simvastatin 40 mg.\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - LDL-C ≥190 mg/dL or >4.9 mmol/L: high-intensity statin therapy recommended.\n    - PCSK9 inhibitors may be considered if LDL-C goals are not met despite therapy.\n  - **URLs/References:** 2018 ACC/AHA Guidelines\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - High-intensity statin therapy for LDL-C ≥190 mg/dL.\n    - PCSK9 inhibitors as add-on therapy if LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy.\n  - **URLs/References:** 2018 ACC/AHA Guidelines\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - Class 1 recommendation for adults with LDL-C >190 mg/dL and for adults aged 40-75 years with diabetes.\n    - Statin therapy reduces cardiovascular events and mortality.\n  - **URLs/References:** 2018 AHA/ACC/MS Guideline, 2022 USPSTF Update\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - Recommendations for various patient groups based on LDL-C levels and ASCVD risk.\n    - Specific dosages and regimens are not detailed.\n  - **URLs/References:** 2018 AHA/ACC/MS Guideline, 2022 USPSTF Update",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "get_general_info_by_protein_or_gene_name",
                "toolsuite": "uniprot",
                "success": true,
                "sse_summary": "The gene **SLCO1B1** (also known as LST1, OATP1B1, OATP2, OATPC, SLC21A6) encodes a transporter protein primarily expressed in the liver, specifically at the basolateral membranes of centrilobular hepatocytes, including fetal liver. It is not detected in heart, brain, placenta, lung, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis (except weak expression in Leydig cells and Sertoli cells’ basal membrane), ovary, small intestine, colon, or leukocytes.\n\n**Function:**  \nSLCO1B1 mediates Na(+)-independent uptake of a broad range of organic anions, including bile acid taurocholate, conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, estrone 3-sulfate), eicosanoids (prostaglandin E2, thromboxane B2, leukotrienes C4 and E4), thyroid hormones (T4/L-thyroxine and T3/3,3',5'-triiodo-L-thyronine), and bilirubin glucuronides, contributing to liver detoxification and clearance of endogenous and exogenous compounds. It also transports by-products of heme synthesis (coproporphyrin I and III) and may regulate organic compound transport across the blood-testis barrier.\n\nClinically important substrates include:  \n- Statins: pravastatin and pitavastatin  \n- Chemotherapeutic drug methotrexate  \n- Antihypertensive agents: enalapril (ACE inhibitor prodrug) and valsartan (angiotensin II AT1-receptor antagonist)\n\nThe transporter exhibits pH-sensitive substrate specificity, with optimum activity at pH 6.5 for prostaglandin E2 and L-thyroxine, likely due to protonation states affecting substrate binding and transport.\n\n**Catalytic activities (substrate transport reactions):**  \n- Taurocholate (RHEA:71703)  \n- Dehydroepiandrosterone 3-sulfate (RHEA:71839)  \n- Estrone 3-sulfate (RHEA:71835)  \n- 3,3',5'-triiodo-L-thyronine (RHEA:71815)  \n- L-thyroxine (RHEA:71819)  \n- Prostaglandin E2 (RHEA:50984)  \n- Thromboxane B2 (RHEA:50992)  \n- 17beta-estradiol 17-O-(beta-D-glucuronate) (RHEA:72691)  \n- Leukotriene C4 (RHEA:72743)  \n- Leukotriene E4 (RHEA:72747)  \n- Bilirubin IXalpha C8-beta-D-glucuronoside (RHEA:72791)  \n- Bilirubin IXalpha bis-beta-D-glucuronoside (RHEA:72795)\n\n**Kinetic parameters (maximum velocities and Michaelis constants):**  \n- Maximum velocities (pmol/min/mg protein):  \n  - Estrone 3-sulfate: 60.3  \n  - Pitavastatin: 230.0  \n  - 17beta-estradiol 17-O-(beta-D-glucuronate): 131.0  \n  - Valsartan: 3.85  \n  - Enalapril: 78.0  \n  - Coproporphyrin I: 17.9  \n  - Coproporphyrin III: 24.9\n\n- Michaelis constants (Km, μM):  \n  - Taurocholate: 13.6  \n  - L-thyroxine: 3.0  \n  - 3,3',5'-triiodo-L-thyronine: 2.7  \n  - Pravastatin: 33.8  \n  - Pitavastatin: 3.0  \n  - Estrone 3-sulfate: 0.458  \n  - 17beta-estradiol 17-O-(beta-D-glucuronate): 8.29  \n  - Valsartan: 1.39  \n  - Enalapril: 262.0  \n  - Coproporphyrin I: 0.13  \n  - Coproporphyrin III: 0.22\n\n**Summary:**  \nSLCO1B1 is a liver-expressed transporter with broad substrate specificity, playing a key role in hepatic uptake and clearance of endogenous compounds (bile acids, steroids, thyroid hormones, eicosanoids, bilirubin conjugates) and clinically relevant drugs, including statins (pravastatin, pitavastatin), methotrexate, and antihypertensives (enalapril, valsartan). It demonstrates pH-dependent activity with optimal function at acidic pH (6.5) for certain substrates. This transporter significantly impacts drug pharmacokinetics and hepatic detoxification pathways.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 22442
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin is metabolized into its active form (simvastatin acid, SVA) primarily via carboxylesterase (CES) and cytochrome P450 (CYP) enzymes. After administration, about 40% of simvastatin delivered (including via pulmonary routes such as pMDI, DPI, or nebulized nanoparticle suspension) is converted intracellularly to its active SVA metabolite. Simvastatin acts by competitively inhibiting HMG-CoA reductase, reducing endogenous cholesterol synthesis, effectively lowering LDL cholesterol and triglycerides in hyperlipidemic patients with proven cardiovascular benefits.\n\nGenetic variation in the SLCO1B1 gene, specifically the rs4149056 (c.521T>C) polymorphism, significantly increases systemic exposure to simvastatin acid and is a well-established risk factor for statin-induced muscle toxicity. Simvastatin’s effects on muscle include impairment of energy metabolism and mitochondrial respiration, with differential impacts observed between its lactone and acid forms in primary human skeletal muscle cells, affecting glucose metabolism and insulin signaling.\n\nIn preclinical models, simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells, indicated by increased alkaline phosphatase activity and bone-related protein expression.\n\nIn PGC-1α overexpressing mice, simvastatin increases lipid droplet accumulation in skeletal muscle and enhances glucose uptake without impairing muscle glucose utilization. These findings suggest simvastatin influences lipid metabolism and muscle energy homeostasis.\n\nKey points:\n- Drug: Simvastatin (prodrug), active metabolite: simvastatin acid (SVA)\n- Metabolism: CES and CYP enzymes; ~40% intracellular conversion to SVA\n- Genetic marker: SLCO1B1 rs4149056 (c.521T>C) increases simvastatin acid exposure and muscle toxicity risk\n- Mechanism: Competitive HMG-CoA reductase inhibition lowering LDL and triglycerides\n- Safety: Muscle toxicity risk associated with SLCO1B1 variant\n- Efficacy: Proven cardiovascular benefit in hyperlipidemia\n- Muscle effects: Impaired energy metabolism and mitochondrial respiration; differential effects of lactone vs acid forms\n- Additional effects: Promotes osteoblastic differentiation in periodontal ligament cells; modulates lipid accumulation and glucose uptake in skeletal muscle in mouse models\n\nNo clinical trial identifiers (NCT numbers) or phase data were available in the retrieved information.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 6380
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 gene variants, particularly the *SLCO1B1*5 allele (rs4149056-C), impair simvastatin metabolism, leading to increased plasma levels of simvastatin acid and a higher risk of muscle-related side effects, including statin-induced myopathy. The *SLCO1B1*5 variant is significantly associated with mild to severe statin-induced muscle symptoms, including creatine kinase (CK) elevation >3× upper limit of normal and treatment discontinuation due to adverse events.\n\nIn a clinical study, *SLCO1B1*5 carriers showed a higher incidence of composite adverse events (CAE), defined as myalgia, CK elevation, or discontinuation for side effects. Female sex and *SLCO1B1*5 genotype were linked to increased risk of these muscle side effects.\n\nRegarding efficacy, the *SLCO1B1* 521C variant was the only genetic factor significantly associated with the cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks in white patients. LDL-C reductions were genotype-dependent: 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T) (*P* = 0.038), and total cholesterol reductions were 43 ± 27, 57 ± 21, and 60 ± 24 mg/dL, respectively (*P* = 0.008).\n\nMetabolomic profiling identified 31 novel metabolites significantly associated with *SLCO1B1* rs4149056-C in both statin-treated and untreated participants, indicating broad metabolic effects of this variant.\n\nThe Clinical Pharmacogenetics Implementation Consortium (CPIC) 2022 guideline provides dosing recommendations based on *SLCO1B1* phenotypes to mitigate statin-associated musculoskeletal symptoms.\n\nKey points:\n- *SLCO1B1*5 (rs4149056-C) allele increases simvastatin acid levels and muscle toxicity risk.\n- Muscle adverse event rates include CK >3× upper limit and treatment discontinuation.\n- Statin efficacy (LDL-C and total cholesterol reduction) varies by *SLCO1B1* genotype, notably in white populations.\n- CPIC guidelines recommend genotype-guided simvastatin dosing.\n- Metabolite profiles differ significantly by *SLCO1B1* rs4149056-C status.\n\nNo resistance markers were reported.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5350
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_disease_name",
                "toolsuite": "opentargets",
                "success": true,
                "sse_summary": "Myopathy (EFO_0004145) is associated with multiple genetic targets, notably ACTA1 (score 0.895), RYR1 (0.891), TTN (0.888), POLG (0.884), DMD (0.883), FKRP (0.883), among others, indicating a diverse genetic basis.\n\nApproved drugs targeting myopathy predominantly act as glucocorticoid receptor agonists (target NR3C1) and include:  \n- Prednisolone (CHEMBL131), phase 4, with multiple trade names such as Cortalone, Dekotil, and Meticortelone.  \n- Cortisone acetate (CHEMBL1650), phase 4, trade names include Cortate and Cortone.  \n- Prednisone (CHEMBL635), phase 4, trade names include Cortan, Deltasone, and Rayos.  \n- Hydrocortisone (CHEMBL389621), phase 4, with numerous trade names including Acticort, Cortef, and Locoid.  \n- Methylprednisolone (CHEMBL650), phase 4, trade names Medrol and Medrone.  \n- Triamcinolone acetonide (CHEMBL1504), phase 4, trade names include Kenalog, Nasacort, and Triderm.\n\nThese drugs share a common mechanism of glucocorticoid receptor agonism and are approved for clinical use without withdrawal.\n\nKey phenotypic features of myopathy include:  \n- Myofibrillar myopathy characterized by abnormal intracellular desmin accumulation (HP_0003715).  \n- Muscle weakness: lower limb (HP_0007340), proximal muscles (HP_0003701), foot dorsiflexors (HP_0009027).  \n- Gait abnormalities: waddling gait (HP_0002515), steppage gait (HP_0003376).  \n- Muscle contractures: knee flexion (HP_0006380), Achilles tendon (HP_0001771), forearm supination (HP_0034394).  \n- Other signs: hyporeflexia (HP_0001265), scapular winging (HP_0003691), skeletal muscle atrophy (HP_0003202), and elevated circulating creatine kinase (HP_0003236).  \n- Onset ranges from young adult (16–40 years, HP_0011462) to middle age (40–60 years, HP_0003596).  \n- Some forms show X-linked dominant inheritance (HP_0001423).  \n- Cardiac involvement may include right bundle branch block (HP_0011712).\n\nNo resistance markers were reported.\n\nIn summary, glucocorticoid receptor agonists like prednisolone, prednisone, and methylprednisolone represent the main approved therapeutic agents for myopathy, targeting NR3C1, with phase 4 clinical status. The disease manifests with characteristic muscle weakness, contractures, and elevated CK levels, with multiple genetic targets implicated.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 20577
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 gene variants, particularly rs4149056 and T521C polymorphisms, are strongly associated with an increased risk of statin-induced myopathy and statin intolerance. These variants result in poor SLCO1B1 function, leading to higher myopathy rates across multiple statins, including simvastatin and atorvastatin. A gene risk score incorporating missense variants in SLCO1B1 correlates with earlier onset of statin intolerance and myopathy, with an odds ratio (OR) for statin-related myopathy reported as 2.51 (95% CI: 1.28–). Clinical Pharmacogenetics Implementation Consortium guidelines recommend considering SLCO1B1 genotype when prescribing statins to mitigate musculoskeletal adverse effects.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3928
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_drug_names_by_animal_pharmacology_info",
                "toolsuite": "fda_drug",
                "success": true,
                "sse_summary": "The hypocholesterolemic effect of ezetimibe, alone or combined with simvastatin, was evaluated in cholesterol-fed Rhesus monkeys, dogs, rats, and mouse models of human cholesterol metabolism. These preclinical findings support ezetimibe's lipid-lowering activity. Additionally, raloxifene hydrochloride demonstrated skeletal antiresorptive effects consistent with human data on radiocalcium kinetics and bone metabolism markers, confirming its role as an antiresorptive agent. No specific clinical trial identifiers, dosages, adverse event rates, or resistance markers were reported in the provided data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 1757
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "Error: Failed after 3 attempts when executing tool: Error executing tool clinvar_query_sequence_variants: 'DBSEARCH' object has no attribute 'clinvar_query_sequence_variants'. Tool_invoke_info: {'item': 'SLCO1B1 gene variants', 'tool': 'clinvar_query_sequence_variants', 'tool_input': {'sequence': '', 'variants': []}}",
                "tool_name": "clinvar_query_sequence_variants",
                "toolsuite": null,
                "success": false
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin prescribing guidelines recommend starting adults at 10-20 mg once daily, taken in the evening, with a maximum dose ranging from 40 mg to 80 mg depending on individual factors. Dosage adjustments should be made by a physician based on patient-specific health conditions.\n\nKey safety notes include:\n\n- Patients on 80 mg daily have increased risk of myopathy and rhabdomyolysis, especially those aged ≥65 years.\n- If an interacting drug that raises myopathy risk is prescribed alongside simvastatin 80 mg, switching to an alternative statin is advised.\n- For stable patients on 80 mg who develop adverse effects, lowering the dose or discontinuing simvastatin and switching to another statin is recommended.\n- No additional cardiovascular benefit was observed when niacin was added to simvastatin 40 mg (with or without ezetimibe 10 mg) in a clinical study with median follow-up of 3.9 years.\n\nClinical monitoring by an interprofessional team (physicians, nurses, pharmacists) is essential to manage efficacy and adverse effects. Pharmacists can recommend equivalent dosing with other statins that may have fewer adverse events.\n\nNo specific resistance markers were noted in the reviewed data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4355
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "For patients with high LDL-C without ASCVD but severe primary hypercholesterolemia (LDL-C ≥190 mg/dL or >4.9 mmol/L), high-intensity statin therapy is recommended as first-line treatment to achieve LDL-C goals (<100 mg/dL). If LDL-C goals are not met despite maximally tolerated statin therapy (or moderate-intensity statin plus ezetimibe), PCSK9 inhibitors may be considered, especially in patients at very high risk for future ASCVD events.\n\nKey points and data include:\n\n- The 2018 ACC/AHA Guidelines recommend high-intensity statins for patients with LDL-C ≥190 mg/dL without clinical ASCVD (Class I recommendation).\n- PCSK9 inhibitors are recommended as add-on therapy if LDL-C remains ≥70 mg/dL (or non-HDL-C >100 mg/dL) despite maximal statin plus ezetimibe therapy.\n- The Cholesterol Treatment Trialists meta-analysis demonstrated a consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C reduction, regardless of baseline LDL-C.\n- Secondary treatment with ezetimibe, with or without PCSK9 inhibitors, is advised for patients who have not achieved at least a 50% LDL-C reduction or have LDL-C levels ≥70 mg/dL despite maximum tolerated statin therapy.\n- USPSTF recommends low- to moderate-dose statins for primary prevention in adults aged 40-75 with one or more CVD risk factors and a 10-year cardiovascular risk ≥10%, though this is less specific to high LDL-C alone.\n- Safety and adverse event rates for high-intensity statins and PCSK9 inhibitors are well-established, with PCSK9 inhibitors generally well tolerated.\n- Risk enhancers influencing therapy decisions include family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory diseases, and elevated biomarkers such as hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL, and apoB ≥130 mg/dL.\n\nIn summary, for patients with severe primary hypercholesterolemia without ASCVD, initiate high-intensity statin therapy aiming for LDL-C <100 mg/dL; if goals are unmet, add ezetimibe and consider PCSK9 inhibitors based on residual LDL-C levels and overall risk.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5951
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "The 2018 guidelines for high LDL-C management recommend the following:\n\n1. **Severe Primary Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L])**:  \n   - Initiate high-intensity statin therapy (or moderate-intensity statin plus ezetimibe) without risk assessment to achieve LDL-C <100 mg/dL.  \n   - If LDL-C goal is not reached, consider adding a PCSK9 inhibitor in selected higher-risk patients.  \n   - Maximally tolerated statin therapy is recommended for patients aged 20-75 years with LDL-C ≥190 mg/dL (Class I recommendation).\n\n2. **Intermediate Risk (LDL-C 70-189 mg/dL [1.8-4.9 mmol/L])**:  \n   - Moderate-intensity statins are recommended for patients 40-75 years without diabetes at intermediate risk (10-year ASCVD risk 7.5%-19.9%) based on high-quality RCT evidence.  \n   - In uncertain cases, coronary artery calcium (CAC) scoring may guide statin therapy decisions:  \n     - CAC = 0 may defer statin unless diabetes, family history of premature CHD, or smoking present.  \n     - CAC 1-99 favors statin initiation, especially after age 55.  \n     - CAC ≥100 or ≥75th percentile warrants statin therapy.\n\n3. **Very High-Risk ASCVD Patients**:  \n   - Use LDL-C threshold of 70 mg/dL for intensifying therapy.  \n   - Add PCSK9 inhibitors if LDL-C remains ≥70 mg/dL despite maximally tolerated statin and ezetimibe.\n\n4. **Diabetes Mellitus Considerations**:  \n   - Age 40-75 with diabetes: moderate-intensity statin (Class I).  \n   - Consider high-intensity statin if additional risk enhancers present (Class IIa).\n\n5. **Lifestyle Modifications**:  \n   - Always recommended as foundational therapy across all risk groups.\n\n6. **Risk Enhancers Include**:  \n   - Family history of premature ASCVD  \n   - Persistently elevated LDL-C ≥160 mg/dL (≥4.1 mmol/L)  \n   - Chronic kidney disease  \n   - Metabolic syndrome  \n   - Conditions specific to women (e.g., preeclampsia, premature menopause)  \n   - Inflammatory diseases (rheumatoid arthritis, psoriasis, HIV)  \n   - South Asian ancestry  \n   - Persistently elevated triglycerides ≥175 mg/dL  \n   - Biomarkers (if measured): hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL or >125 nmol/L, apoB ≥130 mg/dL  \n   - Ankle-brachial index (ABI) <0.9\n\n7. **Efficacy and Safety Data**:  \n   - Cholesterol Treatment Trialists meta-analysis showed consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C reduction across LDL baseline levels.  \n   - Maximally tolerated statin therapy aims for ≥50% LDL-C reduction.\n\n**Key recommendations summary**:  \n- High-intensity statins for LDL-C ≥190 mg/dL or very high-risk ASCVD.  \n- Moderate-intensity statins for intermediate risk with LDL-C 70-189 mg/dL.  \n- PCSK9 inhibitors as add-on therapy for very high-risk patients not reaching LDL-C goals on statins plus ezetimibe.  \n- Use CAC scoring to guide statin initiation when risk decision is uncertain.  \n- Emphasize lifestyle changes in all patients.\n\nNo specific resistance markers were reported in these guidelines.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 6882
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Summary of Statin Therapy Guidelines for Patients Without ASCVD:\n\n1. **2018 AHA/ACC/MS Guideline**  \n   - Statin therapy is **Class 1 recommended** for:  \n     - Adults with LDL-C >190 mg/dL  \n     - Adults aged 40-75 years with diabetes mellitus, regardless of ASCVD risk  \n     - Adults aged 40-75 years with a 10-year ASCVD risk ≥20%  \n   - For borderline (5 to <7.5%) and intermediate (7.5% to <20%) 10-year ASCVD risk, shared decision-making is emphasized, with Class 2b recommendation for borderline risk and Class 1 for intermediate risk.  \n   - The 2022 USPSTF guideline is noted to reduce statin initiation opportunities compared to this guideline, especially in younger adults and those with diabetes.\n\n2. **2022 USPSTF Update**  \n   - Based on an evidence review including 22 RCTs, statin therapy for primary prevention (patients without ASCVD) reduces:  \n     - All-cause mortality  \n     - Fatal or nonfatal myocardial infarction  \n     - Fatal or nonfatal stroke  \n     - Revascularization  \n     - Composite cardiovascular outcomes  \n   - Harms assessed from 19 RCTs and 3 large cohort studies.  \n   - Insufficient data for adults >75 years.\n\n3. **Non-Statin Therapies (NLA Guidance)**  \n   - PCSK9 inhibitors approved for high-risk patients (existing ASCVD or LDL-C >190 mg/dL) who do not achieve >50% LDL-C reduction on maximally tolerated statins.  \n   - Non-statin therapies considered to address gaps in LDL-C lowering for ASCVD risk reduction in high-risk subsets.\n\n4. **Additional Recommendations**  \n   - Patients aged 20-75 years with LDL-C ≥190 mg/dL should receive maximally tolerated statin therapy (moderate-quality evidence, RCTs).  \n   - Patients 40-75 years without diabetes at intermediate risk (LDL-C 70-189 mg/dL, 10-year ASCVD risk 7.5%-19.9%) should receive moderate-intensity statins (high-quality evidence).  \n   - For patients with LDL-C 70-189 mg/dL and 10-year ASCVD risk 7.5%-19.9% where statin therapy decision is uncertain, coronary artery calcium (CAC) scoring is reasonable to guide treatment.\n\n5. **Specific Dosage/Regimens**  \n   - Moderate-intensity statin therapy is recommended for diabetes patients aged 40-75 with LDL-C ≥70 mg/dL.  \n   - Specific statin types and dosages are not detailed in the summary but moderate-intensity statins are implied.\n\n**Key Points:**  \n- Statin therapy is strongly recommended for adults 40-75 with diabetes or LDL-C >190 mg/dL or high ASCVD risk (≥20%).  \n- Shared decision-making is important for borderline/intermediate risk groups.  \n- Statins reduce mortality and major cardiovascular events in primary prevention.  \n- PCSK9 inhibitors are an option for high-risk patients inadequately controlled on statins.  \n- CAC scoring can help decision-making in uncertain cases.  \n- Data on statin efficacy and safety in adults over 75 are insufficient.\n\nNo resistance markers were reported in the provided data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5512
                },
                "additional_info_type": "Others",
                "additional_info": ""
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": true
      },
      "execution_time": 289.5178270339966,
      "error_message": null
    },
    {
      "log_id": "log_1762673034614_organ_heart",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:54.615171",
      "level": 1,
      "level_name": "器官层",
      "agent_id": "organ_heart",
      "agent_name": "organ",
      "agent_type": "organ",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "organ_flows": {
          "drug_flow": "Analysis of Statin + SLCO1B1 for Hypercholesterolemia",
          "bio_signals": "Patient baseline: 45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg",
          "literature_flow": "Starting literature review process"
        }
      },
      "output_data": {
        "round1_analysis": "# Organ Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and a focus on assessing the implications of SLCO1B1 genetic variants.\n- **Key Drug Observations:**\n  - Simvastatin is effectively reducing LDL-C by approximately 55 mg/dL for T/C and 57 mg/dL for T/T genotypes.\n  - Myopathy risk is heightened in patients with the SLCO1B1 521T>C polymorphism, particularly at higher doses.\n  - The heart's response to Simvastatin is being monitored for potential adverse effects related to the patient's genetic background.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating increased risk of myopathy in relation to SLCO1B1 variants are being emitted.\n  - Emitting stress signals in response to the metabolic effects of Simvastatin on lipid profiles.\n  - Active feedback regarding LDL-C levels and cholesterol synthesis modulation.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Organ Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and a focus on assessing the implications of SLCO1B1 genetic variants.\n- **Key Drug Observations:**\n  - Simvastatin is effectively reducing LDL-C by approximately 55 mg/dL for T/C and 57 mg/dL for T/T genotypes.\n  - Myopathy risk is heightened in patients with the SLCO1B1 521T>C polymorphism, particularly at higher doses.\n  - The heart's response to Simvastatin is being monitored for potential adverse effects related to the patient's genetic background.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating increased risk of myopathy in relation to SLCO1B1 variants are being emitted.\n  - Emitting stress signals in response to the metabolic effects of Simvastatin on lipid profiles.\n  - Active feedback regarding LDL-C levels and cholesterol synthesis modulation.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What is the impact of SLCO1B1 polymorphisms on the efficacy and safety of Simvastatin in patients with hypercholesterolemia?",
              "What are the recommended guidelines for statin therapy in patients with high LDL-C and no history of ASCVD?"
            ],
            "tool_result": "- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Simvastatin\n  - **Critical Information**:\n    - Polymorphisms: rs4149056 (521T>C, V174A), rs2306283 (388A>G, N130D)\n    - Association with statin-induced myopathy and intolerance.\n    - Higher risk of myopathy with rs4149056 variant, especially in high-dose simvastatin.\n    - Identified in the SEARCH trial (NCT identifier not specified).\n    - Allele and haplotype frequencies characterized in various populations (1,205 healthy Thai individuals).\n  - **Clinical Implications**:\n    - Genotyping for SLCO1B1 variants can predict myopathy risk and guide therapy.\n    - Importance of awareness of polymorphisms to avoid adverse outcomes.\n  - **References**: None specified.\n\n- **Tool Name**: get_general_info_by_compound_name\n  - **Gene Names**: None specified.\n  - **Drug Names**: Simvastatin (brand name: Zocor), Rosuvastatin\n  - **Critical Information**:\n    - Mechanism: Competitive inhibitor of HMG-CoA reductase.\n    - Indications: Primary hyperlipidemia, familial hypercholesterolemia, secondary prevention in high-risk patients.\n    - Efficacy: Reduces major cardiovascular events by 20%-22% per 1 mmol/L LDL reduction.\n    - Myopathy risk: \n      - 0.03% at 20 mg/day\n      - 0.08% at 40 mg/day\n      - 0.61% at 80 mg/day\n    - Liver enzyme elevations >3x ULN: ~1% of patients.\n    - Clinical trial data: Scandinavian Simvastatin Survival Study (4S), Heart Protection Study (HPS, n=20,536).\n  - **References**: None specified.\n\n- **Tool Name**: get_general_info_by_disease_name\n  - **Gene Names**: LDLR, PCSK9, APOB, HMGCR, NPC1L1, ABCG8, ABCG5, APOE, SORT1, PPARA\n  - **Drug Names**: Amlodipine Besylate, Pitavastatin Calcium (Livalo), Atorvastatin (Cardyl, Lipitor, Prevencor, Sortis, Tahor, Zarator), Rosuvastatin Calcium (Crestor, Ezallor), Evolocumab (Repatha), Bempedoic Acid (Nexletol), Fenofibrate, Pravastatin Sodium (Elisor, Lipemol, Liplat, Lipostat, Pravachol), Simvastatin (Flolipid, Lacersa, Ranzolont, Simvador, Zocor)\n  - **Critical Information**:\n    - All drugs are Phase 4 and not withdrawn.\n    - Mechanisms include HMG-CoA reductase inhibition and PCSK9 inhibition.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Simvastatin\n  - **Critical Information**:\n    - Polymorphisms: rs4149056 (also known as SLCO1B1*5).\n    - Allelic odds ratio (OR) of 4.5 for definite myopathy (CK >10× upper limit of normal) with high doses of simvastatin.\n    - LDL-C reductions: \n      - 44 ± 25 mg/dL (C/C)\n      - 55 ± 19 mg/dL (T/C)\n      - 57 ± 22 mg/dL (T/T)\n      - Total cholesterol reductions: \n        - 43 ± 27 mg/dL (C/C)\n        - 57 ± 21 mg/dL (T/C)\n        - 60 ± 24 mg/dL (T/T)\n    - Statistical significance: *P* = 0.038 for LDL-C; *P* = 0.008 for total cholesterol.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Simvastatin\n  - **Critical Information**:\n    - Genotyping recommendations for patients with SLCO1B1 521 CC or TC genotypes.\n    - Maximum simvastatin dose for TC genotype: 40 mg/day.\n    - LDL-C reduction data provided earlier.\n    - Heart Protection Study (N=18,000 on 40 mg simvastatin) suggested minimal effect (~1% per C allele).\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Atorvastatin\n  - **Critical Information**:\n    - Impact of SLCO1B1 polymorphisms on atorvastatin pharmacokinetics and efficacy.\n    - No linkage found in Brazilian familial hypercholesterolemia cohort.\n    - Studies on SLCO1B1 and MDR1 polymorphisms in Egyptian patients.\n    - Systematic review confirmed genotypic effects on myopathy risk.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: None specified.\n  - **Drug Names**: None specified.\n  - **Critical Information**:\n    - Recommendations for statin therapy:\n      - High-intensity for high 10-year ASCVD risk.\n      - Moderate-intensity for diabetics aged 40-75 years.\n    - 2022 USPSTF recommendations indicate 31.8% of US adults aged 40-75 with LDL-C <190 mg/dL are eligible for statin therapy.\n    - Risk categories defined for ASCVD.\n    - Coronary artery calcium (CAC) scoring recommendations.\n  - **References**: 2018 AHA/ACC/Multisociety cholesterol guidelines, 2019 ACC/AHA Primary Prevention Guideline, 2022 USPSTF recommendations.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: None specified.\n  - **Drug Names**: Evolocumab (Repatha)\n  - **Critical Information**:\n    - LDL-C targets: <55 mg/dL for very high-risk; <70 mg/dL for diabetes or heart disease risk.\n    - Lifestyle modifications recommended.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: None specified.\n  - **Drug Names**: None specified.\n  - **Critical Information**:\n    - Statin therapy recommendations for primary prevention of ASCVD in adults aged 40-75 years.\n    - High-intensity statins for LDL-C ≥190 mg/dL.\n    - Key clinical trials: IMPROVE-IT, FOURIER, ODYSSEY, CLEAR, ACCORD, HPS2-THRIVE.\n  - **References**: 2018 ACC/AHA Guideline on the Management of Blood Cholesterol.\n\n- **Tool Name**: get_general_info_by_disease_name\n  - **Gene Names**: PCSK9, LDLR, HMGCR, APOE, SORT1\n  - **Drug Names**: Bempedoic Acid (Nexletol, Nilemdo), Lovastatin (Altoprev, Mevacor), Pravastatin Sodium (Pravachol), Rosuvastatin Calcium (Crestor), Inclisiran Sodium (Leqvio), Clopidogrel Bisulfate (Plavix), Vorapaxar Sulfate (Zontivity), Amantadine Hydrochloride (Gocovri)\n  - **Critical Information**:\n    - Main therapeutic targets include PCSK9, LDLR, HMGCR.\n    - All drugs listed are approved and at clinical trial phase 4.\n  - **References**: None specified.\n\n- **Tool Name**: get_pharmacogenomics_info_by_drug_name\n  - **Gene Names**: None specified.\n  - **Drug Names**: None specified.\n  - **Critical Information**: No data available due to failure of the tool.\n  - **References**: None specified.",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly alter the transport activity of the hepatic OATP1B1 transporter. These variants are strongly associated with statin-induced myopathy, statin intolerance, and adverse drug reactions (ADRs) due to reduced hepatic uptake of statins.\n\nKey findings include:  \n- The rs4149056 variant is linked to a higher risk of myopathy, especially in patients on high-dose simvastatin, as demonstrated in the SEARCH trial (NCT identifier not specified). This association was identified via a genomewide association study with well-matched controls, showing a large effect size on myopathy risk.  \n- Both polymorphisms affect statin elimination and contribute to variable patient responses and intolerance, including milder forms of statin intolerance.  \n- Allele and haplotype frequencies of these variants (notably *SLCO1B1* *1a*, *1b*, *5*, and *15*) have been characterized in various populations, including a study of 1,205 healthy Thai individuals, indicating population-specific prevalence.  \n\nClinical implications:  \n- Genotyping for SLCO1B1 variants, especially rs4149056, can help predict statin-induced myopathy risk and guide statin therapy selection and dosing to improve safety.  \n- Awareness of these polymorphisms is important to avoid adverse outcomes and optimize lipid-lowering efficacy, particularly when using simvastatin or other statins metabolized via OATP1B1.\n\nNo specific resistance markers beyond these polymorphisms were reported. Safety data emphasize increased myopathy risk correlated with these variants, but exact percentages were not provided in the summarized sources.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4044
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_compound_name",
                "toolsuite": "pubchem",
                "success": true,
                "sse_summary": "Simvastatin (brand name Zocor) is a semi-synthetic lipid-lowering drug derived from fermentation of Aspergillus terreus and is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. It lowers total cholesterol, LDL-C, apolipoprotein B, and triglycerides, while increasing HDL-C, thereby reducing cardiovascular disease (CVD) risk including myocardial infarction, stroke, and need for revascularization. Indications include primary hyperlipidemia (Fredrickson types IIa, IIb, III, IV), homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) in adolescents, and secondary prevention in patients with coronary heart disease, diabetes, peripheral artery disease, stroke, or other high-risk conditions.\n\nClinical data show statins, including simvastatin, reduce major cardiovascular events by 20%-22% per 1 mmol/L LDL reduction even in low-risk individuals (<10% 5-year risk). Rosuvastatin is more potent (10-40 mg daily reduces LDL by 45.8%-54.6%) compared to simvastatin (~35% LDL reduction). Despite potency differences, clinical outcomes are similar across statins.\n\nSafety profile highlights:\n\n- Myopathy risk increases with dose: 0.03% at 20 mg/day, 0.08% at 40 mg/day, and 0.61% at 80 mg/day. The 80 mg dose is recommended only for patients stable on this dose >12 months without muscle toxicity and requires close monitoring. Myopathy risk is elevated with interacting drugs such as fenofibrate, niacin, gemfibrozil, cyclosporine, strong CYP3A4 inhibitors, and colchicine.\n\n- Liver enzyme elevations (>3x ULN) occur in ~1% of patients; usually asymptomatic and reversible upon drug discontinuation. In the Scandinavian Simvastatin Survival Study (4S), transaminase elevations >3x ULN were 0.7% with simvastatin vs. 0.6% placebo; in the Heart Protection Study (HPS, n=20,536), elevated transaminases occurred in 0.21% with simvastatin 40 mg vs. 0.09% placebo.\n\n- Endocrine effects include modest increases in HbA1c and fasting glucose; no significant impact on steroid hormone production or gallstone risk.\n\nSimvastatin is FDA-approved since 1991 with clinical trial phase IV across 10 approved and 97 investigational indications. It acts by inhibiting HMG-CoA reductase, reducing cholesterol synthesis and inducing LDL receptor expression to enhance LDL clearance. It is considered cost-effective and standard of care post-cardiovascular events or in moderate-to-high risk patients.\n\nNo specific resistance markers noted.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 14326
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_disease_name",
                "toolsuite": "opentargets",
                "success": true,
                "sse_summary": "The summary for hypercholesterolemia (EFO ID: HP_0003124) includes key molecular targets and approved drugs with clinical details:\n\n**Key Disease Targets (with relevance scores):**  \n- LDLR (0.8413)  \n- PCSK9 (0.8113)  \n- APOB (0.8045)  \n- HMGCR (0.7478)  \n- NPC1L1 (0.7115)  \n- ABCG8 (0.6585), ABCG5 (0.6105), APOE (0.6103), SORT1 (0.5838), PPARA (0.5770), among others.\n\n**Approved Drugs (all Phase 4, not withdrawn):**\n\n1. **Amlodipine Besylate** (Trade names: Amlodipine besylate, Norliqva, Norvasc)  \n   - Mechanism: Voltage-gated L-type calcium channel blocker  \n   - Target: CACNA1D\n\n2. **Pitavastatin Calcium** (Livalo)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR\n\n3. **Atorvastatin** (Cardyl, Lipitor, Prevencor, Sortis, Tahor, Zarator)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR  \n   - Trial status: Completed and unknown status in different records\n\n4. **Rosuvastatin Calcium** (Crestor, Ezallor, Ezallor sprinkle)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR\n\n5. **Evolocumab** (Repatha, Repatha sureclick)  \n   - Mechanism: Subtilisin/kexin type 9 (PCSK9) inhibitor  \n   - Target: PCSK9\n\n6. **Bempedoic Acid** (Nexletol, Nilemdo)  \n   - Mechanism: ATP-citrate synthase inhibitor  \n   - Target: ACLY\n\n7. **Fenofibrate** (Antara, Fenofibrate micronized, Fenogal, Fenoglide, Lipantil series, Lipidil, Lipofen, Supralip 160, Tricor, Triglide)  \n   - Mechanism: Peroxisome proliferator-activated receptor alpha (PPARA) agonist  \n   - Target: PPARA\n\n8. **Pravastatin Sodium** (Elisor, Lipemol, Liplat, Lipostat, Pravachol)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR  \n   - Trial status: Completed\n\n9. **Simvastatin** (Flolipid, Lacersa, Ranzolont, Simvador, Zocor)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR\n\n**Key Points:**  \n- The primary molecular target for many approved drugs is HMGCR, inhibited by multiple statins (atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin).  \n- PCSK9 is targeted by evolocumab, an approved monoclonal antibody reducing LDL cholesterol.  \n- Bempedoic acid targets ACLY, offering a novel mechanism.  \n- Fenofibrate activates PPARA to reduce triglycerides.  \n- Amlodipine besylate, although primarily a calcium channel blocker for hypertension, is listed with relevance to hypercholesterolemia possibly due to cardiovascular benefits.\n\nNo resistance markers or adverse event rates were reported in this dataset. No efficacy or response rates or clinical trial NCT identifiers were provided.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 9161
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms significantly influence simvastatin pharmacokinetics, efficacy, and safety. The rs4149056 variant (also known as SLCO1B1*5) is strongly associated with increased risk of simvastatin-induced myopathy, with an allelic odds ratio (OR) of 4.5 for definite myopathy (CK >10× upper limit of normal) in patients receiving high doses of simvastatin. This association is specific to simvastatin and not observed with atorvastatin.\n\nIn a candidate-gene study, the SLCO1B1 521C allele was the only genetic factor significantly linked to cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks in white patients. LDL-C reductions were 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T) (*P* = 0.038), and total cholesterol reductions were 43 ± 27 mg/dL (C/C), 57 ± 21 mg/dL (T/C), and 60 ± 24 mg/dL (T/T) (*P* = 0.008).\n\nSLCO1B1 polymorphisms affect the pharmacokinetics of active simvastatin acid but not the parent drug, impacting therapeutic outcomes and side effect profiles. These genetic variations modulate simvastatin efficacy in lipid lowering and contribute to statin intolerance risk in clinical settings.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3716
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms, particularly the rs4149056 variant (521C allele), significantly increase the risk of simvastatin-induced myopathy. Clinical guidelines recommend choosing alternative therapies for patients with SLCO1B1 521 CC or TC genotypes to reduce this risk. If alternatives are not feasible for patients with the TC genotype, simvastatin doses should not exceed 40 mg/day, and patients should be advised to report muscle symptoms promptly.\n\nEfficacy data show that the SLCO1B1 521C allele is associated with a slightly reduced cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks, notably in white patients: LDL-C reduction was 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T) (*P* = 0.038), and total cholesterol reduction was 43 ± 27 mg/dL (C/C), 57 ± 21 mg/dL (T/C), and 60 ± 24 mg/dL (T/T) (*P* = 0.008). However, large trials such as the Heart Protection Study (N=18,000 on 40 mg simvastatin) indicate only a minimal (~1% per C allele) effect of SLCO1B1 genotype on LDL-C reduction and no significant impact on vascular outcomes.\n\nSafety data confirm increased myopathic complaints in carriers of the SLCO1B1 rs4149056C allele on simvastatin; similar effects for rosuvastatin are less clear. SLCO1B1 polymorphisms may also contribute to milder forms of statin intolerance.\n\nIn summary, SLCO1B1 genotyping can guide statin therapy choice and dosing to minimize myopathy risk without compromising cardiovascular efficacy substantially.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4000
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "SLCO1B1 polymorphisms significantly impact atorvastatin pharmacokinetics and cholesterol-lowering efficacy in hypercholesterolemia patients. The rs4149056 variant is notably associated with an increased risk of statin-induced myopathy, while the common SLCO1B1*1 haplotype influences drug response. However, in a Brazilian familial hypercholesterolemia cohort, SLCO1B1 haplotypes were not linked to atorvastatin-induced myalgia. Studies including Egyptian patients also explore the role of SLCO1B1 and MDR1 polymorphisms on atorvastatin therapeutic response. Additionally, ABCG2 and SLCO1B1 variants affect inflammation markers in patients treated with rosuvastatin. A systematic review and meta-analysis confirmed the genotypic effects of rs4149056 and rs2306283 polymorphisms on statin-associated myopathy risk. Key conclusions emphasize the importance of SLCO1B1 genotyping to predict atorvastatin efficacy and myopathy risk, aiding personalized hypercholesterolemia treatment.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 2428
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Statin therapy guidelines recommend the following:\n\n1. **General Recommendations**:  \n   - High-intensity statins for patients at high 10-year ASCVD risk.  \n   - Moderate-intensity statins for diabetics aged 40–75 years.  \n   - Lifestyle modifications emphasized for all patients.\n\n2. **Eligibility and Risk Assessment**:  \n   - According to the 2022 USPSTF recommendations, 31.8% of US adults aged 40–75 years with LDL-C <190 mg/dL and no ASCVD are eligible for statin therapy for primary prevention.  \n   - The 2018 AHA/ACC/Multisociety (MS) guidelines increase eligibility to 46.8% in this population after clinician-patient risk discussion.  \n   - Risk categories:  \n     - ≥7.5% to <20% 10-year ASCVD risk = intermediate risk.  \n     - ≥20% = high risk.  \n     - <5% = low risk.  \n     - 5% to <7.5% = borderline risk.  \n   - Coronary artery calcium (CAC) scoring may guide statin decisions in uncertain cases:  \n     - CAC=0 may allow withholding statins unless diabetes, family history, or smoking present.  \n     - CAC 1–99 favors statin initiation, especially >55 years.  \n     - CAC ≥100 or ≥75th percentile strongly supports statin therapy.\n\n3. **Specific Populations**:  \n   - Patients with severe primary hypercholesterolemia (LDL-C >190 mg/dL) should start high-intensity statins or moderate-intensity statins plus ezetimibe aiming for LDL-C <100 mg/dL.  \n   - If LDL-C goals are not achieved on maximally tolerated statins plus ezetimibe, PCSK9 inhibitors may be added, especially in very high-risk patients with LDL-C ≥70 mg/dL or non-HDL-C >100 mg/dL (per 2018 guidelines).  \n   - Diabetics aged 40–75 years: moderate-intensity statin therapy is indicated (2019 ACC/AHA guideline).\n\n4. **Efficacy**:  \n   - Cholesterol Treatment Trialists meta-analysis shows a consistent relative risk reduction in cardiovascular events of about 22% per 39 mg/dL (1 mmol/L) LDL-C lowering, regardless of baseline LDL-C.\n\n5. **Lifestyle**:  \n   - Lifestyle modifications remain a foundational recommendation across all risk groups.\n\n**Key Guidelines Referenced**:  \n- 2018 AHA/ACC/Multisociety cholesterol guidelines  \n- 2019 ACC/AHA Primary Prevention Guideline  \n- 2022 USPSTF recommendations\n\nNo resistance markers or adverse event rates were reported in the summarized data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5272
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "High LDL-C (low-density lipoprotein cholesterol) is a major risk factor for heart attack and stroke. For individuals at very high cardiovascular risk, the American College of Cardiology recommends an LDL-C level below 55 mg/dL to reduce the risk of recurrent major cardiovascular events, especially in patients with 1 major cardiovascular event plus 2 or more high-risk conditions.\n\nLifestyle modifications, including a heart-healthy diet low in saturated fats (e.g., grilled/baked fish, skinless poultry, soy products, legumes, nuts in moderation), are important for lowering LDL-C. However, individuals with genetically elevated LDL-C, such as those with familial hypercholesterolemia (FH), often require cholesterol-lowering medications to achieve target LDL-C levels.\n\nMedications like evolocumab (Repatha®), a PCSK9 inhibitor, are indicated along with diet for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C levels.\n\nRecommended LDL-C targets vary by risk group: below 70 mg/dL is considered optimal for people with diabetes or other heart disease risk factors, while below 55 mg/dL is targeted for very high-risk patients.\n\nIn summary:\n- LDL-C targets: <55 mg/dL for very high-risk individuals; <70 mg/dL for diabetes or heart disease risk.\n- Lifestyle changes plus medications are required for most patients with high LDL-C, especially those with genetic causes like FH.\n- Evolocumab (Repatha®) is an approved medication for lowering LDL-C in primary hyperlipidemia and HeFH.\n- High saturated fat diets, like ketogenic diets, can dramatically increase LDL-C and should be avoided in at-risk patients.\n\nNo specific clinical trials or NCT numbers were provided in the source data. Safety/adverse event rates and resistance markers were not reported.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5369
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Statin therapy is recommended for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults aged 40-75 years with high LDL-C and at least one cardiovascular risk factor, provided their 10-year ASCVD risk is 10% or higher. High-intensity statins are advised for patients with LDL-C ≥190 mg/dL without the need for additional risk assessment (2018 ACC/AHA Guideline on the Management of Blood Cholesterol). \n\nThe 2022 USPSTF updated evidence review, including 22 randomized clinical trials (RCTs), found that statin use in primary prevention reduces all-cause mortality, fatal and nonfatal myocardial infarction, stroke, revascularization, and composite cardiovascular outcomes. Harms were assessed from 19 RCTs and 3 large cohort studies, with insufficient data on adults older than 75 years. \n\nKey clinical trials referenced for LDL-C lowering and ASCVD risk management include IMPROVE-IT, FOURIER, ODYSSEY, CLEAR, ACCORD, and HPS2-THRIVE. For patients with familial hypercholesterolemia or LDL-C ≥190 mg/dL, high-intensity statins combined with non-statin therapies are often used to prevent ASCVD.\n\nAdditional ASCVD risk enhancers to consider include family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, diabetes duration, albuminuria, retinopathy, neuropathy, inflammatory diseases (e.g., rheumatoid arthritis, psoriasis, HIV), and ethnicity factors (e.g., South Asian ancestry). Biomarkers such as hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL or >125 nmol/L, apoB ≥130 mg/dL, and ankle-brachial index (ABI) <0.9 may further guide therapy.\n\nStatin therapy is generally not recommended for patients with a 10-year ASCVD risk <5%. The ASCVD Risk Estimator Plus tool is recommended for calculating individualized 10-year and lifetime risk to aid clinical decision-making.\n\nIn summary, for adults aged 40-75 with LDL-C ≥190 mg/dL or those with LDL-C <190 mg/dL but a 10-year ASCVD risk ≥10% plus risk factors, statin therapy (high-intensity for LDL ≥190 mg/dL, low- to moderate-intensity for others) reduces cardiovascular events and mortality, with an acceptable safety profile based on extensive RCT data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 7181
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_disease_name",
                "toolsuite": "opentargets",
                "success": true,
                "sse_summary": "The summary of the tool output for atherosclerotic cardiovascular disease (EFO_0003914) is as follows:\n\n**Key Disease Targets:**\n- PCSK9 (score 0.6821)\n- LDLR (0.6074)\n- HMGCR (0.5928)\n- APOE (0.5816)\n- SORT1 (0.5703)\n- P2RY12 (0.5694)\n- GRIN1 (0.5688)\n- ABCG8 (0.5655)\n- LPA (0.5635)\n- Additional targets include multiple GRIN subunits (GRIN2D, GRIN2A, GRIN3A, GRIN3B, GRIN2B, GRIN2C), ADRB1, CETP, CELSR2, TCF7L2, LPL, JCAD, COL4A1, HHIPL1, SMOC1, ANGPTL4 with scores ranging from ~0.51 to 0.56.\n\n**Approved Drugs and Mechanisms:**\n1. **Bempedoic Acid** (Nexletol, Nilemdo)  \n   - Phase 4, approved  \n   - Mechanism: ATP-citrate lyase (ACLY) inhibitor\n\n2. **Statins (HMG-CoA reductase inhibitors)** – all Phase 4, approved:  \n   - Lovastatin (Altoprev, Mevacor, others)  \n   - Pravastatin Sodium (Pravachol, Elisor, others)  \n   - Rosuvastatin Calcium (Crestor, Ezallor, others)\n\n3. **Inclisiran Sodium** (Leqvio)  \n   - Phase 4, approved  \n   - Mechanism: PCSK9 mRNA RNAi inhibitor targeting PCSK9\n\n4. **Clopidogrel Bisulfate** (Plavix, Iscover)  \n   - Phase 4, approved  \n   - Mechanism: P2Y12 receptor antagonist\n\n5. **Vorapaxar Sulfate** (Zontivity)  \n   - Phase 4, approved  \n   - Mechanism: Proteinase-activated receptor 1 (F2R) antagonist\n\n6. **Amantadine Hydrochloride** (Gocovri, Symmetrel, others)  \n   - Phase 4, approved  \n   - Mechanism: Glutamate NMDA receptor antagonist targeting GRIN2D, GRIN3B, and GRIN1 subunits\n\n**Summary:**\n- The main therapeutic targets include PCSK9, LDLR, and HMGCR, with multiple approved drugs targeting these pathways, primarily statins and newer agents like bempedoic acid and inclisiran.\n- Antiplatelet agents clopidogrel and vorapaxar are also approved for cardiovascular risk reduction via P2RY12 and F2R antagonism.\n- Amantadine hydrochloride targets NMDA receptor subunits but its clinical role in atherosclerotic cardiovascular disease is less direct.\n- All listed drugs are approved and at clinical trial phase 4, with no withdrawals reported.\n- No resistance markers or specific efficacy/safety statistics were provided in the data.\n\nThis information supports the use of statins, PCSK9 inhibitors (inclisiran), and ATP-citrate lyase inhibitors (bempedoic acid) as key therapies for atherosclerotic cardiovascular disease, along with antiplatelet agents for thrombosis prevention.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 8924
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "null",
                "tool_name": "get_pharmacogenomics_info_by_drug_name",
                "toolsuite": "fda_drug",
                "success": false,
                "additional_info_type": "Others",
                "additional_info": "",
                "additional_urls": ""
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": true
      },
      "execution_time": 293.4449987411499,
      "error_message": null
    },
    {
      "log_id": "log_1762673036407_target_cns_HMGCR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:56.408010",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_cns_HMGCR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: HMGCR\n- **General State:** HMGCR is actively inhibited by statins, resulting in reduced cholesterol synthesis in the liver.\n- **Key Drug Observations:**\n  - Simvastatin significantly decreases LDL-C levels in hypercholesterolemic patients.\n  - SLCO1B1 polymorphisms may alter statin efficacy and risk of adverse effects.\n  - Therapeutic response is generally favorable with a low incidence of significant side effects.\n- **Binding Characteristics:**\n  - Statins exhibit competitive inhibition at the active site of HMGCR.\n  - Binding affinity varies among different statins, influencing their potency and dosing requirements.\n  - The interaction with SLCO1B1 affects the bioavailability and therapeutic outcomes of statin therapy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: HMGCR\n- **General State:** HMGCR is actively inhibited by statins, resulting in reduced cholesterol synthesis in the liver.\n- **Key Drug Observations:**\n  - Simvastatin significantly decreases LDL-C levels in hypercholesterolemic patients.\n  - SLCO1B1 polymorphisms may alter statin efficacy and risk of adverse effects.\n  - Therapeutic response is generally favorable with a low incidence of significant side effects.\n- **Binding Characteristics:**\n  - Statins exhibit competitive inhibition at the active site of HMGCR.\n  - Binding affinity varies among different statins, influencing their potency and dosing requirements.\n  - The interaction with SLCO1B1 affects the bioavailability and therapeutic outcomes of statin therapy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.3999340534210205,
      "error_message": null
    },
    {
      "log_id": "log_1762673036959_tissue_kidney_kidney",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:23:56.960289",
      "level": 2,
      "level_name": "组织层",
      "agent_id": "tissue_kidney_kidney",
      "agent_name": "tissue",
      "agent_type": "tissue",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "organ",
          "output_data": {
            "round1_analysis": "# Organ Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - Expected conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Potential activation of pathways related to drug metabolism and excretion is occurring.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Organ Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - Expected conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Potential activation of pathways related to drug metabolism and excretion is occurring.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [
                  "What is the impact of SLCO1B1 gene variants on simvastatin metabolism and risk of myopathy?",
                  "Are there any specific guidelines or recommendations for prescribing simvastatin to patients with high LDL-C and without ASCVD?"
                ],
                "tool_result": "- **Tool Name:** get_general_info_by_protein_or_gene_name\n  - **Gene Names:** SLCO1B1, LST1, OATP1B1, OATP2, OATPC, SLC21A6\n  - **Drug Names:** Pravastatin, Pitavastatin, Methotrexate, Enalapril, Valsartan\n  - **Critical Quantitative Information:**\n    - Maximum velocities (pmol/min/mg protein):\n      - Estrone 3-sulfate: 60.3\n      - Pitavastatin: 230.0\n      - 17beta-estradiol 17-O-(beta-D-glucuronate): 131.0\n      - Valsartan: 3.85\n      - Enalapril: 78.0\n      - Coproporphyrin I: 17.9\n      - Coproporphyrin III: 24.9\n    - Michaelis constants (Km, µM):\n      - Taurocholate: 13.6\n      - L-thyroxine: 3.0\n      - 3,3',5'-triiodo-L-thyronine: 2.7\n      - Pravastatin: 33.8\n      - Pitavastatin: 3.0\n      - Estrone 3-sulfate: 0.458\n      - 17beta-estradiol 17-O-(beta-D-glucuronate): 8.29\n      - Valsartan: 1.39\n      - Enalapril: 262.0\n      - Coproporphyrin I: 0.13\n      - Coproporphyrin III: 0.22\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Drug Names:** Simvastatin, Simvastatin Acid (SVA)\n  - **Gene Names:** SLCO1B1\n  - **Critical Quantitative Information:**\n    - Genetic marker: SLCO1B1 rs4149056 (c.521T>C) increases simvastatin acid exposure and muscle toxicity risk.\n    - Approximately 40% of simvastatin is converted to SVA intracellularly.\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Gene Names:** SLCO1B1\n  - **Critical Quantitative Information:**\n    - Variant: SLCO1B1*5 (rs4149056-C) increases simvastatin acid levels and muscle toxicity risk.\n    - Incidence of composite adverse events (myalgia, CK elevation, treatment discontinuation) linked to SLCO1B1*5 carriers.\n    - LDL-C reductions by genotype:\n      - C/C: 44 ± 25 mg/dL\n      - T/C: 55 ± 19 mg/dL\n      - T/T: 57 ± 22 mg/dL (*P* = 0.038)\n    - Total cholesterol reductions:\n      - C/C: 43 ± 27 mg/dL\n      - T/C: 57 ± 21 mg/dL\n      - T/T: 60 ± 24 mg/dL (*P* = 0.008)\n  - **URLs/References:** CPIC 2022 guideline for dosing recommendations based on SLCO1B1 phenotypes.\n\n- **Tool Name:** get_general_info_by_disease_name\n  - **Disease Name:** Myopathy (EFO_0004145)\n  - **Gene Names:** ACTA1, RYR1, TTN, POLG, DMD, FKRP\n  - **Drug Names:** Prednisolone, Cortisone acetate, Prednisone, Hydrocortisone, Methylprednisolone, Triamcinolone acetonide\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Gene Names:** SLCO1B1\n  - **Critical Quantitative Information:**\n    - Odds ratio (OR) for statin-related myopathy: 2.51 (95% CI: 1.28–).\n  - **URLs/References:** CPIC guidelines recommend considering SLCO1B1 genotype when prescribing statins.\n\n- **Tool Name:** get_drug_names_by_animal_pharmacology_info\n  - **Drug Names:** Ezetimibe, Raloxifene hydrochloride\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Drug Names:** Simvastatin\n  - **Critical Quantitative Information:**\n    - Recommended starting dose: 10-20 mg once daily\n    - Maximum dose: 40 mg to 80 mg depending on individual factors.\n    - Increased risk of myopathy and rhabdomyolysis at 80 mg for patients aged ≥65 years.\n    - No additional cardiovascular benefit when niacin is added to simvastatin 40 mg.\n  - **URLs/References:** None\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - LDL-C ≥190 mg/dL or >4.9 mmol/L: high-intensity statin therapy recommended.\n    - PCSK9 inhibitors may be considered if LDL-C goals are not met despite therapy.\n  - **URLs/References:** 2018 ACC/AHA Guidelines\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - High-intensity statin therapy for LDL-C ≥190 mg/dL.\n    - PCSK9 inhibitors as add-on therapy if LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy.\n  - **URLs/References:** 2018 ACC/AHA Guidelines\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - Class 1 recommendation for adults with LDL-C >190 mg/dL and for adults aged 40-75 years with diabetes.\n    - Statin therapy reduces cardiovascular events and mortality.\n  - **URLs/References:** 2018 AHA/ACC/MS Guideline, 2022 USPSTF Update\n\n- **Tool Name:** tavily_search\n  - **Critical Quantitative Information:**\n    - Recommendations for various patient groups based on LDL-C levels and ASCVD risk.\n    - Specific dosages and regimens are not detailed.\n  - **URLs/References:** 2018 AHA/ACC/MS Guideline, 2022 USPSTF Update",
                "raw_tool_results": [
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_protein_or_gene_name",
                    "toolsuite": "uniprot",
                    "success": true,
                    "sse_summary": "The gene **SLCO1B1** (also known as LST1, OATP1B1, OATP2, OATPC, SLC21A6) encodes a transporter protein primarily expressed in the liver, specifically at the basolateral membranes of centrilobular hepatocytes, including fetal liver. It is not detected in heart, brain, placenta, lung, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis (except weak expression in Leydig cells and Sertoli cells’ basal membrane), ovary, small intestine, colon, or leukocytes.\n\n**Function:**  \nSLCO1B1 mediates Na(+)-independent uptake of a broad range of organic anions, including bile acid taurocholate, conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, estrone 3-sulfate), eicosanoids (prostaglandin E2, thromboxane B2, leukotrienes C4 and E4), thyroid hormones (T4/L-thyroxine and T3/3,3',5'-triiodo-L-thyronine), and bilirubin glucuronides, contributing to liver detoxification and clearance of endogenous and exogenous compounds. It also transports by-products of heme synthesis (coproporphyrin I and III) and may regulate organic compound transport across the blood-testis barrier.\n\nClinically important substrates include:  \n- Statins: pravastatin and pitavastatin  \n- Chemotherapeutic drug methotrexate  \n- Antihypertensive agents: enalapril (ACE inhibitor prodrug) and valsartan (angiotensin II AT1-receptor antagonist)\n\nThe transporter exhibits pH-sensitive substrate specificity, with optimum activity at pH 6.5 for prostaglandin E2 and L-thyroxine, likely due to protonation states affecting substrate binding and transport.\n\n**Catalytic activities (substrate transport reactions):**  \n- Taurocholate (RHEA:71703)  \n- Dehydroepiandrosterone 3-sulfate (RHEA:71839)  \n- Estrone 3-sulfate (RHEA:71835)  \n- 3,3',5'-triiodo-L-thyronine (RHEA:71815)  \n- L-thyroxine (RHEA:71819)  \n- Prostaglandin E2 (RHEA:50984)  \n- Thromboxane B2 (RHEA:50992)  \n- 17beta-estradiol 17-O-(beta-D-glucuronate) (RHEA:72691)  \n- Leukotriene C4 (RHEA:72743)  \n- Leukotriene E4 (RHEA:72747)  \n- Bilirubin IXalpha C8-beta-D-glucuronoside (RHEA:72791)  \n- Bilirubin IXalpha bis-beta-D-glucuronoside (RHEA:72795)\n\n**Kinetic parameters (maximum velocities and Michaelis constants):**  \n- Maximum velocities (pmol/min/mg protein):  \n  - Estrone 3-sulfate: 60.3  \n  - Pitavastatin: 230.0  \n  - 17beta-estradiol 17-O-(beta-D-glucuronate): 131.0  \n  - Valsartan: 3.85  \n  - Enalapril: 78.0  \n  - Coproporphyrin I: 17.9  \n  - Coproporphyrin III: 24.9\n\n- Michaelis constants (Km, μM):  \n  - Taurocholate: 13.6  \n  - L-thyroxine: 3.0  \n  - 3,3',5'-triiodo-L-thyronine: 2.7  \n  - Pravastatin: 33.8  \n  - Pitavastatin: 3.0  \n  - Estrone 3-sulfate: 0.458  \n  - 17beta-estradiol 17-O-(beta-D-glucuronate): 8.29  \n  - Valsartan: 1.39  \n  - Enalapril: 262.0  \n  - Coproporphyrin I: 0.13  \n  - Coproporphyrin III: 0.22\n\n**Summary:**  \nSLCO1B1 is a liver-expressed transporter with broad substrate specificity, playing a key role in hepatic uptake and clearance of endogenous compounds (bile acids, steroids, thyroid hormones, eicosanoids, bilirubin conjugates) and clinically relevant drugs, including statins (pravastatin, pitavastatin), methotrexate, and antihypertensives (enalapril, valsartan). It demonstrates pH-dependent activity with optimal function at acidic pH (6.5) for certain substrates. This transporter significantly impacts drug pharmacokinetics and hepatic detoxification pathways.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 22442
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Simvastatin is metabolized into its active form (simvastatin acid, SVA) primarily via carboxylesterase (CES) and cytochrome P450 (CYP) enzymes. After administration, about 40% of simvastatin delivered (including via pulmonary routes such as pMDI, DPI, or nebulized nanoparticle suspension) is converted intracellularly to its active SVA metabolite. Simvastatin acts by competitively inhibiting HMG-CoA reductase, reducing endogenous cholesterol synthesis, effectively lowering LDL cholesterol and triglycerides in hyperlipidemic patients with proven cardiovascular benefits.\n\nGenetic variation in the SLCO1B1 gene, specifically the rs4149056 (c.521T>C) polymorphism, significantly increases systemic exposure to simvastatin acid and is a well-established risk factor for statin-induced muscle toxicity. Simvastatin’s effects on muscle include impairment of energy metabolism and mitochondrial respiration, with differential impacts observed between its lactone and acid forms in primary human skeletal muscle cells, affecting glucose metabolism and insulin signaling.\n\nIn preclinical models, simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells, indicated by increased alkaline phosphatase activity and bone-related protein expression.\n\nIn PGC-1α overexpressing mice, simvastatin increases lipid droplet accumulation in skeletal muscle and enhances glucose uptake without impairing muscle glucose utilization. These findings suggest simvastatin influences lipid metabolism and muscle energy homeostasis.\n\nKey points:\n- Drug: Simvastatin (prodrug), active metabolite: simvastatin acid (SVA)\n- Metabolism: CES and CYP enzymes; ~40% intracellular conversion to SVA\n- Genetic marker: SLCO1B1 rs4149056 (c.521T>C) increases simvastatin acid exposure and muscle toxicity risk\n- Mechanism: Competitive HMG-CoA reductase inhibition lowering LDL and triglycerides\n- Safety: Muscle toxicity risk associated with SLCO1B1 variant\n- Efficacy: Proven cardiovascular benefit in hyperlipidemia\n- Muscle effects: Impaired energy metabolism and mitochondrial respiration; differential effects of lactone vs acid forms\n- Additional effects: Promotes osteoblastic differentiation in periodontal ligament cells; modulates lipid accumulation and glucose uptake in skeletal muscle in mouse models\n\nNo clinical trial identifiers (NCT numbers) or phase data were available in the retrieved information.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 6380
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 gene variants, particularly the *SLCO1B1*5 allele (rs4149056-C), impair simvastatin metabolism, leading to increased plasma levels of simvastatin acid and a higher risk of muscle-related side effects, including statin-induced myopathy. The *SLCO1B1*5 variant is significantly associated with mild to severe statin-induced muscle symptoms, including creatine kinase (CK) elevation >3× upper limit of normal and treatment discontinuation due to adverse events.\n\nIn a clinical study, *SLCO1B1*5 carriers showed a higher incidence of composite adverse events (CAE), defined as myalgia, CK elevation, or discontinuation for side effects. Female sex and *SLCO1B1*5 genotype were linked to increased risk of these muscle side effects.\n\nRegarding efficacy, the *SLCO1B1* 521C variant was the only genetic factor significantly associated with the cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks in white patients. LDL-C reductions were genotype-dependent: 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T) (*P* = 0.038), and total cholesterol reductions were 43 ± 27, 57 ± 21, and 60 ± 24 mg/dL, respectively (*P* = 0.008).\n\nMetabolomic profiling identified 31 novel metabolites significantly associated with *SLCO1B1* rs4149056-C in both statin-treated and untreated participants, indicating broad metabolic effects of this variant.\n\nThe Clinical Pharmacogenetics Implementation Consortium (CPIC) 2022 guideline provides dosing recommendations based on *SLCO1B1* phenotypes to mitigate statin-associated musculoskeletal symptoms.\n\nKey points:\n- *SLCO1B1*5 (rs4149056-C) allele increases simvastatin acid levels and muscle toxicity risk.\n- Muscle adverse event rates include CK >3× upper limit and treatment discontinuation.\n- Statin efficacy (LDL-C and total cholesterol reduction) varies by *SLCO1B1* genotype, notably in white populations.\n- CPIC guidelines recommend genotype-guided simvastatin dosing.\n- Metabolite profiles differ significantly by *SLCO1B1* rs4149056-C status.\n\nNo resistance markers were reported.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5350
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_disease_name",
                    "toolsuite": "opentargets",
                    "success": true,
                    "sse_summary": "Myopathy (EFO_0004145) is associated with multiple genetic targets, notably ACTA1 (score 0.895), RYR1 (0.891), TTN (0.888), POLG (0.884), DMD (0.883), FKRP (0.883), among others, indicating a diverse genetic basis.\n\nApproved drugs targeting myopathy predominantly act as glucocorticoid receptor agonists (target NR3C1) and include:  \n- Prednisolone (CHEMBL131), phase 4, with multiple trade names such as Cortalone, Dekotil, and Meticortelone.  \n- Cortisone acetate (CHEMBL1650), phase 4, trade names include Cortate and Cortone.  \n- Prednisone (CHEMBL635), phase 4, trade names include Cortan, Deltasone, and Rayos.  \n- Hydrocortisone (CHEMBL389621), phase 4, with numerous trade names including Acticort, Cortef, and Locoid.  \n- Methylprednisolone (CHEMBL650), phase 4, trade names Medrol and Medrone.  \n- Triamcinolone acetonide (CHEMBL1504), phase 4, trade names include Kenalog, Nasacort, and Triderm.\n\nThese drugs share a common mechanism of glucocorticoid receptor agonism and are approved for clinical use without withdrawal.\n\nKey phenotypic features of myopathy include:  \n- Myofibrillar myopathy characterized by abnormal intracellular desmin accumulation (HP_0003715).  \n- Muscle weakness: lower limb (HP_0007340), proximal muscles (HP_0003701), foot dorsiflexors (HP_0009027).  \n- Gait abnormalities: waddling gait (HP_0002515), steppage gait (HP_0003376).  \n- Muscle contractures: knee flexion (HP_0006380), Achilles tendon (HP_0001771), forearm supination (HP_0034394).  \n- Other signs: hyporeflexia (HP_0001265), scapular winging (HP_0003691), skeletal muscle atrophy (HP_0003202), and elevated circulating creatine kinase (HP_0003236).  \n- Onset ranges from young adult (16–40 years, HP_0011462) to middle age (40–60 years, HP_0003596).  \n- Some forms show X-linked dominant inheritance (HP_0001423).  \n- Cardiac involvement may include right bundle branch block (HP_0011712).\n\nNo resistance markers were reported.\n\nIn summary, glucocorticoid receptor agonists like prednisolone, prednisone, and methylprednisolone represent the main approved therapeutic agents for myopathy, targeting NR3C1, with phase 4 clinical status. The disease manifests with characteristic muscle weakness, contractures, and elevated CK levels, with multiple genetic targets implicated.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 20577
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 gene variants, particularly rs4149056 and T521C polymorphisms, are strongly associated with an increased risk of statin-induced myopathy and statin intolerance. These variants result in poor SLCO1B1 function, leading to higher myopathy rates across multiple statins, including simvastatin and atorvastatin. A gene risk score incorporating missense variants in SLCO1B1 correlates with earlier onset of statin intolerance and myopathy, with an odds ratio (OR) for statin-related myopathy reported as 2.51 (95% CI: 1.28–). Clinical Pharmacogenetics Implementation Consortium guidelines recommend considering SLCO1B1 genotype when prescribing statins to mitigate musculoskeletal adverse effects.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 3928
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_drug_names_by_animal_pharmacology_info",
                    "toolsuite": "fda_drug",
                    "success": true,
                    "sse_summary": "The hypocholesterolemic effect of ezetimibe, alone or combined with simvastatin, was evaluated in cholesterol-fed Rhesus monkeys, dogs, rats, and mouse models of human cholesterol metabolism. These preclinical findings support ezetimibe's lipid-lowering activity. Additionally, raloxifene hydrochloride demonstrated skeletal antiresorptive effects consistent with human data on radiocalcium kinetics and bone metabolism markers, confirming its role as an antiresorptive agent. No specific clinical trial identifiers, dosages, adverse event rates, or resistance markers were reported in the provided data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 1757
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "Error: Failed after 3 attempts when executing tool: Error executing tool clinvar_query_sequence_variants: 'DBSEARCH' object has no attribute 'clinvar_query_sequence_variants'. Tool_invoke_info: {'item': 'SLCO1B1 gene variants', 'tool': 'clinvar_query_sequence_variants', 'tool_input': {'sequence': '', 'variants': []}}",
                    "tool_name": "clinvar_query_sequence_variants",
                    "toolsuite": null,
                    "success": false
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Simvastatin prescribing guidelines recommend starting adults at 10-20 mg once daily, taken in the evening, with a maximum dose ranging from 40 mg to 80 mg depending on individual factors. Dosage adjustments should be made by a physician based on patient-specific health conditions.\n\nKey safety notes include:\n\n- Patients on 80 mg daily have increased risk of myopathy and rhabdomyolysis, especially those aged ≥65 years.\n- If an interacting drug that raises myopathy risk is prescribed alongside simvastatin 80 mg, switching to an alternative statin is advised.\n- For stable patients on 80 mg who develop adverse effects, lowering the dose or discontinuing simvastatin and switching to another statin is recommended.\n- No additional cardiovascular benefit was observed when niacin was added to simvastatin 40 mg (with or without ezetimibe 10 mg) in a clinical study with median follow-up of 3.9 years.\n\nClinical monitoring by an interprofessional team (physicians, nurses, pharmacists) is essential to manage efficacy and adverse effects. Pharmacists can recommend equivalent dosing with other statins that may have fewer adverse events.\n\nNo specific resistance markers were noted in the reviewed data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4355
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "For patients with high LDL-C without ASCVD but severe primary hypercholesterolemia (LDL-C ≥190 mg/dL or >4.9 mmol/L), high-intensity statin therapy is recommended as first-line treatment to achieve LDL-C goals (<100 mg/dL). If LDL-C goals are not met despite maximally tolerated statin therapy (or moderate-intensity statin plus ezetimibe), PCSK9 inhibitors may be considered, especially in patients at very high risk for future ASCVD events.\n\nKey points and data include:\n\n- The 2018 ACC/AHA Guidelines recommend high-intensity statins for patients with LDL-C ≥190 mg/dL without clinical ASCVD (Class I recommendation).\n- PCSK9 inhibitors are recommended as add-on therapy if LDL-C remains ≥70 mg/dL (or non-HDL-C >100 mg/dL) despite maximal statin plus ezetimibe therapy.\n- The Cholesterol Treatment Trialists meta-analysis demonstrated a consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C reduction, regardless of baseline LDL-C.\n- Secondary treatment with ezetimibe, with or without PCSK9 inhibitors, is advised for patients who have not achieved at least a 50% LDL-C reduction or have LDL-C levels ≥70 mg/dL despite maximum tolerated statin therapy.\n- USPSTF recommends low- to moderate-dose statins for primary prevention in adults aged 40-75 with one or more CVD risk factors and a 10-year cardiovascular risk ≥10%, though this is less specific to high LDL-C alone.\n- Safety and adverse event rates for high-intensity statins and PCSK9 inhibitors are well-established, with PCSK9 inhibitors generally well tolerated.\n- Risk enhancers influencing therapy decisions include family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, inflammatory diseases, and elevated biomarkers such as hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL, and apoB ≥130 mg/dL.\n\nIn summary, for patients with severe primary hypercholesterolemia without ASCVD, initiate high-intensity statin therapy aiming for LDL-C <100 mg/dL; if goals are unmet, add ezetimibe and consider PCSK9 inhibitors based on residual LDL-C levels and overall risk.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5951
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "The 2018 guidelines for high LDL-C management recommend the following:\n\n1. **Severe Primary Hypercholesterolemia (LDL-C ≥190 mg/dL [≥4.9 mmol/L])**:  \n   - Initiate high-intensity statin therapy (or moderate-intensity statin plus ezetimibe) without risk assessment to achieve LDL-C <100 mg/dL.  \n   - If LDL-C goal is not reached, consider adding a PCSK9 inhibitor in selected higher-risk patients.  \n   - Maximally tolerated statin therapy is recommended for patients aged 20-75 years with LDL-C ≥190 mg/dL (Class I recommendation).\n\n2. **Intermediate Risk (LDL-C 70-189 mg/dL [1.8-4.9 mmol/L])**:  \n   - Moderate-intensity statins are recommended for patients 40-75 years without diabetes at intermediate risk (10-year ASCVD risk 7.5%-19.9%) based on high-quality RCT evidence.  \n   - In uncertain cases, coronary artery calcium (CAC) scoring may guide statin therapy decisions:  \n     - CAC = 0 may defer statin unless diabetes, family history of premature CHD, or smoking present.  \n     - CAC 1-99 favors statin initiation, especially after age 55.  \n     - CAC ≥100 or ≥75th percentile warrants statin therapy.\n\n3. **Very High-Risk ASCVD Patients**:  \n   - Use LDL-C threshold of 70 mg/dL for intensifying therapy.  \n   - Add PCSK9 inhibitors if LDL-C remains ≥70 mg/dL despite maximally tolerated statin and ezetimibe.\n\n4. **Diabetes Mellitus Considerations**:  \n   - Age 40-75 with diabetes: moderate-intensity statin (Class I).  \n   - Consider high-intensity statin if additional risk enhancers present (Class IIa).\n\n5. **Lifestyle Modifications**:  \n   - Always recommended as foundational therapy across all risk groups.\n\n6. **Risk Enhancers Include**:  \n   - Family history of premature ASCVD  \n   - Persistently elevated LDL-C ≥160 mg/dL (≥4.1 mmol/L)  \n   - Chronic kidney disease  \n   - Metabolic syndrome  \n   - Conditions specific to women (e.g., preeclampsia, premature menopause)  \n   - Inflammatory diseases (rheumatoid arthritis, psoriasis, HIV)  \n   - South Asian ancestry  \n   - Persistently elevated triglycerides ≥175 mg/dL  \n   - Biomarkers (if measured): hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL or >125 nmol/L, apoB ≥130 mg/dL  \n   - Ankle-brachial index (ABI) <0.9\n\n7. **Efficacy and Safety Data**:  \n   - Cholesterol Treatment Trialists meta-analysis showed consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C reduction across LDL baseline levels.  \n   - Maximally tolerated statin therapy aims for ≥50% LDL-C reduction.\n\n**Key recommendations summary**:  \n- High-intensity statins for LDL-C ≥190 mg/dL or very high-risk ASCVD.  \n- Moderate-intensity statins for intermediate risk with LDL-C 70-189 mg/dL.  \n- PCSK9 inhibitors as add-on therapy for very high-risk patients not reaching LDL-C goals on statins plus ezetimibe.  \n- Use CAC scoring to guide statin initiation when risk decision is uncertain.  \n- Emphasize lifestyle changes in all patients.\n\nNo specific resistance markers were reported in these guidelines.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 6882
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Summary of Statin Therapy Guidelines for Patients Without ASCVD:\n\n1. **2018 AHA/ACC/MS Guideline**  \n   - Statin therapy is **Class 1 recommended** for:  \n     - Adults with LDL-C >190 mg/dL  \n     - Adults aged 40-75 years with diabetes mellitus, regardless of ASCVD risk  \n     - Adults aged 40-75 years with a 10-year ASCVD risk ≥20%  \n   - For borderline (5 to <7.5%) and intermediate (7.5% to <20%) 10-year ASCVD risk, shared decision-making is emphasized, with Class 2b recommendation for borderline risk and Class 1 for intermediate risk.  \n   - The 2022 USPSTF guideline is noted to reduce statin initiation opportunities compared to this guideline, especially in younger adults and those with diabetes.\n\n2. **2022 USPSTF Update**  \n   - Based on an evidence review including 22 RCTs, statin therapy for primary prevention (patients without ASCVD) reduces:  \n     - All-cause mortality  \n     - Fatal or nonfatal myocardial infarction  \n     - Fatal or nonfatal stroke  \n     - Revascularization  \n     - Composite cardiovascular outcomes  \n   - Harms assessed from 19 RCTs and 3 large cohort studies.  \n   - Insufficient data for adults >75 years.\n\n3. **Non-Statin Therapies (NLA Guidance)**  \n   - PCSK9 inhibitors approved for high-risk patients (existing ASCVD or LDL-C >190 mg/dL) who do not achieve >50% LDL-C reduction on maximally tolerated statins.  \n   - Non-statin therapies considered to address gaps in LDL-C lowering for ASCVD risk reduction in high-risk subsets.\n\n4. **Additional Recommendations**  \n   - Patients aged 20-75 years with LDL-C ≥190 mg/dL should receive maximally tolerated statin therapy (moderate-quality evidence, RCTs).  \n   - Patients 40-75 years without diabetes at intermediate risk (LDL-C 70-189 mg/dL, 10-year ASCVD risk 7.5%-19.9%) should receive moderate-intensity statins (high-quality evidence).  \n   - For patients with LDL-C 70-189 mg/dL and 10-year ASCVD risk 7.5%-19.9% where statin therapy decision is uncertain, coronary artery calcium (CAC) scoring is reasonable to guide treatment.\n\n5. **Specific Dosage/Regimens**  \n   - Moderate-intensity statin therapy is recommended for diabetes patients aged 40-75 with LDL-C ≥70 mg/dL.  \n   - Specific statin types and dosages are not detailed in the summary but moderate-intensity statins are implied.\n\n**Key Points:**  \n- Statin therapy is strongly recommended for adults 40-75 with diabetes or LDL-C >190 mg/dL or high ASCVD risk (≥20%).  \n- Shared decision-making is important for borderline/intermediate risk groups.  \n- Statins reduce mortality and major cardiovascular events in primary prevention.  \n- PCSK9 inhibitors are an option for high-risk patients inadequately controlled on statins.  \n- CAC scoring can help decision-making in uncertain cases.  \n- Data on statin efficacy and safety in adults over 75 are insufficient.\n\nNo resistance markers were reported in the provided data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5512
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  }
                ]
              }
            }
          }
        },
        "agent_properties": {
          "organ_name": "kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Tissue Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - The conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Cellular Impact:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Activation of pathways related to drug metabolism and excretion is occurring.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Tissue Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - The conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Cellular Impact:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Activation of pathways related to drug metabolism and excretion is occurring.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 6.27459716796875,
      "error_message": null
    },
    {
      "log_id": "log_1762673040948_tissue_heart_heart",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:00.949344",
      "level": 2,
      "level_name": "组织层",
      "agent_id": "tissue_heart_heart",
      "agent_name": "tissue",
      "agent_type": "tissue",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "organ",
          "output_data": {
            "round1_analysis": "# Organ Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and a focus on assessing the implications of SLCO1B1 genetic variants.\n- **Key Drug Observations:**\n  - Simvastatin is effectively reducing LDL-C by approximately 55 mg/dL for T/C and 57 mg/dL for T/T genotypes.\n  - Myopathy risk is heightened in patients with the SLCO1B1 521T>C polymorphism, particularly at higher doses.\n  - The heart's response to Simvastatin is being monitored for potential adverse effects related to the patient's genetic background.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating increased risk of myopathy in relation to SLCO1B1 variants are being emitted.\n  - Emitting stress signals in response to the metabolic effects of Simvastatin on lipid profiles.\n  - Active feedback regarding LDL-C levels and cholesterol synthesis modulation.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Organ Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and a focus on assessing the implications of SLCO1B1 genetic variants.\n- **Key Drug Observations:**\n  - Simvastatin is effectively reducing LDL-C by approximately 55 mg/dL for T/C and 57 mg/dL for T/T genotypes.\n  - Myopathy risk is heightened in patients with the SLCO1B1 521T>C polymorphism, particularly at higher doses.\n  - The heart's response to Simvastatin is being monitored for potential adverse effects related to the patient's genetic background.\n- **Key Bio-Signals Emitted:**\n  - Signals indicating increased risk of myopathy in relation to SLCO1B1 variants are being emitted.\n  - Emitting stress signals in response to the metabolic effects of Simvastatin on lipid profiles.\n  - Active feedback regarding LDL-C levels and cholesterol synthesis modulation.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [
                  "What is the impact of SLCO1B1 polymorphisms on the efficacy and safety of Simvastatin in patients with hypercholesterolemia?",
                  "What are the recommended guidelines for statin therapy in patients with high LDL-C and no history of ASCVD?"
                ],
                "tool_result": "- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Simvastatin\n  - **Critical Information**:\n    - Polymorphisms: rs4149056 (521T>C, V174A), rs2306283 (388A>G, N130D)\n    - Association with statin-induced myopathy and intolerance.\n    - Higher risk of myopathy with rs4149056 variant, especially in high-dose simvastatin.\n    - Identified in the SEARCH trial (NCT identifier not specified).\n    - Allele and haplotype frequencies characterized in various populations (1,205 healthy Thai individuals).\n  - **Clinical Implications**:\n    - Genotyping for SLCO1B1 variants can predict myopathy risk and guide therapy.\n    - Importance of awareness of polymorphisms to avoid adverse outcomes.\n  - **References**: None specified.\n\n- **Tool Name**: get_general_info_by_compound_name\n  - **Gene Names**: None specified.\n  - **Drug Names**: Simvastatin (brand name: Zocor), Rosuvastatin\n  - **Critical Information**:\n    - Mechanism: Competitive inhibitor of HMG-CoA reductase.\n    - Indications: Primary hyperlipidemia, familial hypercholesterolemia, secondary prevention in high-risk patients.\n    - Efficacy: Reduces major cardiovascular events by 20%-22% per 1 mmol/L LDL reduction.\n    - Myopathy risk: \n      - 0.03% at 20 mg/day\n      - 0.08% at 40 mg/day\n      - 0.61% at 80 mg/day\n    - Liver enzyme elevations >3x ULN: ~1% of patients.\n    - Clinical trial data: Scandinavian Simvastatin Survival Study (4S), Heart Protection Study (HPS, n=20,536).\n  - **References**: None specified.\n\n- **Tool Name**: get_general_info_by_disease_name\n  - **Gene Names**: LDLR, PCSK9, APOB, HMGCR, NPC1L1, ABCG8, ABCG5, APOE, SORT1, PPARA\n  - **Drug Names**: Amlodipine Besylate, Pitavastatin Calcium (Livalo), Atorvastatin (Cardyl, Lipitor, Prevencor, Sortis, Tahor, Zarator), Rosuvastatin Calcium (Crestor, Ezallor), Evolocumab (Repatha), Bempedoic Acid (Nexletol), Fenofibrate, Pravastatin Sodium (Elisor, Lipemol, Liplat, Lipostat, Pravachol), Simvastatin (Flolipid, Lacersa, Ranzolont, Simvador, Zocor)\n  - **Critical Information**:\n    - All drugs are Phase 4 and not withdrawn.\n    - Mechanisms include HMG-CoA reductase inhibition and PCSK9 inhibition.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Simvastatin\n  - **Critical Information**:\n    - Polymorphisms: rs4149056 (also known as SLCO1B1*5).\n    - Allelic odds ratio (OR) of 4.5 for definite myopathy (CK >10× upper limit of normal) with high doses of simvastatin.\n    - LDL-C reductions: \n      - 44 ± 25 mg/dL (C/C)\n      - 55 ± 19 mg/dL (T/C)\n      - 57 ± 22 mg/dL (T/T)\n      - Total cholesterol reductions: \n        - 43 ± 27 mg/dL (C/C)\n        - 57 ± 21 mg/dL (T/C)\n        - 60 ± 24 mg/dL (T/T)\n    - Statistical significance: *P* = 0.038 for LDL-C; *P* = 0.008 for total cholesterol.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Simvastatin\n  - **Critical Information**:\n    - Genotyping recommendations for patients with SLCO1B1 521 CC or TC genotypes.\n    - Maximum simvastatin dose for TC genotype: 40 mg/day.\n    - LDL-C reduction data provided earlier.\n    - Heart Protection Study (N=18,000 on 40 mg simvastatin) suggested minimal effect (~1% per C allele).\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: SLCO1B1\n  - **Drug Names**: Atorvastatin\n  - **Critical Information**:\n    - Impact of SLCO1B1 polymorphisms on atorvastatin pharmacokinetics and efficacy.\n    - No linkage found in Brazilian familial hypercholesterolemia cohort.\n    - Studies on SLCO1B1 and MDR1 polymorphisms in Egyptian patients.\n    - Systematic review confirmed genotypic effects on myopathy risk.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: None specified.\n  - **Drug Names**: None specified.\n  - **Critical Information**:\n    - Recommendations for statin therapy:\n      - High-intensity for high 10-year ASCVD risk.\n      - Moderate-intensity for diabetics aged 40-75 years.\n    - 2022 USPSTF recommendations indicate 31.8% of US adults aged 40-75 with LDL-C <190 mg/dL are eligible for statin therapy.\n    - Risk categories defined for ASCVD.\n    - Coronary artery calcium (CAC) scoring recommendations.\n  - **References**: 2018 AHA/ACC/Multisociety cholesterol guidelines, 2019 ACC/AHA Primary Prevention Guideline, 2022 USPSTF recommendations.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: None specified.\n  - **Drug Names**: Evolocumab (Repatha)\n  - **Critical Information**:\n    - LDL-C targets: <55 mg/dL for very high-risk; <70 mg/dL for diabetes or heart disease risk.\n    - Lifestyle modifications recommended.\n  - **References**: None specified.\n\n- **Tool Name**: tavily_search\n  - **Gene Names**: None specified.\n  - **Drug Names**: None specified.\n  - **Critical Information**:\n    - Statin therapy recommendations for primary prevention of ASCVD in adults aged 40-75 years.\n    - High-intensity statins for LDL-C ≥190 mg/dL.\n    - Key clinical trials: IMPROVE-IT, FOURIER, ODYSSEY, CLEAR, ACCORD, HPS2-THRIVE.\n  - **References**: 2018 ACC/AHA Guideline on the Management of Blood Cholesterol.\n\n- **Tool Name**: get_general_info_by_disease_name\n  - **Gene Names**: PCSK9, LDLR, HMGCR, APOE, SORT1\n  - **Drug Names**: Bempedoic Acid (Nexletol, Nilemdo), Lovastatin (Altoprev, Mevacor), Pravastatin Sodium (Pravachol), Rosuvastatin Calcium (Crestor), Inclisiran Sodium (Leqvio), Clopidogrel Bisulfate (Plavix), Vorapaxar Sulfate (Zontivity), Amantadine Hydrochloride (Gocovri)\n  - **Critical Information**:\n    - Main therapeutic targets include PCSK9, LDLR, HMGCR.\n    - All drugs listed are approved and at clinical trial phase 4.\n  - **References**: None specified.\n\n- **Tool Name**: get_pharmacogenomics_info_by_drug_name\n  - **Gene Names**: None specified.\n  - **Drug Names**: None specified.\n  - **Critical Information**: No data available due to failure of the tool.\n  - **References**: None specified.",
                "raw_tool_results": [
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly rs4149056 (521T>C, V174A) and rs2306283 (388A>G, N130D), significantly alter the transport activity of the hepatic OATP1B1 transporter. These variants are strongly associated with statin-induced myopathy, statin intolerance, and adverse drug reactions (ADRs) due to reduced hepatic uptake of statins.\n\nKey findings include:  \n- The rs4149056 variant is linked to a higher risk of myopathy, especially in patients on high-dose simvastatin, as demonstrated in the SEARCH trial (NCT identifier not specified). This association was identified via a genomewide association study with well-matched controls, showing a large effect size on myopathy risk.  \n- Both polymorphisms affect statin elimination and contribute to variable patient responses and intolerance, including milder forms of statin intolerance.  \n- Allele and haplotype frequencies of these variants (notably *SLCO1B1* *1a*, *1b*, *5*, and *15*) have been characterized in various populations, including a study of 1,205 healthy Thai individuals, indicating population-specific prevalence.  \n\nClinical implications:  \n- Genotyping for SLCO1B1 variants, especially rs4149056, can help predict statin-induced myopathy risk and guide statin therapy selection and dosing to improve safety.  \n- Awareness of these polymorphisms is important to avoid adverse outcomes and optimize lipid-lowering efficacy, particularly when using simvastatin or other statins metabolized via OATP1B1.\n\nNo specific resistance markers beyond these polymorphisms were reported. Safety data emphasize increased myopathy risk correlated with these variants, but exact percentages were not provided in the summarized sources.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4044
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_compound_name",
                    "toolsuite": "pubchem",
                    "success": true,
                    "sse_summary": "Simvastatin (brand name Zocor) is a semi-synthetic lipid-lowering drug derived from fermentation of Aspergillus terreus and is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol biosynthesis. It lowers total cholesterol, LDL-C, apolipoprotein B, and triglycerides, while increasing HDL-C, thereby reducing cardiovascular disease (CVD) risk including myocardial infarction, stroke, and need for revascularization. Indications include primary hyperlipidemia (Fredrickson types IIa, IIb, III, IV), homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH) in adolescents, and secondary prevention in patients with coronary heart disease, diabetes, peripheral artery disease, stroke, or other high-risk conditions.\n\nClinical data show statins, including simvastatin, reduce major cardiovascular events by 20%-22% per 1 mmol/L LDL reduction even in low-risk individuals (<10% 5-year risk). Rosuvastatin is more potent (10-40 mg daily reduces LDL by 45.8%-54.6%) compared to simvastatin (~35% LDL reduction). Despite potency differences, clinical outcomes are similar across statins.\n\nSafety profile highlights:\n\n- Myopathy risk increases with dose: 0.03% at 20 mg/day, 0.08% at 40 mg/day, and 0.61% at 80 mg/day. The 80 mg dose is recommended only for patients stable on this dose >12 months without muscle toxicity and requires close monitoring. Myopathy risk is elevated with interacting drugs such as fenofibrate, niacin, gemfibrozil, cyclosporine, strong CYP3A4 inhibitors, and colchicine.\n\n- Liver enzyme elevations (>3x ULN) occur in ~1% of patients; usually asymptomatic and reversible upon drug discontinuation. In the Scandinavian Simvastatin Survival Study (4S), transaminase elevations >3x ULN were 0.7% with simvastatin vs. 0.6% placebo; in the Heart Protection Study (HPS, n=20,536), elevated transaminases occurred in 0.21% with simvastatin 40 mg vs. 0.09% placebo.\n\n- Endocrine effects include modest increases in HbA1c and fasting glucose; no significant impact on steroid hormone production or gallstone risk.\n\nSimvastatin is FDA-approved since 1991 with clinical trial phase IV across 10 approved and 97 investigational indications. It acts by inhibiting HMG-CoA reductase, reducing cholesterol synthesis and inducing LDL receptor expression to enhance LDL clearance. It is considered cost-effective and standard of care post-cardiovascular events or in moderate-to-high risk patients.\n\nNo specific resistance markers noted.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 14326
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_disease_name",
                    "toolsuite": "opentargets",
                    "success": true,
                    "sse_summary": "The summary for hypercholesterolemia (EFO ID: HP_0003124) includes key molecular targets and approved drugs with clinical details:\n\n**Key Disease Targets (with relevance scores):**  \n- LDLR (0.8413)  \n- PCSK9 (0.8113)  \n- APOB (0.8045)  \n- HMGCR (0.7478)  \n- NPC1L1 (0.7115)  \n- ABCG8 (0.6585), ABCG5 (0.6105), APOE (0.6103), SORT1 (0.5838), PPARA (0.5770), among others.\n\n**Approved Drugs (all Phase 4, not withdrawn):**\n\n1. **Amlodipine Besylate** (Trade names: Amlodipine besylate, Norliqva, Norvasc)  \n   - Mechanism: Voltage-gated L-type calcium channel blocker  \n   - Target: CACNA1D\n\n2. **Pitavastatin Calcium** (Livalo)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR\n\n3. **Atorvastatin** (Cardyl, Lipitor, Prevencor, Sortis, Tahor, Zarator)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR  \n   - Trial status: Completed and unknown status in different records\n\n4. **Rosuvastatin Calcium** (Crestor, Ezallor, Ezallor sprinkle)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR\n\n5. **Evolocumab** (Repatha, Repatha sureclick)  \n   - Mechanism: Subtilisin/kexin type 9 (PCSK9) inhibitor  \n   - Target: PCSK9\n\n6. **Bempedoic Acid** (Nexletol, Nilemdo)  \n   - Mechanism: ATP-citrate synthase inhibitor  \n   - Target: ACLY\n\n7. **Fenofibrate** (Antara, Fenofibrate micronized, Fenogal, Fenoglide, Lipantil series, Lipidil, Lipofen, Supralip 160, Tricor, Triglide)  \n   - Mechanism: Peroxisome proliferator-activated receptor alpha (PPARA) agonist  \n   - Target: PPARA\n\n8. **Pravastatin Sodium** (Elisor, Lipemol, Liplat, Lipostat, Pravachol)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR  \n   - Trial status: Completed\n\n9. **Simvastatin** (Flolipid, Lacersa, Ranzolont, Simvador, Zocor)  \n   - Mechanism: HMG-CoA reductase inhibitor  \n   - Target: HMGCR\n\n**Key Points:**  \n- The primary molecular target for many approved drugs is HMGCR, inhibited by multiple statins (atorvastatin, pitavastatin, rosuvastatin, pravastatin, simvastatin).  \n- PCSK9 is targeted by evolocumab, an approved monoclonal antibody reducing LDL cholesterol.  \n- Bempedoic acid targets ACLY, offering a novel mechanism.  \n- Fenofibrate activates PPARA to reduce triglycerides.  \n- Amlodipine besylate, although primarily a calcium channel blocker for hypertension, is listed with relevance to hypercholesterolemia possibly due to cardiovascular benefits.\n\nNo resistance markers or adverse event rates were reported in this dataset. No efficacy or response rates or clinical trial NCT identifiers were provided.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 9161
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms significantly influence simvastatin pharmacokinetics, efficacy, and safety. The rs4149056 variant (also known as SLCO1B1*5) is strongly associated with increased risk of simvastatin-induced myopathy, with an allelic odds ratio (OR) of 4.5 for definite myopathy (CK >10× upper limit of normal) in patients receiving high doses of simvastatin. This association is specific to simvastatin and not observed with atorvastatin.\n\nIn a candidate-gene study, the SLCO1B1 521C allele was the only genetic factor significantly linked to cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks in white patients. LDL-C reductions were 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T) (*P* = 0.038), and total cholesterol reductions were 43 ± 27 mg/dL (C/C), 57 ± 21 mg/dL (T/C), and 60 ± 24 mg/dL (T/T) (*P* = 0.008).\n\nSLCO1B1 polymorphisms affect the pharmacokinetics of active simvastatin acid but not the parent drug, impacting therapeutic outcomes and side effect profiles. These genetic variations modulate simvastatin efficacy in lipid lowering and contribute to statin intolerance risk in clinical settings.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 3716
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms, particularly the rs4149056 variant (521C allele), significantly increase the risk of simvastatin-induced myopathy. Clinical guidelines recommend choosing alternative therapies for patients with SLCO1B1 521 CC or TC genotypes to reduce this risk. If alternatives are not feasible for patients with the TC genotype, simvastatin doses should not exceed 40 mg/day, and patients should be advised to report muscle symptoms promptly.\n\nEfficacy data show that the SLCO1B1 521C allele is associated with a slightly reduced cholesterol-lowering response to simvastatin 40 mg daily over 6 weeks, notably in white patients: LDL-C reduction was 44 ± 25 mg/dL (C/C), 55 ± 19 mg/dL (T/C), and 57 ± 22 mg/dL (T/T) (*P* = 0.038), and total cholesterol reduction was 43 ± 27 mg/dL (C/C), 57 ± 21 mg/dL (T/C), and 60 ± 24 mg/dL (T/T) (*P* = 0.008). However, large trials such as the Heart Protection Study (N=18,000 on 40 mg simvastatin) indicate only a minimal (~1% per C allele) effect of SLCO1B1 genotype on LDL-C reduction and no significant impact on vascular outcomes.\n\nSafety data confirm increased myopathic complaints in carriers of the SLCO1B1 rs4149056C allele on simvastatin; similar effects for rosuvastatin are less clear. SLCO1B1 polymorphisms may also contribute to milder forms of statin intolerance.\n\nIn summary, SLCO1B1 genotyping can guide statin therapy choice and dosing to minimize myopathy risk without compromising cardiovascular efficacy substantially.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 4000
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "SLCO1B1 polymorphisms significantly impact atorvastatin pharmacokinetics and cholesterol-lowering efficacy in hypercholesterolemia patients. The rs4149056 variant is notably associated with an increased risk of statin-induced myopathy, while the common SLCO1B1*1 haplotype influences drug response. However, in a Brazilian familial hypercholesterolemia cohort, SLCO1B1 haplotypes were not linked to atorvastatin-induced myalgia. Studies including Egyptian patients also explore the role of SLCO1B1 and MDR1 polymorphisms on atorvastatin therapeutic response. Additionally, ABCG2 and SLCO1B1 variants affect inflammation markers in patients treated with rosuvastatin. A systematic review and meta-analysis confirmed the genotypic effects of rs4149056 and rs2306283 polymorphisms on statin-associated myopathy risk. Key conclusions emphasize the importance of SLCO1B1 genotyping to predict atorvastatin efficacy and myopathy risk, aiding personalized hypercholesterolemia treatment.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 2428
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Statin therapy guidelines recommend the following:\n\n1. **General Recommendations**:  \n   - High-intensity statins for patients at high 10-year ASCVD risk.  \n   - Moderate-intensity statins for diabetics aged 40–75 years.  \n   - Lifestyle modifications emphasized for all patients.\n\n2. **Eligibility and Risk Assessment**:  \n   - According to the 2022 USPSTF recommendations, 31.8% of US adults aged 40–75 years with LDL-C <190 mg/dL and no ASCVD are eligible for statin therapy for primary prevention.  \n   - The 2018 AHA/ACC/Multisociety (MS) guidelines increase eligibility to 46.8% in this population after clinician-patient risk discussion.  \n   - Risk categories:  \n     - ≥7.5% to <20% 10-year ASCVD risk = intermediate risk.  \n     - ≥20% = high risk.  \n     - <5% = low risk.  \n     - 5% to <7.5% = borderline risk.  \n   - Coronary artery calcium (CAC) scoring may guide statin decisions in uncertain cases:  \n     - CAC=0 may allow withholding statins unless diabetes, family history, or smoking present.  \n     - CAC 1–99 favors statin initiation, especially >55 years.  \n     - CAC ≥100 or ≥75th percentile strongly supports statin therapy.\n\n3. **Specific Populations**:  \n   - Patients with severe primary hypercholesterolemia (LDL-C >190 mg/dL) should start high-intensity statins or moderate-intensity statins plus ezetimibe aiming for LDL-C <100 mg/dL.  \n   - If LDL-C goals are not achieved on maximally tolerated statins plus ezetimibe, PCSK9 inhibitors may be added, especially in very high-risk patients with LDL-C ≥70 mg/dL or non-HDL-C >100 mg/dL (per 2018 guidelines).  \n   - Diabetics aged 40–75 years: moderate-intensity statin therapy is indicated (2019 ACC/AHA guideline).\n\n4. **Efficacy**:  \n   - Cholesterol Treatment Trialists meta-analysis shows a consistent relative risk reduction in cardiovascular events of about 22% per 39 mg/dL (1 mmol/L) LDL-C lowering, regardless of baseline LDL-C.\n\n5. **Lifestyle**:  \n   - Lifestyle modifications remain a foundational recommendation across all risk groups.\n\n**Key Guidelines Referenced**:  \n- 2018 AHA/ACC/Multisociety cholesterol guidelines  \n- 2019 ACC/AHA Primary Prevention Guideline  \n- 2022 USPSTF recommendations\n\nNo resistance markers or adverse event rates were reported in the summarized data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5272
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "High LDL-C (low-density lipoprotein cholesterol) is a major risk factor for heart attack and stroke. For individuals at very high cardiovascular risk, the American College of Cardiology recommends an LDL-C level below 55 mg/dL to reduce the risk of recurrent major cardiovascular events, especially in patients with 1 major cardiovascular event plus 2 or more high-risk conditions.\n\nLifestyle modifications, including a heart-healthy diet low in saturated fats (e.g., grilled/baked fish, skinless poultry, soy products, legumes, nuts in moderation), are important for lowering LDL-C. However, individuals with genetically elevated LDL-C, such as those with familial hypercholesterolemia (FH), often require cholesterol-lowering medications to achieve target LDL-C levels.\n\nMedications like evolocumab (Repatha®), a PCSK9 inhibitor, are indicated along with diet for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C levels.\n\nRecommended LDL-C targets vary by risk group: below 70 mg/dL is considered optimal for people with diabetes or other heart disease risk factors, while below 55 mg/dL is targeted for very high-risk patients.\n\nIn summary:\n- LDL-C targets: <55 mg/dL for very high-risk individuals; <70 mg/dL for diabetes or heart disease risk.\n- Lifestyle changes plus medications are required for most patients with high LDL-C, especially those with genetic causes like FH.\n- Evolocumab (Repatha®) is an approved medication for lowering LDL-C in primary hyperlipidemia and HeFH.\n- High saturated fat diets, like ketogenic diets, can dramatically increase LDL-C and should be avoided in at-risk patients.\n\nNo specific clinical trials or NCT numbers were provided in the source data. Safety/adverse event rates and resistance markers were not reported.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 5369
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "tavily_search",
                    "toolsuite": "search",
                    "success": true,
                    "sse_summary": "Statin therapy is recommended for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults aged 40-75 years with high LDL-C and at least one cardiovascular risk factor, provided their 10-year ASCVD risk is 10% or higher. High-intensity statins are advised for patients with LDL-C ≥190 mg/dL without the need for additional risk assessment (2018 ACC/AHA Guideline on the Management of Blood Cholesterol). \n\nThe 2022 USPSTF updated evidence review, including 22 randomized clinical trials (RCTs), found that statin use in primary prevention reduces all-cause mortality, fatal and nonfatal myocardial infarction, stroke, revascularization, and composite cardiovascular outcomes. Harms were assessed from 19 RCTs and 3 large cohort studies, with insufficient data on adults older than 75 years. \n\nKey clinical trials referenced for LDL-C lowering and ASCVD risk management include IMPROVE-IT, FOURIER, ODYSSEY, CLEAR, ACCORD, and HPS2-THRIVE. For patients with familial hypercholesterolemia or LDL-C ≥190 mg/dL, high-intensity statins combined with non-statin therapies are often used to prevent ASCVD.\n\nAdditional ASCVD risk enhancers to consider include family history of premature ASCVD, persistently elevated LDL-C ≥160 mg/dL, chronic kidney disease, metabolic syndrome, diabetes duration, albuminuria, retinopathy, neuropathy, inflammatory diseases (e.g., rheumatoid arthritis, psoriasis, HIV), and ethnicity factors (e.g., South Asian ancestry). Biomarkers such as hs-CRP ≥2.0 mg/L, Lp(a) >50 mg/dL or >125 nmol/L, apoB ≥130 mg/dL, and ankle-brachial index (ABI) <0.9 may further guide therapy.\n\nStatin therapy is generally not recommended for patients with a 10-year ASCVD risk <5%. The ASCVD Risk Estimator Plus tool is recommended for calculating individualized 10-year and lifetime risk to aid clinical decision-making.\n\nIn summary, for adults aged 40-75 with LDL-C ≥190 mg/dL or those with LDL-C <190 mg/dL but a 10-year ASCVD risk ≥10% plus risk factors, statin therapy (high-intensity for LDL ≥190 mg/dL, low- to moderate-intensity for others) reduces cardiovascular events and mortality, with an acceptable safety profile based on extensive RCT data.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 7181
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "",
                    "tool_name": "get_general_info_by_disease_name",
                    "toolsuite": "opentargets",
                    "success": true,
                    "sse_summary": "The summary of the tool output for atherosclerotic cardiovascular disease (EFO_0003914) is as follows:\n\n**Key Disease Targets:**\n- PCSK9 (score 0.6821)\n- LDLR (0.6074)\n- HMGCR (0.5928)\n- APOE (0.5816)\n- SORT1 (0.5703)\n- P2RY12 (0.5694)\n- GRIN1 (0.5688)\n- ABCG8 (0.5655)\n- LPA (0.5635)\n- Additional targets include multiple GRIN subunits (GRIN2D, GRIN2A, GRIN3A, GRIN3B, GRIN2B, GRIN2C), ADRB1, CETP, CELSR2, TCF7L2, LPL, JCAD, COL4A1, HHIPL1, SMOC1, ANGPTL4 with scores ranging from ~0.51 to 0.56.\n\n**Approved Drugs and Mechanisms:**\n1. **Bempedoic Acid** (Nexletol, Nilemdo)  \n   - Phase 4, approved  \n   - Mechanism: ATP-citrate lyase (ACLY) inhibitor\n\n2. **Statins (HMG-CoA reductase inhibitors)** – all Phase 4, approved:  \n   - Lovastatin (Altoprev, Mevacor, others)  \n   - Pravastatin Sodium (Pravachol, Elisor, others)  \n   - Rosuvastatin Calcium (Crestor, Ezallor, others)\n\n3. **Inclisiran Sodium** (Leqvio)  \n   - Phase 4, approved  \n   - Mechanism: PCSK9 mRNA RNAi inhibitor targeting PCSK9\n\n4. **Clopidogrel Bisulfate** (Plavix, Iscover)  \n   - Phase 4, approved  \n   - Mechanism: P2Y12 receptor antagonist\n\n5. **Vorapaxar Sulfate** (Zontivity)  \n   - Phase 4, approved  \n   - Mechanism: Proteinase-activated receptor 1 (F2R) antagonist\n\n6. **Amantadine Hydrochloride** (Gocovri, Symmetrel, others)  \n   - Phase 4, approved  \n   - Mechanism: Glutamate NMDA receptor antagonist targeting GRIN2D, GRIN3B, and GRIN1 subunits\n\n**Summary:**\n- The main therapeutic targets include PCSK9, LDLR, and HMGCR, with multiple approved drugs targeting these pathways, primarily statins and newer agents like bempedoic acid and inclisiran.\n- Antiplatelet agents clopidogrel and vorapaxar are also approved for cardiovascular risk reduction via P2RY12 and F2R antagonism.\n- Amantadine hydrochloride targets NMDA receptor subunits but its clinical role in atherosclerotic cardiovascular disease is less direct.\n- All listed drugs are approved and at clinical trial phase 4, with no withdrawals reported.\n- No resistance markers or specific efficacy/safety statistics were provided in the data.\n\nThis information supports the use of statins, PCSK9 inhibitors (inclisiran), and ATP-citrate lyase inhibitors (bempedoic acid) as key therapies for atherosclerotic cardiovascular disease, along with antiplatelet agents for thrombosis prevention.",
                    "content_meta": {
                      "oversized": true,
                      "original_size_bytes": 8924
                    },
                    "additional_info_type": "Others",
                    "additional_info": ""
                  },
                  {
                    "content": "null",
                    "tool_name": "get_pharmacogenomics_info_by_drug_name",
                    "toolsuite": "fda_drug",
                    "success": false,
                    "additional_info_type": "Others",
                    "additional_info": "",
                    "additional_urls": ""
                  }
                ]
              }
            }
          }
        },
        "agent_properties": {
          "organ_name": "heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Tissue Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and scrutiny of SLCO1B1 genetic factors.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C by approximately 55-57 mg/dL depending on genotype.\n  - Myopathy risk is elevated in patients with the SLCO1B1 521T>C polymorphism, especially at higher doses.\n  - Monitoring for adverse effects related to genetic background is ongoing.\n- **Cellular Impact:**\n  - Emitting stress signals due to metabolic changes from Simvastatin.\n  - Increased risk of myopathy observed in relation to SLCO1B1 variants.\n  - Active feedback mechanisms regarding cholesterol synthesis are engaged.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Tissue Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and scrutiny of SLCO1B1 genetic factors.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C by approximately 55-57 mg/dL depending on genotype.\n  - Myopathy risk is elevated in patients with the SLCO1B1 521T>C polymorphism, especially at higher doses.\n  - Monitoring for adverse effects related to genetic background is ongoing.\n- **Cellular Impact:**\n  - Emitting stress signals due to metabolic changes from Simvastatin.\n  - Increased risk of myopathy observed in relation to SLCO1B1 variants.\n  - Active feedback mechanisms regarding cholesterol synthesis are engaged.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 6.3331379890441895,
      "error_message": null
    },
    {
      "log_id": "log_1762673042598_cell_kidney_cell_kidney",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:02.598926",
      "level": 3,
      "level_name": "细胞层",
      "agent_id": "cell_kidney_cell_kidney",
      "agent_name": "cell",
      "agent_type": "cell",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "tissue",
          "output_data": {
            "round1_analysis": "# Tissue Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - The conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Cellular Impact:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Activation of pathways related to drug metabolism and excretion is occurring.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Tissue Status Report: Kidney\n- **General State:** The kidney is currently processing simvastatin, with considerations for potential metabolism-related risks based on the SLCO1B1 gene variant.\n- **Key Drug Observations:**\n  - Simvastatin metabolism may increase muscle toxicity risk, particularly in those with SLCO1B1 variants.\n  - The conversion of simvastatin to simvastatin acid (SVA) is significant, contributing to pharmacological effects.\n- **Cellular Impact:**\n  - Signals indicating muscle toxicity risk are being emitted due to the presence of simvastatin.\n  - Activation of pathways related to drug metabolism and excretion is occurring.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "tissue_name": "kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 5.636415004730225,
      "error_message": null
    },
    {
      "log_id": "log_1762673043258_target_cns_SLCO1B1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:03.258858",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_cns_SLCO1B1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning normally in the context of simvastatin administration, effectively mediating drug uptake.\n- **Key Drug Observations:**\n  - Simvastatin is effectively transported into hepatocytes via SLCO1B1, enhancing its cholesterol-lowering effects.\n  - Increased SLCO1B1 activity correlates with improved therapeutic outcomes for hypercholesterolemia treatment.\n- **Binding Characteristics:**\n  - Simvastatin exhibits high affinity binding to the SLCO1B1 transporter.\n  - The interaction is characterized by competitive inhibition with other substrates, influencing the pharmacokinetics of simvastatin.\n  - Variants in SLCO1B1 can affect drug response and risk of adverse effects.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning normally in the context of simvastatin administration, effectively mediating drug uptake.\n- **Key Drug Observations:**\n  - Simvastatin is effectively transported into hepatocytes via SLCO1B1, enhancing its cholesterol-lowering effects.\n  - Increased SLCO1B1 activity correlates with improved therapeutic outcomes for hypercholesterolemia treatment.\n- **Binding Characteristics:**\n  - Simvastatin exhibits high affinity binding to the SLCO1B1 transporter.\n  - The interaction is characterized by competitive inhibition with other substrates, influencing the pharmacokinetics of simvastatin.\n  - Variants in SLCO1B1 can affect drug response and risk of adverse effects.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.8505859375,
      "error_message": null
    },
    {
      "log_id": "log_1762673047997_target_cns_LDLR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:07.997383",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_cns_LDLR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: LDLR\n- **General State:** LDLR is currently upregulated due to simvastatin treatment, enhancing its ability to clear LDL-C from circulation.\n- **Key Drug Observations:**\n  - Simvastatin effectively increases LDLR expression on hepatocytes.\n  - The SLCO1B1 genotype can affect simvastatin metabolism and efficacy.\n  - Significant reductions in LDL-C levels are observed in patients treated with simvastatin.\n- **Binding Characteristics:**\n  - Simvastatin exhibits high affinity for HMG-CoA reductase, leading to potent inhibition of cholesterol synthesis.\n  - The drug's pharmacokinetics are influenced by SLCO1B1, affecting its hepatic uptake.\n  - The interaction of simvastatin with LDLR is crucial for its therapeutic effects.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: LDLR\n- **General State:** LDLR is currently upregulated due to simvastatin treatment, enhancing its ability to clear LDL-C from circulation.\n- **Key Drug Observations:**\n  - Simvastatin effectively increases LDLR expression on hepatocytes.\n  - The SLCO1B1 genotype can affect simvastatin metabolism and efficacy.\n  - Significant reductions in LDL-C levels are observed in patients treated with simvastatin.\n- **Binding Characteristics:**\n  - Simvastatin exhibits high affinity for HMG-CoA reductase, leading to potent inhibition of cholesterol synthesis.\n  - The drug's pharmacokinetics are influenced by SLCO1B1, affecting its hepatic uptake.\n  - The interaction of simvastatin with LDLR is crucial for its therapeutic effects.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.738249063491821,
      "error_message": null
    },
    {
      "log_id": "log_1762673048656_cell_heart_cell_heart",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:08.656085",
      "level": 3,
      "level_name": "细胞层",
      "agent_id": "cell_heart_cell_heart",
      "agent_name": "cell",
      "agent_type": "cell",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "tissue",
          "output_data": {
            "round1_analysis": "# Tissue Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and scrutiny of SLCO1B1 genetic factors.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C by approximately 55-57 mg/dL depending on genotype.\n  - Myopathy risk is elevated in patients with the SLCO1B1 521T>C polymorphism, especially at higher doses.\n  - Monitoring for adverse effects related to genetic background is ongoing.\n- **Cellular Impact:**\n  - Emitting stress signals due to metabolic changes from Simvastatin.\n  - Increased risk of myopathy observed in relation to SLCO1B1 variants.\n  - Active feedback mechanisms regarding cholesterol synthesis are engaged.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Tissue Status Report: heart\n- **General State:** The heart is currently engaged in processing Simvastatin, with active modulation of cholesterol levels and scrutiny of SLCO1B1 genetic factors.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C by approximately 55-57 mg/dL depending on genotype.\n  - Myopathy risk is elevated in patients with the SLCO1B1 521T>C polymorphism, especially at higher doses.\n  - Monitoring for adverse effects related to genetic background is ongoing.\n- **Cellular Impact:**\n  - Emitting stress signals due to metabolic changes from Simvastatin.\n  - Increased risk of myopathy observed in relation to SLCO1B1 variants.\n  - Active feedback mechanisms regarding cholesterol synthesis are engaged.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "tissue_name": "heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": true
      },
      "execution_time": 7.70602011680603,
      "error_message": null
    },
    {
      "log_id": "log_1762673052968_target_cns_ABCA1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:12.968970",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_cns_ABCA1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is crucial for lipid metabolism and cholesterol efflux, with implications for cardiovascular health. Its expression and function are influenced by statins.\n- **Key Drug Observations:**\n  - Statins like simvastatin enhance SLCO1B1-mediated transport, promoting cholesterol clearance.\n  - Statin therapy reduces LDL-C levels, positively impacting ABCA1 activity.\n  - Increased expression of ABCA1 may occur due to statin-induced changes in lipid profiles.\n- **Binding Characteristics:**\n  - Statins show high affinity for SLCO1B1, facilitating effective drug delivery to hepatic tissues.\n  - The interaction results in significant modulation of cholesterol homeostasis via ABCA1 pathways.\n  - Competitive inhibition of SLCO1B1 can occur with other substrates, influencing statin efficacy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is crucial for lipid metabolism and cholesterol efflux, with implications for cardiovascular health. Its expression and function are influenced by statins.\n- **Key Drug Observations:**\n  - Statins like simvastatin enhance SLCO1B1-mediated transport, promoting cholesterol clearance.\n  - Statin therapy reduces LDL-C levels, positively impacting ABCA1 activity.\n  - Increased expression of ABCA1 may occur due to statin-induced changes in lipid profiles.\n- **Binding Characteristics:**\n  - Statins show high affinity for SLCO1B1, facilitating effective drug delivery to hepatic tissues.\n  - The interaction results in significant modulation of cholesterol homeostasis via ABCA1 pathways.\n  - Competitive inhibition of SLCO1B1 can occur with other substrates, influencing statin efficacy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.971395969390869,
      "error_message": null
    },
    {
      "log_id": "log_1762673053419_target_kidney_HMGCR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:13.419279",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_kidney_HMGCR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: HMGCR\n- **General State:** HMGCR is currently inhibited by statin therapy, leading to decreased cholesterol synthesis in patients with hypercholesterolemia.\n- **Key Drug Observations:**\n  - Statins significantly lower LDL-C levels, improving lipid profiles.\n  - SLCO1B1 polymorphisms may affect statin pharmacokinetics, influencing efficacy and risk of myopathy.\n  - The therapeutic effect is maximized at doses like 40mg of simvastatin.\n- **Binding Characteristics:**\n  - Statins competitively inhibit the active site of HMGCR.\n  - The effectiveness of statins is dose-dependent, with higher doses leading to greater inhibition.\n  - SLCO1B1 influences the absorption and hepatic uptake of statins, impacting their bioavailability.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: HMGCR\n- **General State:** HMGCR is currently inhibited by statin therapy, leading to decreased cholesterol synthesis in patients with hypercholesterolemia.\n- **Key Drug Observations:**\n  - Statins significantly lower LDL-C levels, improving lipid profiles.\n  - SLCO1B1 polymorphisms may affect statin pharmacokinetics, influencing efficacy and risk of myopathy.\n  - The therapeutic effect is maximized at doses like 40mg of simvastatin.\n- **Binding Characteristics:**\n  - Statins competitively inhibit the active site of HMGCR.\n  - The effectiveness of statins is dose-dependent, with higher doses leading to greater inhibition.\n  - SLCO1B1 influences the absorption and hepatic uptake of statins, impacting their bioavailability.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.026713848114014,
      "error_message": null
    },
    {
      "log_id": "log_1762673057104_target_cns_PCSK9",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:17.104502",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_cns_PCSK9",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_cns\n- **General State:** The cells are actively adapting to decreased cholesterol synthesis while managing altered lipid homeostasis.\n- **Key Drug Observations:**\n  - Statin administration effectively lowers intracellular cholesterol levels.\n  - Enhanced expression of LDL receptors is observed, promoting LDL uptake.\n  - Potential compensatory mechanisms may activate to counteract decreased isoprenoid levels.\n- **Molecular Changes:**\n  - Decreased activity of HMG-CoA reductase and subsequent reduction in mevalonate.\n  - Altered signaling pathways due to isoprenoid depletion, affecting cell growth and survival.\n  - Upregulation of genes involved in cholesterol uptake and metabolism.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_cns"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is a critical regulator of LDL receptor degradation, impacting cholesterol homeostasis and cardiovascular health.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C levels, aiding in hypercholesterolemia management.\n  - SLCO1B1 genetic variants can lead to altered pharmacokinetics of simvastatin, impacting therapeutic outcomes.\n  - Statin therapy may lead to compensatory increases in PCSK9 levels, which could diminish LDL receptor availability over time.\n- **Binding Characteristics:**\n  - Simvastatin's mechanism involves competitive inhibition of HMG-CoA reductase, leading to decreased cholesterol synthesis.\n  - SLCO1B1 influences the hepatic uptake of simvastatin, affecting its bioavailability and action.\n  - The interaction between statins and PCSK9 is indirect but significant for long-term cholesterol management.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is a critical regulator of LDL receptor degradation, impacting cholesterol homeostasis and cardiovascular health.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C levels, aiding in hypercholesterolemia management.\n  - SLCO1B1 genetic variants can lead to altered pharmacokinetics of simvastatin, impacting therapeutic outcomes.\n  - Statin therapy may lead to compensatory increases in PCSK9 levels, which could diminish LDL receptor availability over time.\n- **Binding Characteristics:**\n  - Simvastatin's mechanism involves competitive inhibition of HMG-CoA reductase, leading to decreased cholesterol synthesis.\n  - SLCO1B1 influences the hepatic uptake of simvastatin, affecting its bioavailability and action.\n  - The interaction between statins and PCSK9 is indirect but significant for long-term cholesterol management.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.135303735733032,
      "error_message": null
    },
    {
      "log_id": "log_1762673058534_target_kidney_SLCO1B1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:18.534444",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_kidney_SLCO1B1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning effectively, facilitating the hepatic uptake of statins, particularly simvastatin.\n- **Key Drug Observations:**\n  - Simvastatin enhances SLCO1B1-mediated transport, improving the drug's efficacy.\n  - Increased hepatic uptake leads to significant reductions in circulating LDL-C levels.\n  - The patient has no ASCVD, suggesting a favorable risk profile for statin therapy.\n- **Binding Characteristics:**\n  - High affinity binding of simvastatin to SLCO1B1 promotes effective drug transport.\n  - Competitive inhibition may occur with other drugs metabolized by SLCO1B1, but current therapy is expected to be well-tolerated.\n  - Transport kinetics suggest rapid uptake in the liver post-administration.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning effectively, facilitating the hepatic uptake of statins, particularly simvastatin.\n- **Key Drug Observations:**\n  - Simvastatin enhances SLCO1B1-mediated transport, improving the drug's efficacy.\n  - Increased hepatic uptake leads to significant reductions in circulating LDL-C levels.\n  - The patient has no ASCVD, suggesting a favorable risk profile for statin therapy.\n- **Binding Characteristics:**\n  - High affinity binding of simvastatin to SLCO1B1 promotes effective drug transport.\n  - Competitive inhibition may occur with other drugs metabolized by SLCO1B1, but current therapy is expected to be well-tolerated.\n  - Transport kinetics suggest rapid uptake in the liver post-administration.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 5.114867925643921,
      "error_message": null
    },
    {
      "log_id": "log_1762673061194_target_heart_LDLR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:21.194317",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_heart_LDLR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: LDLR\n- **General State:** The LDL receptor (LDLR) is actively involved in mediating the effects of statins, with enhanced expression due to reduced intracellular cholesterol levels.\n- **Key Drug Observations:**\n  - Statin therapy significantly increases LDLR expression, promoting LDL clearance.\n  - SLCO1B1 polymorphisms may affect simvastatin efficacy and safety, necessitating consideration in therapy.\n  - The patient has high LDL-C levels, indicating a strong potential benefit from statin therapy.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to increased LDLR expression.\n  - The binding affinity of simvastatin to SLCO1B1 influences its pharmacokinetics and effectiveness.\n  - Higher doses of statins correlate with greater LDLR-mediated LDL uptake.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: LDLR\n- **General State:** The LDL receptor (LDLR) is actively involved in mediating the effects of statins, with enhanced expression due to reduced intracellular cholesterol levels.\n- **Key Drug Observations:**\n  - Statin therapy significantly increases LDLR expression, promoting LDL clearance.\n  - SLCO1B1 polymorphisms may affect simvastatin efficacy and safety, necessitating consideration in therapy.\n  - The patient has high LDL-C levels, indicating a strong potential benefit from statin therapy.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to increased LDLR expression.\n  - The binding affinity of simvastatin to SLCO1B1 influences its pharmacokinetics and effectiveness.\n  - Higher doses of statins correlate with greater LDLR-mediated LDL uptake.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 9.366529941558838,
      "error_message": null
    },
    {
      "log_id": "log_1762673062071_target_kidney_LDLR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:22.072025",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_kidney_LDLR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: LDLR\n- **General State:** LDLR is currently upregulated in response to decreased intracellular cholesterol levels due to statin therapy.\n- **Key Drug Observations:**\n  - Simvastatin enhances LDLR expression, facilitating uptake of LDL cholesterol.\n  - The drug reduces circulating LDL-C levels significantly in hypercholesterolemic patients.\n  - There may be an impact on liver lipid metabolism and overall cholesterol homeostasis.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to decreased cholesterol synthesis.\n  - Increased availability of LDLR on the cell surface enhances LDL clearance.\n  - The interaction between statins and SLCO1B1 may influence the pharmacokinetics and efficacy of simvastatin.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: LDLR\n- **General State:** LDLR is currently upregulated in response to decreased intracellular cholesterol levels due to statin therapy.\n- **Key Drug Observations:**\n  - Simvastatin enhances LDLR expression, facilitating uptake of LDL cholesterol.\n  - The drug reduces circulating LDL-C levels significantly in hypercholesterolemic patients.\n  - There may be an impact on liver lipid metabolism and overall cholesterol homeostasis.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, leading to decreased cholesterol synthesis.\n  - Increased availability of LDLR on the cell surface enhances LDL clearance.\n  - The interaction between statins and SLCO1B1 may influence the pharmacokinetics and efficacy of simvastatin.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 3.5372698307037354,
      "error_message": null
    },
    {
      "log_id": "log_1762673066771_target_kidney_ABCA1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:26.772057",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_kidney_ABCA1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is involved in cholesterol efflux and is crucial for maintaining lipid homeostasis. Current research highlights its role in the response to statin therapy.\n- **Key Drug Observations:**\n  - Statins may indirectly influence ABCA1 expression and activity, enhancing cholesterol efflux.\n  - Increased HDL levels from statin therapy could be associated with improved ABCA1 function.\n  - ABCA1's activity may be modulated by the lipid-lowering effects of statins, contributing to overall cholesterol metabolism.\n- **Binding Characteristics:**\n  - Statins do not directly bind to ABCA1 but can influence its activity through modulation of lipid levels.\n  - The interaction between statins and SLCO1B1 transporter may affect the bioavailability of drugs impacting ABCA1 indirectly.\n  - Statin-induced changes in cellular cholesterol levels may enhance the expression of ABCA1.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is involved in cholesterol efflux and is crucial for maintaining lipid homeostasis. Current research highlights its role in the response to statin therapy.\n- **Key Drug Observations:**\n  - Statins may indirectly influence ABCA1 expression and activity, enhancing cholesterol efflux.\n  - Increased HDL levels from statin therapy could be associated with improved ABCA1 function.\n  - ABCA1's activity may be modulated by the lipid-lowering effects of statins, contributing to overall cholesterol metabolism.\n- **Binding Characteristics:**\n  - Statins do not directly bind to ABCA1 but can influence its activity through modulation of lipid levels.\n  - The interaction between statins and SLCO1B1 transporter may affect the bioavailability of drugs impacting ABCA1 indirectly.\n  - Statin-induced changes in cellular cholesterol levels may enhance the expression of ABCA1.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.699735164642334,
      "error_message": null
    },
    {
      "log_id": "log_1762673067559_target_heart_HMGCR",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:27.559697",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_heart_HMGCR",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: HMGCR\n- **General State:** HMGCR is currently targeted by statins, effectively inhibiting its activity and reducing cholesterol synthesis.\n- **Key Drug Observations:**\n  - Simvastatin effectively lowers LDL-C levels in patients with hypercholesterolemia.\n  - Enhanced uptake of LDL-C by the liver due to HMGCR inhibition.\n  - Potential for significant reduction in cardiovascular risk factors in treated patients.\n- **Binding Characteristics:**\n  - Statins exhibit competitive inhibition of HMGCR.\n  - High affinity binding of statins to the active site of HMGCR.\n  - Pharmacokinetics influenced by SLCO1B1 transporters, affecting statin efficacy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: HMGCR\n- **General State:** HMGCR is currently targeted by statins, effectively inhibiting its activity and reducing cholesterol synthesis.\n- **Key Drug Observations:**\n  - Simvastatin effectively lowers LDL-C levels in patients with hypercholesterolemia.\n  - Enhanced uptake of LDL-C by the liver due to HMGCR inhibition.\n  - Potential for significant reduction in cardiovascular risk factors in treated patients.\n- **Binding Characteristics:**\n  - Statins exhibit competitive inhibition of HMGCR.\n  - High affinity binding of statins to the active site of HMGCR.\n  - Pharmacokinetics influenced by SLCO1B1 transporters, affecting statin efficacy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.365153074264526,
      "error_message": null
    },
    {
      "log_id": "log_1762673071486_target_kidney_PCSK9",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:31.486387",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_kidney_PCSK9",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_kidney\n- **General State:** The kidney cells are functioning optimally with enhanced lipid metabolism and no signs of acute toxicity from statin treatment.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors enhances clearance of LDL-C from the bloodstream.\n  - Statin treatment leads to a decrease in cellular cholesterol levels, promoting healthier cell membrane composition.\n  - No significant adverse reactions or cellular stress indicators observed.\n- **Molecular Changes:**\n  - Downregulation of HMG-CoA reductase activity reduces cholesterol synthesis.\n  - Alterations in the mevalonate pathway impact protein prenylation and cell signaling.\n  - Potential upregulation of antioxidant responses to counteract any oxidative stress.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_kidney"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is a key regulator of LDL receptor degradation, impacting cholesterol metabolism and homeostasis.\n- **Key Drug Observations:**\n  - Statins lower LDL-C levels by enhancing LDL receptor recycling through inhibition of PCSK9.\n  - Variants in SLCO1B1 can lead to altered statin exposure, influencing efficacy and side effects.\n- **Binding Characteristics:**\n  - Statins bind competitively to HMG-CoA reductase, impacting cholesterol synthesis.\n  - SLCO1B1 variants can affect the hepatic uptake of statins, altering their pharmacological action.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is a key regulator of LDL receptor degradation, impacting cholesterol metabolism and homeostasis.\n- **Key Drug Observations:**\n  - Statins lower LDL-C levels by enhancing LDL receptor recycling through inhibition of PCSK9.\n  - Variants in SLCO1B1 can lead to altered statin exposure, influencing efficacy and side effects.\n- **Binding Characteristics:**\n  - Statins bind competitively to HMG-CoA reductase, impacting cholesterol synthesis.\n  - SLCO1B1 variants can affect the hepatic uptake of statins, altering their pharmacological action.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.714069128036499,
      "error_message": null
    },
    {
      "log_id": "log_1762673072356_target_heart_PCSK9",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:32.356763",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_heart_PCSK9",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is currently a critical target for lowering LDL-C levels and managing hypercholesterolemia.\n- **Key Drug Observations:**\n  - Statins reduce LDL-C by enhancing LDL receptor activity.\n  - SLCO1B1 polymorphisms can affect statin metabolism and effectiveness.\n  - Simvastatin is expected to significantly lower cholesterol levels in the patient.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, indirectly affecting PCSK9 levels.\n  - PCSK9 binds to LDL receptors, promoting their degradation; statins can modulate this interaction indirectly.\n  - Statin efficacy can vary based on SLCO1B1 genetic variants, impacting overall treatment outcomes.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: PCSK9\n- **General State:** PCSK9 is currently a critical target for lowering LDL-C levels and managing hypercholesterolemia.\n- **Key Drug Observations:**\n  - Statins reduce LDL-C by enhancing LDL receptor activity.\n  - SLCO1B1 polymorphisms can affect statin metabolism and effectiveness.\n  - Simvastatin is expected to significantly lower cholesterol levels in the patient.\n- **Binding Characteristics:**\n  - Statins competitively inhibit HMG-CoA reductase, indirectly affecting PCSK9 levels.\n  - PCSK9 binds to LDL receptors, promoting their degradation; statins can modulate this interaction indirectly.\n  - Statin efficacy can vary based on SLCO1B1 genetic variants, impacting overall treatment outcomes.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.796820163726807,
      "error_message": null
    },
    {
      "log_id": "log_1762673076705_target_heart_ABCA1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:36.705483",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_heart_ABCA1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is involved in cholesterol efflux and lipid metabolism, but its direct interaction with statins is minimal.\n- **Key Drug Observations:**\n  - Statins primarily target HMG-CoA reductase rather than ABCA1.\n  - Indirectly, statins may influence ABCA1 expression through changes in cellular cholesterol levels.\n  - Enhanced LDL receptor activity leads to reduced plasma LDL-C, which may positively affect ABCA1 function over time.\n- **Binding Characteristics:**\n  - Statins do not directly bind to ABCA1.\n  - Binding affinity to SLCO1B1 is crucial for statin efficacy in cholesterol management.\n  - Indirect effects on ABCA1 may occur through altered lipid profiles.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: ABCA1\n- **General State:** ABCA1 is involved in cholesterol efflux and lipid metabolism, but its direct interaction with statins is minimal.\n- **Key Drug Observations:**\n  - Statins primarily target HMG-CoA reductase rather than ABCA1.\n  - Indirectly, statins may influence ABCA1 expression through changes in cellular cholesterol levels.\n  - Enhanced LDL receptor activity leads to reduced plasma LDL-C, which may positively affect ABCA1 function over time.\n- **Binding Characteristics:**\n  - Statins do not directly bind to ABCA1.\n  - Binding affinity to SLCO1B1 is crucial for statin efficacy in cholesterol management.\n  - Indirect effects on ABCA1 may occur through altered lipid profiles.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 4.348434925079346,
      "error_message": null
    },
    {
      "log_id": "log_1762673083192_target_heart_SLCO1B1",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:24:43.193007",
      "level": 4,
      "level_name": "靶点层",
      "agent_id": "target_heart_SLCO1B1",
      "agent_name": "target",
      "agent_type": "target",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "Statin + SLCO1B1",
          "disease": "Hypercholesterolemia",
          "patient": "45岁, 高LDL-C, 无ASCVD, 计划辛伐他汀40mg"
        },
        "parent_analysis": {
          "agent_id": "cell",
          "output_data": {
            "round1_analysis": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
            "round2_analysis": {
              "llm_analysis": {
                "content": "# Cell Status Report: cell_heart\n- **General State:** The cell is actively responding to statin treatment, showing improved lipid profiles and enhanced cellular uptake of LDL-C.\n- **Key Drug Observations:**\n  - Increased expression of LDL receptors on the cell surface, promoting LDL uptake.\n  - Decreased intracellular cholesterol levels, leading to improved cellular function.\n  - Enhanced antioxidant response due to reduced oxidative stress from altered lipid profiles.\n- **Molecular Changes:**\n  - Inhibition of HMG-CoA reductase activity, leading to decreased cholesterol synthesis.\n  - Altered expression of genes involved in lipid metabolism and inflammation.\n  - Changes in signaling pathways related to cellular stress response and apoptosis.",
                "confidence": 0.5
              },
              "mcp_analysis": {
                "tool_queries": [],
                "tool_result": "",
                "raw_tool_results": []
              }
            }
          }
        },
        "agent_properties": {
          "cell_type": "cell_heart"
        }
      },
      "output_data": {
        "round1_analysis": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning normally, facilitating the hepatic uptake of simvastatin in the patient.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C levels due to enhanced hepatic uptake via SLCO1B1.\n  - Variability in response may occur due to genetic polymorphisms affecting SLCO1B1 function.\n  - No adverse drug interactions reported at the planned dosage of 40mg.\n- **Binding Characteristics:**\n  - Simvastatin exhibits high affinity for the SLCO1B1 transporter, promoting efficient hepatic uptake.\n  - The interaction is influenced by the presence of competing substrates and inhibitors of SLCO1B1.\n  - Genetic variations (e.g., SLCO1B1*5, *15) can significantly impact drug transport and efficacy.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Target Status Report: SLCO1B1\n- **General State:** SLCO1B1 is functioning normally, facilitating the hepatic uptake of simvastatin in the patient.\n- **Key Drug Observations:**\n  - Simvastatin effectively reduces LDL-C levels due to enhanced hepatic uptake via SLCO1B1.\n  - Variability in response may occur due to genetic polymorphisms affecting SLCO1B1 function.\n  - No adverse drug interactions reported at the planned dosage of 40mg.\n- **Binding Characteristics:**\n  - Simvastatin exhibits high affinity for the SLCO1B1 transporter, promoting efficient hepatic uptake.\n  - The interaction is influenced by the presence of competing substrates and inhibitors of SLCO1B1.\n  - Genetic variations (e.g., SLCO1B1*5, *15) can significantly impact drug transport and efficacy.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [],
            "tool_result": "",
            "raw_tool_results": []
          }
        },
        "analysis_mode": "single_round",
        "activate_next_level": false
      },
      "execution_time": 6.487205266952515,
      "error_message": null
    },
    {
      "log_id": "log_1762673185507_observer_main",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:26:25.508145",
      "level": 5,
      "level_name": "观察层",
      "agent_id": "observer_main",
      "agent_name": "observer",
      "agent_type": "observer",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "",
          "disease": "",
          "patient": ""
        }
      },
      "output_data": {
        "round1_analysis": "# Systemic Impact Summary\n\n## Primary Therapeutic Effect:\nSimvastatin is expected to significantly lower LDL-C levels, achieving reductions of approximately 55-57 mg/dL based on genotype, thus effectively treating hypercholesterolemia.\n\n## Key Adverse Effects:\n- Increased risk of statin-induced myopathy, especially at higher doses in patients with SLCO1B1 variants.\n- Potential for elevated creatine kinase levels (>3× upper limit of normal) indicating muscle damage.\n\n## Critical Contraindications & Precautions:\n- **Contraindications:** Use of simvastatin is contraindicated in patients with SLCO1B1 521 CC or TC genotype due to increased myopathy risk. Caution is advised for patients with severe renal impairment.\n- **Precautions:** Monitor for muscle-related symptoms, liver function tests, and potential drug interactions with medications that increase the risk of myopathy (e.g., gemfibrozil, certain antibiotics).\n\n## Critical Organ Interactions:\n- Liver metabolism of simvastatin impacts its efficacy and safety, with increased exposure leading to higher risks of muscle toxicity. The kidney's role in drug clearance is also significant, especially for patients with impaired renal function.\n\n## Net Systemic Outcome:\nThe drug demonstrates a strong potential for lowering LDL-C; however, there is a notable risk of myopathy and elevated CK levels, necessitating careful monitoring and possible dose adjustments based on genetic factors.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# Systemic Impact Summary\n\n## Primary Therapeutic Effect:\nSimvastatin is expected to significantly lower LDL-C levels, achieving reductions of approximately 55-57 mg/dL based on genotype, thus effectively treating hypercholesterolemia.\n\n## Key Adverse Effects:\n- Increased risk of statin-induced myopathy, especially at higher doses in patients with SLCO1B1 variants.\n- Potential for elevated creatine kinase levels (>3× upper limit of normal) indicating muscle damage.\n\n## Critical Contraindications & Precautions:\n- **Contraindications:** Use of simvastatin is contraindicated in patients with SLCO1B1 521 CC or TC genotype due to increased myopathy risk. Caution is advised for patients with severe renal impairment.\n- **Precautions:** Monitor for muscle-related symptoms, liver function tests, and potential drug interactions with medications that increase the risk of myopathy (e.g., gemfibrozil, certain antibiotics).\n\n## Critical Organ Interactions:\n- Liver metabolism of simvastatin impacts its efficacy and safety, with increased exposure leading to higher risks of muscle toxicity. The kidney's role in drug clearance is also significant, especially for patients with impaired renal function.\n\n## Net Systemic Outcome:\nThe drug demonstrates a strong potential for lowering LDL-C; however, there is a notable risk of myopathy and elevated CK levels, necessitating careful monitoring and possible dose adjustments based on genetic factors.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What are the absolute contraindications for simvastatin in patients with SLCO1B1 polymorphisms?",
              "What specific precautions should be taken when prescribing simvastatin to a 45-year-old patient with high LDL-C and no history of ASCVD?",
              "What are the recommended monitoring requirements for simvastatin therapy, including lab values and symptoms to watch for in this patient population?"
            ],
            "tool_result": "- **Tool Name:** tavily_search  \n  - **Gene Names:** SLCO1B1  \n  - **Drug Names:** simvastatin, atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, Crixivan®, Kaletra®, Lexiva®, Norvir®, Prezista®, Reyataz®, cyclosporine (Gengraf®, Neoral®, Sandimmune®), boceprevir (Victrelis®), cobicistat-containing products (Stribild®), danazol (Danocrine®), gemfibrozil (Lopid®), nefazodone (Serzone®), telaprevir (Incivek®), clarithromycin, daptomycin, erythromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole, Nizoral®  \n  - **Critical Information:**  \n    - Absolute contraindications for simvastatin include concurrent use with certain HIV/AIDS medications, cyclosporine, boceprevir, cobicistat, danazol, gemfibrozil, nefazodone, telaprevir, and specific antibiotics/antifungals.  \n    - Avoid simvastatin in patients with liver disease, history of liver problems, or during pregnancy.  \n    - FDA recommends limiting simvastatin to 80 mg daily due to increased risk of myopathy and rhabdomyolysis, especially in patients aged 65 years and older.  \n    - Adverse events include myopathy, muscle weakness, kidney problems, erectile dysfunction, interstitial lung disease, and rare cognitive impairment.  \n    - Symptoms warranting immediate medical attention include headache, stomach pain, vomiting, dark urine, loss of appetite, weight loss, fatigue, light-colored stools, upper right abdominal pain, and jaundice.  \n    - Clinical study: No additional cardiovascular benefit from adding niacin to simvastatin 40 mg/day (with or without ezetimibe 10 mg/day) over a median follow-up of 3.9 years in high cardiovascular risk patients.  \n\n- **Tool Name:** get_general_info_by_protein_or_gene_name  \n  - **Gene Names:** SLCO1B1 (also known as LST1, OATP1B1, OATP2, OATPC, SLC21A6)  \n  - **Drug Names:** pravastatin, pitavastatin, methotrexate, enalapril, valsartan  \n  - **Critical Information:**  \n    - SLCO1B1 encodes a transporter mediating Na(+)-independent uptake of a broad range of organic anions, including bile acids, steroids, eicosanoids, thyroid hormones, and bilirubin glucuronides.  \n    - Kinetic parameters: Vmax for pitavastatin (230.0 pmol/min/mg), 17beta-estradiol 17-O-(beta-D-glucuronate) (131.0 pmol/min/mg), enalapril (78.0 pmol/min/mg), estrone 3-sulfate (60.3 pmol/min/mg), coproporphyrins III (24.9 pmol/min/mg) and I (17.9 pmol/min/mg), valsartan (3.85 pmol/min/mg).  \n    - Km values: pravastatin (33.8 µM), pitavastatin (3.0 µM), estrone 3-sulfate (0.458 µM), enalapril (262 µM), valsartan (1.39 µM), coproporphyrins I (0.13 µM) and III (0.22 µM), taurocholate (13.6 µM), L-thyroxine (3.0 µM), 3,3',5'-triiodo-L-thyronine (2.7 µM).  \n    - Highly expressed in liver at basolateral membranes of centrilobular hepatocytes.  \n    - Plays a critical role in hepatic clearance of endogenous compounds and clinically important drugs, impacting their plasma and tissue distribution.  \n\n- **Tool Name:** tavily_search  \n  - **Gene Names:** SLCO1B1  \n  - **Drug Names:** simvastatin  \n  - **Critical Information:**  \n    - Simvastatin is contraindicated in patients with the SLCO1B1 rs4149056 521 CC or TC genotype due to increased risk of myopathy.  \n    - For patients with the 521 TC genotype, simvastatin doses should not exceed 40 mg/day, and alternative statins are recommended when possible.  \n    - Key findings: SLCO1B1*5 allele (rs4149056, c.521T>C) reduces OATP1B1 function, impairing simvastatin clearance and increasing myopathy risk.  \n    - Heart Protection Study showed minimal effect of SLCO1B1 genotype on LDL-C reduction and no significant impact on vascular outcomes.  \n    - Clinical guidelines recommend alternative statins for patients with SLCO1B1 521 CC or TC genotypes and dose limitation for 521 TC genotype if alternatives are not feasible.  \n    - Genotyping is useful to guide simvastatin use to minimize myopathy risk without compromising efficacy significantly.  \n\n- **Tool Name:** get_associated_drugs_by_target_name  \n  - **Success:** false  \n  - **Error Message:** Error: Failed after 3 attempts when executing tool: unhandled errors in a TaskGroup (1 sub-exception).  \n\n- **Tool Name:** get_general_info_by_compound_name  \n  - **Drug Names:** simvastatin (brand name Zocor)  \n  - **Critical Information:**  \n    - Simvastatin is a semi-synthetic lipid-lowering statin that competitively inhibits hepatic HMG-CoA reductase.  \n    - Indications: primary and mixed hyperlipidemia, homozygous familial hypercholesterolemia as adjunct therapy, reducing cardiovascular morbidity and mortality in high-risk patients.  \n    - Clinical efficacy: reduces LDL-C by approximately 35% on average; rosuvastatin lowers LDL-C by 45.8% to 54.6% at 10–40 mg/day.  \n    - Myopathy incidence: ~0.03% at 20 mg/day, 0.08% at 40 mg/day, and 0.61% at 80 mg/day; liver enzyme elevations (>3x ULN) in ~1% of patients.  \n    - Key recommendations: statins are first-line for dyslipidemia management; monitor liver enzymes and muscle symptoms; avoid drug interactions increasing myopathy risk.  \n\n- **Tool Name:** tavily_search  \n  - **Drug Names:** simvastatin  \n  - **Critical Information:**  \n    - Simvastatin should be prescribed with caution in patients with severe renal impairment, starting at a low dose of 5 mg.  \n    - High-dose simvastatin (80 mg/day) is associated with an increased risk of muscle injury and should generally be avoided.  \n    - Significant drug interactions with multiple medications including boceprevir, cobicistat, cyclosporine, danazol, gemfibrozil, nefazodone, telaprevir, and various antibiotics and HIV/AIDS treatments.  \n    - Patients should be monitored for signs of muscle toxicity and liver dysfunction.  \n    - Discontinuation of simvastatin and switching to an alternative statin recommended if adverse effects occur.  \n\n- **Tool Name:** get_disease_description_by_name  \n  - **Success:** false  \n  - **Error Message:** Error: Failed after 3 attempts when executing tool: unhandled errors in a TaskGroup (1 sub-exception).  \n\n- **Tool Name:** get_disease_description_by_name  \n  - **Success:** false  \n  - **Error Message:** Error: Failed after 3 attempts when executing tool: Error executing tool get_disease_description_by_name: object str can't be used in 'await' expression.  \n\n- **Tool Name:** tavily_search  \n  - **Critical Information:**  \n    - For patients with high LDL-C and no history of ASCVD, guidelines recommend initiating high-intensity statin therapy, especially for those with LDL-C ≥ 190 mg/dL (4.9 mmol/L), aiming for LDL-C <100 mg/dL.  \n    - If LDL-C goals are not met, adding a PCSK9 inhibitor is reasonable for very high-risk patients or with LDL-C ≥ 70 mg/dL (1.8 mmol/L) or non-HDL-C >100 mg/dL (2.6 mmol/L).  \n    - High-risk conditions include age ≥ 65, heterozygous familial hypercholesterolemia, diabetes, hypertension, CKD (eGFR 15-59 mL/min/1.73m²), and smoking.  \n    - Key recommendations: start high-intensity statin for LDL-C ≥ 190 mg/dL without ASCVD, monitor for statin adverse effects, and implement lifestyle changes.  \n    - The Cholesterol Treatment Trialists’ meta-analysis showed consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C reduction.  ",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Absolute contraindications for simvastatin include concurrent use with certain HIV/AIDS medications (atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, Crixivan®, Kaletra®, Lexiva®, Norvir®, Prezista®, Reyataz®), cyclosporine (Gengraf®, Neoral®, Sandimmune®), boceprevir (Victrelis®), cobicistat-containing products (Stribild®), danazol (Danocrine®), gemfibrozil (Lopid®), nefazodone (Serzone®), telaprevir (Incivek®), and specific antibiotics/antifungals (clarithromycin, daptomycin, erythromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole, Nizoral®). Avoid simvastatin in patients with liver disease, history of liver problems, or during pregnancy.\n\nThe FDA recommends limiting simvastatin 80 mg daily due to increased risk of myopathy and rhabdomyolysis, especially in patients ≥65 years old, based on data from the SEARCH trial and other safety reviews. Patients on 80 mg simvastatin with interacting drugs should be switched to alternative statins. \n\nAdverse events include myopathy, muscle weakness, kidney problems, erectile dysfunction, interstitial lung disease, and rare cognitive impairment. Symptoms warranting immediate medical attention include headache, stomach pain, vomiting, dark urine, loss of appetite, weight loss, fatigue, light-colored stools, upper right abdominal pain, and jaundice.\n\nA clinical study with a median follow-up of 3.9 years in high cardiovascular risk patients showed no additional cardiovascular benefit from adding niacin to simvastatin 40 mg/day (with or without ezetimibe 10 mg/day).\n\nIn summary, simvastatin use is absolutely contraindicated with specific drug interactions and in liver disease or pregnancy; high-dose (80 mg) use carries significant myopathy risk, especially in older adults, and careful monitoring for muscle and liver-related adverse events is essential.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4579
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_protein_or_gene_name",
                "toolsuite": "uniprot",
                "success": true,
                "sse_summary": "The SLCO1B1 gene (also known as LST1, OATP1B1, OATP2, OATPC, SLC21A6) encodes a transporter mediating Na(+)-independent uptake of a broad range of organic anions. It transports bile acid taurocholate, conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, estrone 3-sulfate), eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, leukotriene E4), thyroid hormones (T4/L-thyroxine, T3/3,3',5'-triiodo-L-thyronine), bilirubin glucuronides, and coproporphyrins I and III. It may regulate organic compound transport in testes and mediates hepatic uptake of drugs including statins (pravastatin, pitavastatin), methotrexate, ACE inhibitor prodrug enalapril, and angiotensin II receptor antagonist valsartan.\n\nKinetic parameters include maximum velocities (Vmax) of 230.0 pmol/min/mg for pitavastatin, 131.0 pmol/min/mg for 17beta-estradiol 17-O-(beta-D-glucuronate), 78.0 pmol/min/mg for enalapril, 60.3 pmol/min/mg for estrone 3-sulfate, 24.9 and 17.9 pmol/min/mg for coproporphyrins III and I respectively, 3.85 pmol/min/mg for valsartan. Michaelis constants (Km) are 33.8 µM for pravastatin, 3.0 µM for pitavastatin, 0.458 µM for estrone 3-sulfate, 8.29 µM for 17beta-estradiol 17-O-(beta-D-glucuronate), 262 µM for enalapril, 1.39 µM for valsartan, 0.13 and 0.22 µM for coproporphyrins I and III, 13.6 µM for taurocholate, 3.0 µM for L-thyroxine, and 2.7 µM for 3,3',5'-triiodo-L-thyronine. The optimum pH for transport of prostaglandin E2 and L-thyroxine is 6.5, with substrate transport stimulated in acidic microenvironments.\n\nSLCO1B1 is highly expressed in liver, specifically at basolateral membranes of centrilobular hepatocytes, including fetal liver. It is not detected in heart, brain, placenta, lung, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, or leukocytes at the protein level, though in testes it localizes primarily to the basal membrane of Sertoli cells and weakly in Leydig cells and tubules.\n\nThe transporter exchanges organic anions with hydrogencarbonate (HCO3-) as the probable counteranion.\n\nThis protein plays a critical role in hepatic clearance of endogenous compounds and clinically important drugs such as statins, methotrexate, enalapril, and valsartan, impacting their plasma and tissue distribution.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 22442
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin is contraindicated in patients with the SLCO1B1 rs4149056 521 CC or TC genotype due to an increased risk of myopathy. For patients with the 521 TC genotype, simvastatin doses should not exceed 40 mg/day, and alternative statins are recommended when possible. Patients should be advised to report muscle symptoms promptly.\n\nKey findings include:\n\n- The SLCO1B1*5 allele (rs4149056, c.521T>C) reduces OATP1B1 transporter function, impairing simvastatin clearance and increasing risk of myopathy, including mild statin-induced muscle side effects and creatine kinase (CK) elevations >3× upper limit of normal.\n- The Heart Protection Study (NCT number not specified) with 18,000 participants on 40 mg simvastatin showed only a minimal (~1% per C allele) effect of SLCO1B1 genotype on LDL-C reduction and no significant impact on vascular outcomes.\n- Genotype-guided simvastatin therapy results in noninferior lipid-lowering efficacy and reduces statin-associated muscle symptoms by avoiding simvastatin use in patients with decreased or poor OATP1B1 function.\n- Clinical guidelines (e.g., DPWG) recommend alternative statins for patients with SLCO1B1 521 CC or TC genotypes and dose limitation for 521 TC genotype if alternatives are not feasible.\n\nIn summary, SLCO1B1 genotyping is useful to guide simvastatin use to minimize myopathy risk without compromising efficacy significantly, and simvastatin doses >40 mg/day should be avoided in patients with the 521 TC genotype.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5055
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "Error: Failed after 3 attempts when executing tool: unhandled errors in a TaskGroup (1 sub-exception). Tool_invoke_info: {'item': 'SLCO1B1', 'tool': 'get_associated_drugs_by_target_name', 'tool_input': {'target_name': 'SLCO1B1'}}",
                "tool_name": "get_associated_drugs_by_target_name",
                "toolsuite": null,
                "success": false
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_compound_name",
                "toolsuite": "pubchem",
                "success": true,
                "sse_summary": "Simvastatin (brand name Zocor) is a semi-synthetic lipid-lowering statin derived from fermentation of Aspergillus terreus. It competitively inhibits hepatic HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, reducing LDL cholesterol (LDL-C), total cholesterol, apolipoprotein B (Apo B), and triglycerides (TG), while increasing HDL cholesterol (HDL-C). Simvastatin is indicated for primary and mixed hyperlipidemia (Fredrickson types IIa, IIb, III, IV), homozygous familial hypercholesterolemia (HoFH) as adjunct therapy, and to reduce cardiovascular morbidity and mortality in patients at high risk (e.g., coronary heart disease, diabetes, peripheral vascular disease, stroke, chronic kidney disease).\n\n**Clinical Efficacy and Dosing:**\n- Simvastatin reduces LDL-C by approximately 35% on average.\n- Rosuvastatin is more potent, lowering LDL-C by 45.8% to 54.6% at 10–40 mg/day.\n- Landmark studies show statins reduce major cardiovascular events by 20%-22% per 1 mmol/L LDL reduction, even in low-risk individuals (<10% 5-year risk).\n- Statins reduce all-cause mortality, fatal/non-fatal CVD events, and need for revascularization.\n\n**Safety and Adverse Events:**\n- Myopathy incidence: ~0.03% at 20 mg/day, 0.08% at 40 mg/day, and 0.61% at 80 mg/day; rhabdomyolysis is rare but serious.\n- 80 mg dose is recommended only for patients on chronic therapy (>12 months) without muscle toxicity; close monitoring required.\n- Myopathy risk increases with age ≥65, female sex, renal impairment, hypothyroidism, Chinese ethnicity, and concomitant use of CYP3A4 inhibitors, fenofibrate, niacin, gemfibrozil, cyclosporine, and colchicine.\n- Liver enzyme elevations (>3x ULN) occur in ~1% of patients; usually asymptomatic and reversible upon drug discontinuation.\n- Scandinavian Simvastatin Survival Study (4S) and Heart Protection Study (HPS) showed no significant difference in serious liver injury vs placebo.\n- Slight increases in HbA1c and fasting glucose reported; no clinical impact on steroidogenesis or gallstone risk.\n\n**Pharmacology:**\n- Simvastatin is lipophilic, entering endothelial cells via passive diffusion.\n- It induces hepatic LDL receptors, increasing LDL breakdown.\n- It also suppresses MHC II expression on interferon gamma-stimulated antigen-presenting cells, modulating immune responses.\n- It is a prodrug hydrolyzed in vivo to active metabolite.\n\n**Regulatory and Development Status:**\n- First approved in 1991.\n- Maximum clinical trial phase IV.\n- Has 10 approved and 97 investigational indications.\n\n**Key Recommendations:**\n- Statins, including simvastatin, are first-line for dyslipidemia management and CVD risk reduction.\n- Use of 80 mg simvastatin requires caution and monitoring.\n- Avoid or carefully manage drug interactions increasing myopathy risk.\n- Monitor liver enzymes periodically.\n\nNo resistance markers are reported for simvastatin.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 14326
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin should be prescribed with caution in patients with severe renal impairment, starting at a low dose of 5 mg. High-dose simvastatin (80 mg/day) is associated with an increased risk of muscle injury and is generally advised to be avoided. Significant drug interactions occur with medications including boceprevir, cobicistat-containing products, cyclosporine, danazol, gemfibrozil, nefazodone, telaprevir, certain antibiotics (clarithromycin, daptomycin, erythromycin, itraconazole, ketoconazole, posaconazole, telithromycin, voriconazole), and various HIV/AIDS treatments (atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, and combination drugs such as Stribild®, Kaletra®, Norvir®, Prezista®, Reyataz®). These interactions increase the risk of muscle injury and kidney problems.\n\nPatients should be monitored for signs of muscle toxicity (e.g., muscle pain, weakness) and liver dysfunction (e.g., headache, stomach pain, vomiting, dark urine, jaundice, light-colored stools). If adverse effects occur at high doses or upon re-challenge at lower doses, discontinuation of simvastatin and switching to an alternative statin is recommended.\n\nThe interprofessional healthcare team, including clinicians and pharmacists, should collaborate to monitor efficacy and safety, adjusting therapy as needed to minimize adverse events.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4854
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "Error: Failed after 3 attempts when executing tool: unhandled errors in a TaskGroup (1 sub-exception). Tool_invoke_info: {'item': 'high LDL-C', 'tool': 'get_disease_description_by_name', 'tool_input': {'disease_name': 'high LDL-C'}}",
                "tool_name": "get_disease_description_by_name",
                "toolsuite": null,
                "success": false
              },
              {
                "content": "Error: Failed after 3 attempts when executing tool: Error executing tool get_disease_description_by_name: object str can't be used in 'await' expression. Tool_invoke_info: {'item': 'ASCVD', 'tool': 'get_disease_description_by_name', 'tool_input': {'disease_name': 'atherosclerotic cardiovascular disease'}}",
                "tool_name": "get_disease_description_by_name",
                "toolsuite": null,
                "success": false
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "For patients with high LDL-C and no history of ASCVD, current guidelines recommend initiating high-intensity statin therapy, especially for those with LDL-C ≥190 mg/dL (4.9 mmol/L), aiming for LDL-C <100 mg/dL. If LDL-C goals are not met despite maximally tolerated statin therapy plus ezetimibe, adding a PCSK9 inhibitor is reasonable for patients at very high risk or with LDL-C ≥70 mg/dL (1.8 mmol/L) or non-HDL-C >100 mg/dL (2.6 mmol/L) (2018 ACC/AHA Guidelines, NCBI NBK305897; CardioSmart 2020). \n\nHigh-risk conditions warranting intensified therapy include age ≥65, heterozygous familial hypercholesterolemia, diabetes, hypertension, CKD (eGFR 15-59 mL/min/1.73m²), smoking, and persistent LDL-C elevation despite maximal statin and ezetimibe (AHA Pocket Guide). For patients aged ≤75 years without very high-risk ASCVD, high-intensity statins are recommended; moderate-intensity statins if high-intensity is not tolerated (Class I/IIa recommendations). For patients >75 years, continuing high-intensity statin therapy is reasonable (Class IIa). \n\nLifestyle modifications (healthy diet, weight loss, aerobic exercise, tobacco cessation, alcohol moderation) are essential adjuncts to pharmacotherapy.\n\nMonitoring includes liver enzymes and muscle symptoms due to statin-associated risks. The Cholesterol Treatment Trialists’ meta-analysis showed consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C reduction regardless of baseline LDL-C levels.\n\nKey recommendations:\n- Start high-intensity statin for LDL-C ≥190 mg/dL without ASCVD.\n- Add ezetimibe if LDL-C remains ≥70 mg/dL on maximal statin.\n- Consider PCSK9 inhibitors for very high-risk patients not achieving LDL-C targets.\n- Monitor for statin adverse effects (elevated liver enzymes, muscle symptoms).\n- Implement lifestyle changes universally.\n\nNo resistance markers were noted in the context of simvastatin precautions.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5894
                },
                "additional_info_type": "Others",
                "additional_info": ""
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": false
      },
      "execution_time": 102.308100938797,
      "error_message": null
    },
    {
      "log_id": "log_1762673288934_decision_main",
      "session_id": "vh_session_1762672447",
      "timestamp": "2025-11-09T15:28:08.935559",
      "level": 6,
      "level_name": "决策层",
      "agent_id": "decision_main",
      "agent_name": "decision",
      "agent_type": "decision",
      "phase": "complete",
      "input_data": {
        "original_input": {
          "drug": "",
          "disease": "",
          "patient": ""
        }
      },
      "output_data": {
        "round1_analysis": "# 1. Executive Summary\n- **Decision:** CONDITIONAL\n- **Confidence Level:** Medium\n- **Primary Recommendation:** Initiate simvastatin at 40 mg with close monitoring for muscle-related symptoms and liver function tests.\n\n# 2. Comprehensive Risk Assessment\n**2.1 Absolute Contraindications:**\n- None identified based on available patient information.\n\n**2.2 Relative Contraindications & Precautions:**\n- Patients with known SLCO1B1 521 CC or TC genotypes are at significantly increased risk for myopathy.\n- Care should be taken with renal function; monitor closely for any signs of renal impairment.\n\n**2.3 Patient-Specific Factors:**\n- Age is appropriate for starting statin therapy without additional considerations.\n- Genetic testing for SLCO1B1 variants is advisable to guide therapy.\n\n**2.4 Drug-Related Risks:**\n- Significant drug interactions exist with CYP3A4 inhibitors (e.g., gemfibrozil, certain antibiotics), increasing the risk of myopathy.\n- Myopathy risk increases with higher doses of simvastatin (especially >40 mg).\n\n**2.5 Monitoring & Surveillance Risks:**\n- Monitor for muscle symptoms and CK levels regularly, especially in the first few months of therapy.\n- Liver enzyme levels should be checked periodically, particularly if the patient is on other medications that may affect liver function.\n\n**2.6 Genetic/Pharmacogenomic Risks:**\n- The SLCO1B1 rs4149056 variant (521 TC or CC) significantly impacts simvastatin clearance and increases myopathy risk.\n- Genotyping is recommended to optimize therapy and minimize risks.\n\n# 3. Evidence-Based Rationale\n**3.1 Primary Evidence:**\n- Clinical studies indicate that simvastatin reduces LDL-C by approximately 35% and has a well-established safety profile.\n- The Heart Protection Study demonstrated efficacy in reducing cardiovascular events.\n\n**3.2 Supporting Evidence:**\n- The risk of myopathy is significantly higher in patients with SLCO1B1 variants, necessitating genotype-guided therapy to minimize adverse effects.\n\n**3.3 Conflicting Evidence:**\n- While the efficacy of simvastatin is well-documented, the variability in response due to genetic factors presents a conflict requiring careful consideration in prescribing.\n\n# 4. Stepwise Action Plan with Sequencing\n**Phase 1: Immediate Actions (Day 1-3)**\n1. Initiate simvastatin at 40 mg once daily, with emphasis on adherence to lifestyle modifications (diet, exercise).\n2. Schedule follow-up appointments to assess muscle symptoms and liver function.\n3. Obtain genetic testing for SLCO1B1 variants to tailor future management.\n\n**Phase 2: Short-term (Week 1-2)**\n1. Review patient for any adverse effects or new symptoms, particularly muscle pain or weakness.\n2. Monitor liver enzymes and CK levels at the end of week 2.\n\n**Phase 3: Long-term (Month 1-3)**\n1. Adjust therapy based on genotype results; consider alternative statins if high-risk variants are present.\n2. Continue regular follow-ups every 3 months to monitor efficacy and safety.\n\n**Phase 4: Ongoing Monitoring**\n1. Regularly assess muscle symptoms and liver function every 6 months.\n2. Monitor for drug interactions with new medications.\n\n# 5. Alternative Pathways\n**Alternative A:** Switch to an alternative statin (e.g., rosuvastatin) if significant myopathy occurs or if SLCO1B1 variants indicate high risk.\n- Rationale: Minimize myopathy risk while maintaining lipid-lowering efficacy.\n- Conditions: Use this alternative if muscle symptoms arise or genetic testing indicates high-risk SLCO1B1 variants.\n- Trade-offs: Alternative statins may offer different dosing regimens and side effect profiles.\n\n**Alternative B:** Consider adding ezetimibe if LDL-C goals are not met after 3 months of therapy.\n- Rationale: Ezetimibe can enhance LDL-C reduction without increasing myopathy risk.\n- Conditions: If LDL-C remains above target levels despite statin therapy.\n- Trade-offs: Additional medication may increase costs and the complexity of treatment regimens.\n\n# 6. Success Criteria & Triggers\n**Success Indicators:**\n- LDL-C levels reduced to <100 mg/dL within 3 months.\n- No significant muscle symptoms or liver enzyme abnormalities reported.\n- Patient adheres to follow-up appointments and monitoring.\n\n**Warning Triggers (requiring intervention):**\n- IF CK levels exceed 3x ULN THEN consider dose reduction or discontinuation of simvastatin.\n- IF muscle pain or weakness develops THEN evaluate for myopathy and consider alternative therapies.\n- IF liver enzymes exceed 3x ULN THEN discontinue therapy and investigate further.\n\n**Stop Triggers (requiring immediate action):**\n- IF severe muscle pain or weakness occurs THEN discontinue simvastatin immediately.\n- IF jaundice or significant abdominal pain develops THEN seek immediate medical evaluation.\n\n# 7. Critical Next Steps (Prioritized)\n1. Initiate simvastatin at 40 mg with patient education on symptoms to monitor.\n2. Schedule genetic testing for SLCO1B1 variants and follow-up in 2 weeks.\n3. Monitor for any adverse effects and adjust therapy as necessary.\n\n# 8. Information Gaps & Uncertainties\n- Patient's exact SLCO1B1 genotype is currently unknown, which may affect the safety and efficacy of simvastatin.\n- Consider obtaining comprehensive metabolic panel to assess baseline liver function and renal status.",
        "round2_analysis": {
          "llm_analysis": {
            "content": "# 1. Executive Summary\n- **Decision:** CONDITIONAL\n- **Confidence Level:** Medium\n- **Primary Recommendation:** Initiate simvastatin at 40 mg with close monitoring for muscle-related symptoms and liver function tests.\n\n# 2. Comprehensive Risk Assessment\n**2.1 Absolute Contraindications:**\n- None identified based on available patient information.\n\n**2.2 Relative Contraindications & Precautions:**\n- Patients with known SLCO1B1 521 CC or TC genotypes are at significantly increased risk for myopathy.\n- Care should be taken with renal function; monitor closely for any signs of renal impairment.\n\n**2.3 Patient-Specific Factors:**\n- Age is appropriate for starting statin therapy without additional considerations.\n- Genetic testing for SLCO1B1 variants is advisable to guide therapy.\n\n**2.4 Drug-Related Risks:**\n- Significant drug interactions exist with CYP3A4 inhibitors (e.g., gemfibrozil, certain antibiotics), increasing the risk of myopathy.\n- Myopathy risk increases with higher doses of simvastatin (especially >40 mg).\n\n**2.5 Monitoring & Surveillance Risks:**\n- Monitor for muscle symptoms and CK levels regularly, especially in the first few months of therapy.\n- Liver enzyme levels should be checked periodically, particularly if the patient is on other medications that may affect liver function.\n\n**2.6 Genetic/Pharmacogenomic Risks:**\n- The SLCO1B1 rs4149056 variant (521 TC or CC) significantly impacts simvastatin clearance and increases myopathy risk.\n- Genotyping is recommended to optimize therapy and minimize risks.\n\n# 3. Evidence-Based Rationale\n**3.1 Primary Evidence:**\n- Clinical studies indicate that simvastatin reduces LDL-C by approximately 35% and has a well-established safety profile.\n- The Heart Protection Study demonstrated efficacy in reducing cardiovascular events.\n\n**3.2 Supporting Evidence:**\n- The risk of myopathy is significantly higher in patients with SLCO1B1 variants, necessitating genotype-guided therapy to minimize adverse effects.\n\n**3.3 Conflicting Evidence:**\n- While the efficacy of simvastatin is well-documented, the variability in response due to genetic factors presents a conflict requiring careful consideration in prescribing.\n\n# 4. Stepwise Action Plan with Sequencing\n**Phase 1: Immediate Actions (Day 1-3)**\n1. Initiate simvastatin at 40 mg once daily, with emphasis on adherence to lifestyle modifications (diet, exercise).\n2. Schedule follow-up appointments to assess muscle symptoms and liver function.\n3. Obtain genetic testing for SLCO1B1 variants to tailor future management.\n\n**Phase 2: Short-term (Week 1-2)**\n1. Review patient for any adverse effects or new symptoms, particularly muscle pain or weakness.\n2. Monitor liver enzymes and CK levels at the end of week 2.\n\n**Phase 3: Long-term (Month 1-3)**\n1. Adjust therapy based on genotype results; consider alternative statins if high-risk variants are present.\n2. Continue regular follow-ups every 3 months to monitor efficacy and safety.\n\n**Phase 4: Ongoing Monitoring**\n1. Regularly assess muscle symptoms and liver function every 6 months.\n2. Monitor for drug interactions with new medications.\n\n# 5. Alternative Pathways\n**Alternative A:** Switch to an alternative statin (e.g., rosuvastatin) if significant myopathy occurs or if SLCO1B1 variants indicate high risk.\n- Rationale: Minimize myopathy risk while maintaining lipid-lowering efficacy.\n- Conditions: Use this alternative if muscle symptoms arise or genetic testing indicates high-risk SLCO1B1 variants.\n- Trade-offs: Alternative statins may offer different dosing regimens and side effect profiles.\n\n**Alternative B:** Consider adding ezetimibe if LDL-C goals are not met after 3 months of therapy.\n- Rationale: Ezetimibe can enhance LDL-C reduction without increasing myopathy risk.\n- Conditions: If LDL-C remains above target levels despite statin therapy.\n- Trade-offs: Additional medication may increase costs and the complexity of treatment regimens.\n\n# 6. Success Criteria & Triggers\n**Success Indicators:**\n- LDL-C levels reduced to <100 mg/dL within 3 months.\n- No significant muscle symptoms or liver enzyme abnormalities reported.\n- Patient adheres to follow-up appointments and monitoring.\n\n**Warning Triggers (requiring intervention):**\n- IF CK levels exceed 3x ULN THEN consider dose reduction or discontinuation of simvastatin.\n- IF muscle pain or weakness develops THEN evaluate for myopathy and consider alternative therapies.\n- IF liver enzymes exceed 3x ULN THEN discontinue therapy and investigate further.\n\n**Stop Triggers (requiring immediate action):**\n- IF severe muscle pain or weakness occurs THEN discontinue simvastatin immediately.\n- IF jaundice or significant abdominal pain develops THEN seek immediate medical evaluation.\n\n# 7. Critical Next Steps (Prioritized)\n1. Initiate simvastatin at 40 mg with patient education on symptoms to monitor.\n2. Schedule genetic testing for SLCO1B1 variants and follow-up in 2 weeks.\n3. Monitor for any adverse effects and adjust therapy as necessary.\n\n# 8. Information Gaps & Uncertainties\n- Patient's exact SLCO1B1 genotype is currently unknown, which may affect the safety and efficacy of simvastatin.\n- Consider obtaining comprehensive metabolic panel to assess baseline liver function and renal status.",
            "confidence": 0.5
          },
          "mcp_analysis": {
            "tool_queries": [
              "What are the specific contraindications for prescribing simvastatin to a patient with SLCO1B1 variants, particularly in relation to renal function?",
              "What precautions should be considered for a 45-year-old patient with high LDL-C and no history of ASCVD when initiating simvastatin therapy?",
              "What monitoring protocols should be established for this patient to track potential adverse effects associated with simvastatin use?"
            ],
            "tool_result": "- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Gene Name:** SLCO1B1  \n  - **Drug Name:** Simvastatin  \n  - **Critical Information:**  \n    - 521C allele (rs4149056, c.521T>C) associated with increased risk of myopathy.  \n    - High doses of simvastatin (notably 80 mg) significantly elevate the risk of myopathy in carriers of the SLCO1B1 521C allele.  \n    - Relative risk per copy of the C allele: 2.6 at 40 mg and higher at 80 mg doses.  \n    - CPIC guidelines recommend avoiding simvastatin doses >20 mg in individuals with SLCO1B1 521C allele.  \n    - Heart Protection Study: 24 cases of myopathy among 10,269 patients on 40 mg simvastatin.  \n    - Genotype classifications:  \n      - *1/*1 (TT) – normal/high activity (55–88% of patients)  \n      - *1/*5 (TC) – intermediate activity (11–36%)  \n      - *5/*5 (CC) – low activity (0–6%)  \n  - **Dosing Algorithms:**  \n    - Avoid simvastatin doses >20 mg in patients with SLCO1B1 521C allele.  \n    - Consider alternative statins or lower doses in patients with SLCO1B1 reduced-function genotypes.  \n  - **Clinical Trial Names/Details:**  \n    - SEARCH trial  \n    - Heart Protection Study  \n  - **References:**  \n    - CPIC guidelines  \n    - Genome-wide association studies confirming the link between SLCO1B1 variants and simvastatin-induced myopathy.  \n\n- **Tool Name:** get_general_info_by_protein_or_gene_name  \n  **Details:**  \n  - **Gene Name:** SLCO1B1 (also known as LST1, OATP1B1, OATP2, OATPC, SLC21A6)  \n  - **Drug Names:** Pravastatin, Pitavastatin, Methotrexate, Enalapril, Valsartan  \n  - **Critical Information:**  \n    - Mediates Na(+)-independent uptake of organic anions including bile acid taurocholate, conjugated steroids, eicosanoids, and thyroid hormones.  \n    - Kinetic parameters:  \n      - Vmax (pmol/min/mg protein): estrone 3-sulfate 60.3, pitavastatin 230.0, etc.  \n      - Km (μM): taurocholate 13.6, L-thyroxine 3.0, etc.  \n  - **References:**  \n    - PDB ID 8HNB (protein structure available).  \n\n- **Tool Name:** get_general_info_by_compound_name  \n  **Details:**  \n  - **Drug Name:** Simvastatin (brand name Zocor)  \n  - **Critical Information:**  \n    - Efficacy: Simvastatin lowers LDL-C by ~35% on average.  \n    - Indications include primary hyperlipidemia, familial hypercholesterolemia, and reducing cardiovascular morbidity/mortality.  \n    - Myopathy incidence: 0.03% at 20 mg/day, 0.08% at 40 mg/day, 0.61% at 80 mg/day.  \n    - Liver enzyme elevations >3x ULN occur in ~1% of patients.  \n  - **Clinical Recommendations:**  \n    - Statins are standard post-cardiovascular event therapy.  \n    - Monitor muscle symptoms and liver enzymes, especially with interacting drugs.  \n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug Name:** Simvastatin  \n  - **Critical Information:**  \n    - Contraindicated in patients with severe renal impairment.  \n    - Lower doses recommended for mild to moderate renal impairment.  \n    - FDA restrictions on the highest approved dose (80 mg) due to muscle damage risk.  \n  - **Dosing Algorithms:**  \n    - If severe adverse effects occur, discontinue simvastatin and consider alternative statins if necessary.  \n\n- **Tool Name:** get_pharmacogenomics_info_by_drug_name  \n  **Details:**  \n  - **Status:** Failed to retrieve data.  \n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug Name:** Simvastatin  \n  - **Critical Information:**  \n    - Precautions include taking with food and avoiding high doses or certain interacting drugs.  \n    - Usual adult dose ranges from 10 mg to 40 mg once daily.  \n    - Monitor for muscle symptoms and liver issues.  \n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug Name:** Simvastatin  \n  - **Critical Information:**  \n    - Management of high LDL cholesterol involves statins aiming for LDL-C levels below 70 mg/dL.  \n    - 2018 guidelines recommend PCSK9 inhibitors for patients with LDL-C ≥ 70 mg/dL despite statins.  \n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug Name:** Simvastatin  \n  - **Critical Information:**  \n    - Adverse effects include muscle pain, liver damage, and increased blood sugar levels.  \n    - Contraindications include liver disease, pregnancy, and breastfeeding.  \n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Drug Name:** Simvastatin  \n  - **Critical Information:**  \n    - Interacts with numerous drugs including clarithromycin, itraconazole, ritonavir, gemfibrozil, and more.  \n    - Higher risk of muscle injury and kidney problems with these interactions.  \n\n- **Tool Name:** tavily_search  \n  **Details:**  \n  - **Critical Information:**  \n    - 2022 USPSTF update recommends statin therapy for primary prevention of ASCVD in adults aged 40-75 with cardiovascular risk factors.  \n    - Statins reduce cardiovascular events and mortality.  \n    - Data insufficient for adults older than 75 years.",
            "raw_tool_results": [
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin is contraindicated in individuals carrying SLCO1B1 variants, particularly the 521C allele (rs4149056, c.521T>C), and in patients with impaired renal function due to increased risk of myopathy and other side effects. High doses of simvastatin (notably 80 mg) significantly elevate the risk of myopathy in carriers of the SLCO1B1 521C allele, as demonstrated in the SEARCH trial, where the relative risk per copy of the C allele was 2.6 at 40 mg and higher at 80 mg doses.\n\nThe Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines recommend avoiding simvastatin doses greater than 20 mg in individuals with the SLCO1B1 521C allele to reduce myopathy risk. The Heart Protection Study, which randomized over 20,000 subjects to 40 mg simvastatin or placebo, identified 24 cases of myopathy among 10,269 patients on simvastatin, with genotyping confirming increased risk associated with the minor C allele.\n\nSLCO1B1 genotype classifications and their expected transporter activity are:  \n- *1/*1 (TT) – normal/high activity (55–88% of patients)  \n- *1/*5 (TC) – intermediate activity (11–36%)  \n- *5/*5 (CC) – low activity (0–6%)  \n\nReduced function of the OATP1B1 transporter encoded by SLCO1B1 leads to impaired statin clearance, diminished lipid-lowering efficacy, and increased muscle-related side effects including myalgia and creatine kinase (CK) elevation (>3× upper limit of normal). Studies indicate that clinical genotyping and genotype-guided simvastatin prescribing avoid statin use in at-risk individuals, resulting in noninferior lipid-lowering outcomes and reduced muscle symptoms.\n\nRenal impairment independently increases simvastatin side effect risk, further contraindicating its use in patients with compromised renal function.\n\nKey conclusions/recommendations:  \n- Avoid simvastatin doses >20 mg in patients with SLCO1B1 521C allele.  \n- Consider alternative statins or lower doses in patients with SLCO1B1 reduced-function genotypes.  \n- Monitor renal function closely, as impairment raises risk of simvastatin toxicity.  \n- Genotype-guided therapy reduces incidence of statin-associated muscle symptoms without compromising efficacy.\n\nReferences include the SEARCH trial, Heart Protection Study, CPIC guidelines, and genome-wide association studies confirming the strong link between SLCO1B1 variants and simvastatin-induced myopathy.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 6262
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_protein_or_gene_name",
                "toolsuite": "uniprot",
                "success": true,
                "sse_summary": "The gene SLCO1B1 (also known as LST1, OATP1B1, OATP2, OATPC, SLC21A6) mediates Na(+)-independent uptake of a broad range of organic anions including bile acid taurocholate, conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, estrone 3-sulfate), eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4 and E4), and thyroid hormones (T4/L-thyroxine, T3/3,3',5'-triiodo-L-thyronine). It contributes to hepatic clearance of endogenous and exogenous substrates, including bilirubin glucuronides, coproporphyrin I and III, and may regulate transport across the blood-testis barrier.\n\nSLCO1B1 transports clinically important drugs such as HMG-CoA reductase inhibitors (statins) pravastatin and pitavastatin, the chemotherapeutic agent methotrexate, and antihypertensives including enalapril (ACE inhibitor prodrug) and valsartan (angiotensin II AT1-receptor antagonist). It exhibits pH-sensitive substrate specificity, with optimum activity at pH 6.5 for prostaglandin E2 and L-thyroxine, likely due to protonation states enhancing transport in acidic microenvironments. Hydrogencarbonate (HCO3-) likely serves as a counteranion exchanging for organic anions.\n\nKinetic parameters include maximum velocities (Vmax) and Michaelis constants (Km) for various substrates:  \n- Vmax (pmol/min/mg protein): estrone 3-sulfate 60.3, pitavastatin 230.0, 17beta-estradiol 17-O-(beta-D-glucuronate) 131.0, valsartan 3.85, enalapril 78.0, coproporphyrin I 17.9, coproporphyrin III 24.9.  \n- Km (μM): taurocholate 13.6, L-thyroxine 3.0, 3,3',5'-triiodo-L-thyronine 2.7, pravastatin 33.8, pitavastatin 3.0, estrone 3-sulfate 0.458, 17beta-estradiol 17-O-(beta-D-glucuronate) 8.29, valsartan 1.39, enalapril 262.0, coproporphyrin I 0.13, coproporphyrin III 0.22.\n\nSLCO1B1 is highly expressed in liver, specifically at the basolateral membranes of centrilobular hepatocytes, and also in fetal liver. It is not detected in heart, brain, placenta, lung, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon, or leukocytes at the protein level, although in testis it is localized mainly to the basal membrane of Sertoli cells with weak expression in Leydig cells and tubules.\n\nNo resistance markers are indicated. The protein structure is available with PDB ID 8HNB.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 22442
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "get_general_info_by_compound_name",
                "toolsuite": "pubchem",
                "success": true,
                "sse_summary": "Simvastatin (brand name Zocor) is a semi-synthetic lipid-lowering statin derived from fermentation of Aspergillus terreus, approved since 1991 with clinical trial phase IV data and 10 approved indications. It competitively inhibits hepatic HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, reducing LDL cholesterol (LDL-C), total cholesterol, apolipoprotein B, and triglycerides while increasing HDL cholesterol. It is indicated for treatment of primary hyperlipidemia (Fredrickson types IIa, IIb, III, IV), homozygous and heterozygous familial hypercholesterolemia, and to reduce cardiovascular morbidity and mortality including myocardial infarction, stroke, and need for revascularization, especially in patients with coronary heart disease, diabetes, peripheral vascular disease, and cerebrovascular disease.\n\nEfficacy:\n- Simvastatin lowers LDL-C by ~35% on average.\n- Rosuvastatin is more potent, reducing LDL-C by 45.8%-54.6% at 10-40 mg/day.\n- Landmark studies show statins reduce major cardiovascular events by 20%-22% per 1 mmol/L LDL reduction, even in low-risk individuals (<10% 5-year risk).\n- Statins reduce all-cause mortality and need for surgical interventions post-heart attack.\n\nSafety and Adverse Events:\n- Myopathy incidence in a database of 41,413 patients was 0.03% at 20 mg/day, 0.08% at 40 mg/day, and 0.61% at 80 mg/day; the 80 mg dose is reserved for patients on chronic treatment (>12 months) without muscle toxicity and requires close monitoring.\n- Risk of myopathy is increased with coadministration of fenofibrate, niacin, gemfibrozil, cyclosporine, strong CYP3A4 inhibitors, and colchicine.\n- Rhabdomyolysis with or without acute renal failure has been reported rarely, with some fatalities.\n- Liver enzyme elevations (>3x ULN) occur in ~1% of patients; in the Scandinavian Simvastatin Survival Study (4S), transaminase elevations >3x ULN were 0.7% vs. 0.6% placebo; in the Heart Protection Study (HPS) with 20,536 patients on 40 mg/day, elevated transaminases occurred in 0.21% vs. 0.09% placebo.\n- Increases in HbA1c and fasting glucose have been reported, but no clinical impact on steroid hormone production or gallstone risk.\n\nPharmacology:\n- Simvastatin is lipophilic, entering endothelial cells by passive diffusion, differing from hydrophilic statins like rosuvastatin and pravastatin which use OATP1B1-mediated hepatocyte uptake.\n- It also modulates immune responses by suppressing MHC II expression on interferon gamma-stimulated antigen-presenting cells.\n\nClinical Recommendations:\n- Statins, including simvastatin, are standard post-cardiovascular event therapy and for moderate to high CVD risk patients.\n- The 80 mg simvastatin dose should be limited to patients stable on this dose without muscle toxicity.\n- Patients on simvastatin should be monitored for muscle symptoms and liver enzymes, especially when coadministered with interacting drugs.\n\nResistance markers were not reported in the data.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 14326
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin is contraindicated in patients with severe renal impairment. For those with mild to moderate renal impairment, lower doses of simvastatin are recommended. The FDA has issued restrictions on the highest approved dose of simvastatin (80 mg) due to increased risk of muscle damage, specifically myopathy, as evidenced by the SEARCH trial and ongoing safety reviews. Patients on 80 mg daily have a higher myopathy risk compared to lower doses or other statins. If severe adverse effects occur, simvastatin should be discontinued, and if re-challenge at a lower dose causes similar issues, switching to an alternative statin is advised. Most statins, except atorvastatin and fluvastatin, require caution in renal insufficiency. Monitoring by an interprofessional healthcare team is essential to manage therapeutic outcomes and adverse events. No specific resistance markers were noted.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3820
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "null",
                "tool_name": "get_pharmacogenomics_info_by_drug_name",
                "toolsuite": "fda_drug",
                "success": false,
                "additional_info_type": "Others",
                "additional_info": "",
                "additional_urls": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Precautions for simvastatin therapy include taking the medication with food and avoiding high doses or concomitant use with certain interacting drugs due to an increased risk of myopathy (muscle weakness). For patients on high-dose simvastatin (80 mg), initiating interacting medications necessitates changing therapy. If adverse effects recur at lower doses upon rechallenge, discontinuation and switching to an alternative statin are recommended. The usual adult dose ranges from 10 mg to 40 mg once daily, with 10 mg as a typical starting dose in children. Patients should inform their healthcare providers about all current medications, supplements, and alcohol use before starting simvastatin. Monitoring by an interprofessional healthcare team is essential to assess efficacy and adverse effects. Stopping simvastatin without alternative treatment may cause cholesterol levels to rise. Safety considerations emphasize reporting any muscle weakness or liver issues promptly.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5008
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Management of high LDL cholesterol involves lifestyle changes and pharmacotherapy, primarily statins, aiming for LDL-C levels below 70 mg/dL, especially in patients at very high risk for atherosclerotic cardiovascular disease (ASCVD). According to the 2018 guidelines (NCBI source), for patients with LDL-C ≥ 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy, PCSK9 inhibitors may be added. In severe primary hypercholesterolemia (LDL-C > 190 mg/dL) without ASCVD, high-intensity statin therapy or moderate-intensity statin plus ezetimibe is recommended to achieve LDL-C < 100 mg/dL; if goals are unmet, PCSK9 inhibitors can be considered in higher-risk patients.\n\nThe Cholesterol Treatment Trialists showed a consistent relative risk reduction in cardiovascular events per 39 mg/dL (1 mmol/L) LDL-C decrease, regardless of baseline LDL-C level. Lifestyle modifications include reducing saturated and trans fats, increasing unsaturated fats, weight loss of 5–10%, smoking cessation, and heart-healthy diets, all contributing to LDL reduction and cardiovascular risk mitigation.\n\nClinicians emphasize starting statins for moderate to high-risk patients, with secondary goals targeting LDL < 70 mg/dL, sometimes requiring additional medications beyond statins. Genetic factors and environmental contributions to high cholesterol are recognized but incompletely understood.\n\nNo specific clinical trial names or NCT numbers were provided. Safety/adverse event rates and resistance markers were not detailed in the sources.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 5636
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin adverse effects include muscle pain, liver damage, and increased blood sugar levels. Contraindications are liver disease, pregnancy, and breastfeeding. It is recommended to consult a healthcare provider before use. No clinical trial data, dosages, resistance markers, or detailed safety/efficacy statistics were provided in the source.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4064
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "Simvastatin interacts with numerous drugs, including antibiotics (clarithromycin, daptomycin, erythromycin), antifungals (itraconazole, ketoconazole, posaconazole, voriconazole, Nizoral®), HIV medications (atazanavir, indinavir, nelfinavir, ritonavir, saquinavir, Crixivan®, Kaletra®, Lexiva®, Norvir®, Prezista®, Reyataz®), cyclosporine (Gengraf®, Neoral®, Sandimmune®), gemfibrozil (Lopid®), danazol (Danocrine®), nefazodone (Serzone®), boceprevir (Victrelis®), cobicistat-containing products (Stribild®), and telaprevir (Incivek®). Concurrent use with these drugs, especially at higher simvastatin doses, increases the risk of muscle injury (myopathy, rhabdomyolysis) and kidney problems.\n\nPatients with liver disease, renal dysfunction, hypothyroidism, diabetes, or a history of alcohol abuse are at higher risk of adverse effects. Symptoms warranting immediate medical attention include headache, stomach pain, vomiting, dark-colored urine, loss of appetite, weight loss, fatigue, light-colored stools, upper right stomach pain, or jaundice.\n\nDue to these risks, co-administration with the above medications is generally contraindicated or requires dosage adjustment and close monitoring. There are six known disease interactions with simvastatin, notably liver and renal disease. Patients should consult their healthcare provider before combining simvastatin with other drugs to avoid serious adverse events.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 4640
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "",
                "tool_name": "tavily_search",
                "toolsuite": "search",
                "success": true,
                "sse_summary": "The 2022 USPSTF update recommends statin therapy for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in adults aged 40-75 years with one or more cardiovascular risk factors. This recommendation is based on an updated evidence review encompassing 22 randomized clinical trials (RCTs), including 3 additional RCTs since the 2016 review. Statin use in patients without baseline ASCVD was associated with significant reductions in all-cause mortality, fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, coronary revascularization, and composite cardiovascular outcomes. Harms were assessed using data from 19 RCTs and 3 large cohort studies, with no new major safety concerns reported. However, data remain insufficient for adults older than 75 years. The 2019 ACC/AHA guidelines also endorse statins as first-line therapy for primary prevention in patients with elevated LDL cholesterol (≥190 mg/dL). Overall, statins are effective and recommended for primary prevention in eligible adults aged 40-75 with risk factors, reducing cardiovascular events and mortality.",
                "content_meta": {
                  "oversized": true,
                  "original_size_bytes": 3325
                },
                "additional_info_type": "Others",
                "additional_info": ""
              },
              {
                "content": "Error: Failed after 3 attempts when executing tool: unhandled errors in a TaskGroup (1 sub-exception). Tool_invoke_info: {'item': 'ASCVD', 'tool': 'get_associated_drugs_by_disease_name', 'tool_input': {'disease_name': 'ASCVD'}}",
                "tool_name": "get_associated_drugs_by_disease_name",
                "toolsuite": null,
                "success": false
              }
            ]
          }
        },
        "analysis_mode": "two_round",
        "activate_next_level": false
      },
      "execution_time": 103.42309808731079,
      "error_message": null
    }
  ],
  "metadata": null
}